
<html lang="en"     class="pb-page"  data-request-id="6a2a8aa8-e27d-478e-aefb-9bc0e25a5207"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2018.61.issue-6;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b01612;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Structure–Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors" /></meta><meta name="dc.Creator" content="Qiuju  Xun" /></meta><meta name="dc.Creator" content="Zhang  Zhang" /></meta><meta name="dc.Creator" content="Jinfeng  Luo" /></meta><meta name="dc.Creator" content="Linjiang  Tong" /></meta><meta name="dc.Creator" content="Minhao  Huang" /></meta><meta name="dc.Creator" content="Zhen  Wang" /></meta><meta name="dc.Creator" content="Jian  Zou" /></meta><meta name="dc.Creator" content="Yingqiang  Liu" /></meta><meta name="dc.Creator" content="Yong  Xu" /></meta><meta name="dc.Creator" content="Hua  Xie" /></meta><meta name="dc.Creator" content="Zheng-Chao  Tu" /></meta><meta name="dc.Creator" content="Xiaoyun  Lu" /></meta><meta name="dc.Creator" content="Ke  Ding" /></meta><meta name="dc.Description" content="Colony stimulating factor 1 receptor kinase (CSF1R) is a well validated molecular target for anticancer drug discovery. Herein, we report the design, synthesis, and structure–activity relationship ..." /></meta><meta name="Description" content="Colony stimulating factor 1 receptor kinase (CSF1R) is a well validated molecular target for anticancer drug discovery. Herein, we report the design, synthesis, and structure–activity relationship ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 2, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01612" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01612" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01612" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01612" /></link>
        
    
    

<title>Design, Synthesis, and Structure–Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01612" /></meta><meta property="og:title" content="Design, Synthesis, and Structure–Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0015.jpeg" /></meta><meta property="og:description" content="Colony stimulating factor 1 receptor kinase (CSF1R) is a well validated molecular target for anticancer drug discovery. Herein, we report the design, synthesis, and structure–activity relationship study of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as new orally bioavailable CSF1R inhibitors. One of the most promising compounds, 3bw, potently inhibits CSF1R kinase with an IC50 value of 3.0 nM, while it is less potent against structurally related epidermal growth factor receptor (EGFR) and other kinases. The kinase inhibition of 3bw was further validated by Western blotting analysis in RAW264.7 macrophages. The molecule also potently blocks macrophage infiltration, abrogates the protumorigenic influences of macrophages, and exhibits reasonable pharmacokinetic profile. Compound 3bw may serve as a new valuable lead compound for future anticancer drug discovery." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01612"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01612">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01612&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01612&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01612&amp;href=/doi/10.1021/acs.jmedchem.7b01612" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2353-2371</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01581" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01641" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Structure–Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Qiuju Xun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qiuju Xun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qiuju++Xun">Qiuju Xun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhang Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhang Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhang++Zhang">Zhang Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jinfeng Luo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinfeng Luo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinfeng++Luo">Jinfeng Luo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linjiang Tong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linjiang Tong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linjiang++Tong">Linjiang Tong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Minhao Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minhao Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minhao++Huang">Minhao Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhen Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhen Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhen++Wang">Zhen Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Zou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Zou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Zou">Jian Zou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yingqiang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yingqiang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China</div><div class="loa-info-affiliations-info">School of Life Sciences, Shanghai University, No. 99 Shangda Road, Shanghai 200444, China</div><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yingqiang++Liu">Yingqiang Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yong Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yong Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Xu">Yong Xu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3601-0246" title="Orcid link">http://orcid.org/0000-0003-3601-0246</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hua Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hua Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hua++Xie">Hua Xie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zheng-Chao Tu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zheng-Chao Tu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zheng-Chao++Tu">Zheng-Chao Tu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoyun Lu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoyun Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div></div><span class="conrtib-corresp"><strong>*</strong>X.L.: e-mail, <a href="/cdn-cgi/l/email-protection#7418010c0d46444542341e1a015a1110015a171a"><span class="__cf_email__" data-cfemail="e78b929f9ed5d7d6d1a78d8992c9828392c98489">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyun++Lu">Xiaoyun Lu</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ke Ding</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ke Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</div><div class="loa-info-affiliations-info">School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</div><div class="loa-info-affiliations-info">Guangzhou City Key Laboratory of Precision Chemical Drug Development, Guangzhou 510632, China</div><div class="loa-info-affiliations-info">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MOE) of People’s Republic of China, Guangzhou 510632, China</div></div><span class="conrtib-corresp"><strong>*</strong>K.D.: phone, +86-20-85223764; fax, +86-20-85224766; e-mail, <a href="/cdn-cgi/l/email-protection#6d0904030a3206082d07031843080918430e03"><span class="__cf_email__" data-cfemail="f99d90979ea6929cb993978cd79c9d8cd79a97">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ke++Ding">Ke Ding</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9016-812X" title="Orcid link">http://orcid.org/0000-0001-9016-812X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01612&amp;href=/doi/10.1021%2Facs.jmedchem.7b01612" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2353–2371</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 2, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 November 2017</li><li><span class="item_label"><b>Published</b> online</span>2 March 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 March 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01612" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01612</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2353%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DQiuju%2BXun%252C%2BZhang%2BZhang%252C%2BJinfeng%2BLuo%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D6%26contentID%3Dacs.jmedchem.7b01612%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BStructure%25E2%2580%2593Activity%2BRelationship%2BStudy%2Bof%2B2-Oxo-3%252C4-dihydropyrimido%255B4%252C5-d%255Dpyrimidines%2Bas%2BNew%2BColony%2BStimulating%2BFactor%2B1%2BReceptor%2B%2528CSF1R%2529%2BKinase%2BInhibitors%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2371%26publicationDate%3DMarch%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01612"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3084</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">11</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01612" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Structure–Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Qiuju&quot;,&quot;last_name&quot;:&quot;Xun&quot;},{&quot;first_name&quot;:&quot;Zhang&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Jinfeng&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Linjiang&quot;,&quot;last_name&quot;:&quot;Tong&quot;},{&quot;first_name&quot;:&quot;Minhao&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Zhen&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;Yingqiang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Hua&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Zheng-Chao&quot;,&quot;last_name&quot;:&quot;Tu&quot;},{&quot;first_name&quot;:&quot;Xiaoyun&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Ke&quot;,&quot;last_name&quot;:&quot;Ding&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;2353-2371&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01612&quot;},&quot;abstract&quot;:&quot;Colony stimulating factor 1 receptor kinase (CSF1R) is a well validated molecular target for anticancer drug discovery. Herein, we report the design, synthesis, and structure–activity relationship study of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as new orally bioavailable CSF1R inhibitors. One of the most promising compounds, 3bw, potently inhibits CSF1R kinase with an IC50 value of 3.0 nM, while it is less potent against structurally related epidermal growth factor receptor (EGFR) and other kinases. The kinase inhibition of 3bw was further validated by Western blotting analysis in RAW264.7 macrophages. The molecule also potently blocks macrophage infiltration, abrogates the protumorigenic influences of macrophages, and exhibits reasonable pharmacokinetic profile. Compound 3bw may serve as a new valuable lead compound for future anticancer drug discovery.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01612&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01612" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01612&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01612" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01612&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01612" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01612&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01612&amp;href=/doi/10.1021/acs.jmedchem.7b01612" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01612" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01612" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01612%26sid%3Dliteratum%253Aachs%26pmid%3D29499108%26genre%3Darticle%26aulast%3DXun%26date%3D2018%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BStructure%25E2%2580%2593Activity%2BRelationship%2BStudy%2Bof%2B2-Oxo-3%252C4-dihydropyrimido%255B4%252C5-d%255Dpyrimidines%2Bas%2BNew%2BColony%2BStimulating%2BFactor%2B1%2BReceptor%2B%2528CSF1R%2529%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D6%26spage%3D2353%26epage%3D2371%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=290723" title="Solutions">Solutions</a>,</li><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/jmcmar.2018.61.issue-6/20180322/jmcmar.2018.61.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Colony stimulating factor 1 receptor kinase (CSF1R) is a well validated molecular target for anticancer drug discovery. Herein, we report the design, synthesis, and structure–activity relationship study of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidines as new orally bioavailable CSF1R inhibitors. One of the most promising compounds, <b>3bw</b>, potently inhibits CSF1R kinase with an IC<sub>50</sub> value of 3.0 nM, while it is less potent against structurally related epidermal growth factor receptor (EGFR) and other kinases. The kinase inhibition of <b>3bw</b> was further validated by Western blotting analysis in RAW264.7 macrophages. The molecule also potently blocks macrophage infiltration, abrogates the protumorigenic influences of macrophages, and exhibits reasonable pharmacokinetic profile. Compound <b>3bw</b> may serve as a new valuable lead compound for future anticancer drug discovery.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23157" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23157" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Colony stimulating factor 1 receptor (CSF1R, also known as FMS)<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> belongs to the type III growth factor receptor family that includes FMS-like tyrosine kinase 3 (FLT-3), stem cell factor receptor (KIT), and platelet-derived growth factor receptor (PDGFR) α and β, etc. CSF1R structurally distinguishes itself from the other family members by the presence of five immunoglobulin-like extracellular domains and a kinase insert dividing the intracellular kinase domain into two lobes.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> CSF1R is primarily expressed in macrophage lineage including monocytes,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> tissue macrophages, dendritic cells, osteoclasts and is involved in many fundamental biological processes, such as macrophage lineage’s tissue normal development,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> body’s immune defense, and embryonic development.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Upon activation by the intracellular ligand CSF-1,<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> CSF1R signaling is crucial for the differentiation and survival of macrophages<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> and plays crucial roles in the tumor promoting and immune suppressive functions of tumor-associated macrophages (TAMs, also termed M2 macrophages).<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> TAMs are highly plastic dominant immune cells expressing immunosuppressive molecules (e.g., interleukin 10 (IL-10), prostaglandin E2 (PGE2), and transforming growth factor β (TGFβ), etc.) to recruit T regulatory cells (TREG) via the C–C motif chemokine 22 (CCL22) in both early stage and metastatic stage of human cancers.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> TAMs also express the inhibitory ligands of programmed cell death protein 1 receptor (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) to suppress the activation of T lymphocytes and natural killer cells (NK cells).<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a> Both CSF-1 expression and the intratumoral presence of CSF-1R<sup>+</sup> macrophages have demonstrated close correlation with poor survival in various solid tumors and hematological malignancies.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Moreover, genetic or pharmacological blockade of CSF-1 or its receptor has been proven to markedly decrease the infiltration of macrophages at the tumor site and to slow primary tumor growth, reduce metastatic potential, and improve long-term survival of prostate tumor-bearing mice.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> CSF1R inhibition was also reported to alter macrophage polarization and blocked glioma progression.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Thus, suppression of TAM survival/activation by inhibiting CSF-1/CSF1R signaling becomes a highly attractive strategy for cancer immunotherapy. In addition, studies also revealed the potential therapeutic applications of CSF1R inhibitors in several types of clinical diseases besides cancer, such as inflammatory disorders, autoimmunity, and bone diseases.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a></div><div class="NLM_p">A number of selective or nonselective small molecule CSF1R inhibitors have been reported to date,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> several of which have been advanced into different stages of clinical investigation. For instance, 5-((5-chloro-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)methyl)-<i>N</i>-((6-(trifluoromethyl)pyridin-3-yl)methyl)pyridin-2-amine (<b>1</b>, PLX3397 or pexidartinib),<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> an oral tyrosine kinase inhibitor of CSF1R, c-KIT, and mutant Flt3, is undergoing phase 3 clinical studies in patients with diffuse type giant cell tumor (dt-GCT or PVNS). PLX7486 (structure undisclosed),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> ARRY-382 (structure undisclosed),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and JNJ-40346527 (structure undisclosed)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> are also being investigated in solid tumors and classical Hodgkin’s lymphoma (cHL). However, there is no CSF1R inhibitor approved by U.S. Food and Drug Administration (FDA) to date. It is still highly desirable to identify new CSF1R inhibitors with distinct chemical scaffolds. Herein, we report the identification of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidines as new orally bioavailable and selective CSF1R inhibitors by structural modification of an irreversible EGFR inhibitor (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidines as CSF1R inhibitors by structural modification of an irreversible EGFR inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86617" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86617" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Synthesis of the designed 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl analogues was outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Commercially available ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (<b>4</b>) was reacted with protected aliphatic amines (<b>5</b>) to produce adducts (<b>6</b>) in high yields. The reduction of (<b>6)</b> with lithium aluminum hydride (LiAlH<sub>4</sub>) gave alcohols (<b>7</b>) which were subsequently oxidized by MnO<sub>2</sub> to yield aldehydes (<b>8</b>). Compounds <b>9</b> were obtained through reductive amination of aldehydes (<b>8</b>) with the corresponding amines. Intermediates (<b>11</b>) were prepared by direct cyclization using triphosgene and subsequent oxidation with 3-chloroperbenzoic acid (m-CPBA). A coupling of compounds (<b>11)</b> with different substituted amines generated intermediates (<b>12</b>) which were deprotected by trifluoroacetic acid to produce the key intermediates (<b>13</b>). With compounds (<b>13)</b> in hand, the designed molecules were readily prepared by coupling with various carboxylic acids or 1-iodopropane.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>3</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub> (2.0 equiv), <i>N</i>,<i>N</i>-dimethylformamide (DMF), 60 °C, 80–95%; (b) lithium aluminum hydride (LiAlH<sub>4</sub>) (2.0 equiv), tetrahydrofuran (THF), −40 to 0 °C, 45–58%; (c) MnO<sub>2</sub> (5.0 equiv), dichloromethane (DCM), room temperature (rt), 80–95%; (d) R<sub>1</sub>NH<sub>2</sub> (2.0 equiv), AcOH (1.0 equiv), NaBH<sub>4</sub> (2.0 equiv), PhMe, 0 °C to rt, 60–80%; (e) triphosgene (0.34 equiv), triethylamine (Et<sub>3</sub>N) (3.0 equiv), DCM, 0 °C to rt, 80–95%; (f) 3-chloroperbenzoic acid (m-CPBA) (3.0 equiv), DCM, rt, 80–92%; (g) RNH<sub>2</sub> (1.2 equiv), trifluoroacetic acid (F<sub>3</sub>CCOOH) (1.2 equiv), 2-butanol (2-BuOH), 110 °C; (h) F<sub>3</sub>CCOOH (10 equiv), DCM, rt, 45–60% (for two steps); (i) RCOOH (1.2 equiv), 2-(7-aza-1<i>H</i>-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (1.2 equiv), ethyl diisopropylamine (DIPEA) (2.0 equiv), DCM, rt, 75–90%; (j) 1-iodopropane (1.5 equiv), DIPEA (1.5 equiv), DCM, 0 °C, 56%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50433" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50433" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In order to identify a “hit” molecule as the starting point for the new CSF1R inhibitor discovery, a random screening was performed against our in-house kinase inhibitor library.<a onclick="showRef(event, 'ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37">(30−37)</a> A number of compounds displayed obvious inhibition against CSF1R kinase, among which compound <b>2</b>, a previously designed irreversible EGFR inhibitor,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> exhibited the strongest suppression against CSF1R with an IC<sub>50</sub> value of 30 nM under the conditions of a FRET-based Z′-Lyte assay.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Not surprisingly, this molecule also potently suppressed the kinase activity of EGFR with an IC<sub>50</sub> value of 0.5 nM.</div><div class="NLM_p">A preliminary computational investigation suggested that compound <b>2</b> might bind to the active conformation of EGFR (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VJO">3VJO</a>) with a typical type I binding mode, and the acrylamide warhead reacted with the Cys797 residue to form a critical covalent bond contributing greatly to the strong protein occupancy (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). The anilinopyrimidine moiety of <b>2</b> forms bidentate hydrogen bonds with Met793 in the hinge region, and the 2-chlorophenyl is directed toward the back pocket (Glu762, Met766, Leu788 in the present structure) and forms a strong cation−π interaction with Lys745 of the protein. Study also suggested compound <b>2</b> could fit nicely into the ATP binding pocket of CSF1R with similar orientation and hydrogen bonding interactions (i.e., the bidentate hydrogen-bonds with Cys666, a cation−π interaction with Lys616 etc.) to that in EGFR protein (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C), which might be due to their high sequence identity (approximate 42%) (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_001.pdf" class="ext-link">Supporting Information, Figure S2</a>). However, there is no covalent bond formation between the molecule and CSF1R because of the absence of a cysteine residue in the corresponding position of CSF1R.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding mode analysis of compound <b>2</b> to EGFR kinase and CSF1R kinase. (A) Molecular docking of compound <b>2</b> (yellow) into EGFR kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VJO">3VJO</a>, orange). Hydrogen bonds and cation−π interaction are indicated by red and green dashed lines, respectively. (B) Molecular docking of compound <b>2</b> (yellow) docked into CSF1R kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK">3DPK</a>, blue). Hydrogen bonds and cation−π interaction are indicated by red and green dashed lines, respectively. (C) Superposition of EGFR (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VJO">3VJO</a>, orange) and CSF1R kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK">3DPK</a>, blue). All the procedures were performed in Maestro (version 9.9, Schrödinger, LLC, New York, NY; 2014) implemented in the Schrödinger program.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the structural observation, the acryl moiety in compound <b>2</b> was first saturated to yield compound <b>3a</b> which exhibited significantly decreased inhibition against EGFR with an IC<sub>50</sub> value of 15.7 nM. Interestingly, compound <b>3a</b> displayed an obvious potency improvement against CSF1R with an IC<sub>50</sub> value of 5.0 nM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Further investigation revealed that the propionyl moiety in <b>3a</b> could be replaced with a variety of substituted carbonyl groups (e.g., acetyl (<b>3b</b>), isobutyryl (<b>3c</b>), <i>n</i>-butyryl (<b>3d</b>), 3-methylbutyryl (<b>3e</b>)), without obviously affecting the CSF1R inhibitory potency. Compounds <b>3b</b>, <b>3c</b>, <b>3d</b>, and <b>3e</b> exhibited IC<sub>50</sub> values which ranged from 5.5 to 10.3 nM against CSF1R kianse. However, when the propionyl moiety in <b>3a</b> was replaced with a relatively large hydrophobic 2,2-dimethyl propionyl group (<b>3f</b>) or a cyclic alkycarbonyl group (e.g., cyclopropyl acyl (<b>3g</b>), cyclopentyl acyl (<b>3h</b>), or cyclohexyl acyl (<b>3i</b>)), the resulting molecules displayed 4- to 6-fold potency loss. For instance, cyclohexyl acyl substituted analogue (<b>3i</b>) exhibited an IC<sub>50</sub> value of 30.6 nM against CSF1R, which was approximately 6-fold less potent than <b>3a</b>. The compounds with hydrophilic substituents (<b>3j</b> and <b>3k</b>) also displayed less potency. It was noteworthy that when the propionyl moiety in <b>3a</b> was replaced with a propyl group, the resulting compound (<b>3l</b>) dramatically decreased the CSF1R inhibitory potency by a factor of 36-fold, indicating a potentially critical interaction between the corresponding carbonyl group with the protein. The investigation also suggested that <i>S</i>-configuration in <b>3a</b> was important for the compound to display selective CSF1R inhibitory potency, and the <i>R</i>-isomer <b>3m</b> displayed a 4-fold less potency against the target kinase. However, the enantiomers exhibited almost identical suppressive potencies against EGFR kinase.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro CSF1R Kinase Inhibitory Activities of Inhibitors <b>3a</b>–<b>m</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">CSF1R and EGFR<sup>WT</sup> kinase inhibition was determined by using a FRET-based Z′-Lyte assay according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The data are mean values from at least three independent experiments, and the variations are less than 20%.</p></div></div><div></div></div><div class="NLM_p">The computational study also suggested that CSF1R possessed a relatively larger 2-Cl-phenyl binding pocket than EGFR because of its outward shifting αC-helix domain (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). Substitution optimization on the position might be a reasonable strategy for potency and selectivity improvement. We first investigated potential impact of the substituted position in the phenyl ring by moving the chloro substituent from 2-position to 3-position (<b>3ae</b>) or 4-position (<b>3af</b>), respectively. Both <b>3ae</b> and <b>3af</b> exhibited 2- to 3-fold less potency than the parent molecule <b>3a</b>, suggesting the 2-position might be optimal for the compounds to suppress the kinase function of CSF1R. Similar phenomena were observed by using the substitution patterns of floro (<b>3aa</b>, <b>3ac</b>, and <b>3ad</b>) and methyl (<b>3ab, 3ag</b>, and <b>3ah</b>) groups. However, the 3- or 4-substitution induced greater potency decrease against EGFR than what it did against CSF1R. This differentiation caused compounds <b>3ae</b> and <b>3af</b> to exhibit improved target selectivity compared with <b>3a</b>. Interestingly, the substituted position had no obvious impact on CSF1R kinase inhibition when a methoxyl substituent was utilized. Compounds <b>3ai</b>, <b>3aj</b>, and <b>3ak</b> displayed almost equal potencies against CSF1R with IC<sub>50</sub> values of 5.1, 4.5, and 5.8 nM, respectively. Similar to the above observation, compound <b>3aj</b> demonstrated the most selective profile between CSF1R and EGFR with a factor of 92-fold. However, when the methoxyl group in <b>3aj</b> was replaced with a metabolically more stable difloromethoxyl (<b>3al</b>) or trifloromethoxyl (<b>3am</b>) substituent, the resulting compounds exhibited 6- to 33-fold less potency. These results suggested that the electron-donating effect of methoxyl might contribute greatly to the activity by potentially enhancing the cation−π interaction between the phenyl ring and Lys616 in CSF1R protein. The disubstituted derivatives (<b>3an</b>, <b>3ao</b>, <b>3ap</b>, and <b>3aq</b>) were further designed and synthesized based on the SAR information obtained, all of which exhibited strong inhibition against CSF1R with IC<sub>50</sub> values of 4.5, 2.0, 4.4, and 2.1 nM, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The disubstituted molecules also displayed 99- to 200-fold target selectivity over EGFR.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro CSF1R Kinase Inhibitory Activities of Inhibitors <b>3aa</b>–<b>aq</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">CSF1R and EGFR<sup>WT</sup> kinase inhibition was determined by using a FRET-based Z′-Lyte assay according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The data are mean values from at least three independent experiments, and the variations are less than 20%.</p></div></div><div></div></div><div class="NLM_p">To rationalize potency and selectivity improvement of the disubstituted derivatives, a computational study was conducted to investigate the potential binding mode of <b>3aq</b> with the CSF1R protein (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). It was found that the disubstituted phenyl ring was orthogonal to the plane of the basic parent structure, within the favorable angle and distance range to form multihydrophobic interactions with the protein. In addition, the disubstituted phenyl ring also formed a strong cation−π interaction with Lys616 of the protein. The chloro atom was involved in favorable contacts with the gate keeper Thr663 and Val661, respectively, and the OMe moiety potentially formed an H-bond with the backbone NH of Asp796 located in the DFG motif with a measured distance of 2.8 Å, which further benefited the binding with CSF1R.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representation of the predicted binding mode of compound <b>3aq</b> in the active site of CSF1R (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK">3DPK</a>). Blue lines represent important amino acid residues of CSF1R. The ligand is shown in a yellow stick representation. Interactions of <b>3aq</b> with D796 and the backbone of C666 are illustrated with red dash lines. Interaction of <b>3aq</b> with K616 is illustrated with green dash lines. The docking model is visualized using PyMOL Molecular Graphics System, version 1.3 (Schrödinger, LLC).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given their outstanding potency and target selectivity, inhibitors <b>3ao</b> and <b>3aq</b> were chosen for a preliminary pharmacokinetic (PK) investigation in Sprague-Dawley (SD) rats (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Both of the compounds exhibited reasonable PK profiles with high plasma exposure AUC<sub>(0–∞)</sub> values of 1630 and 5311 ((μg/L)·h) and oral bioavailability (<i>F</i>) values of 17.1% and 38.6%, respectively, after a 25 mg/kg oral administration. However, they demonstrated relatively low maximum plasma concentration (<i>C</i><sub>max</sub>) of 396 and 988 μg/L, and short <i>T</i><sub>1/2</sub> values of 1.6 and 1.89 h, respectively.</div><div class="NLM_p">Further structural modification was then conducted with the aim to improve the PK profiles of <b>3ao</b> and <b>3aq</b> and maintain the CSF1R inhibitory potency by optimizing both the lipophilic and hydrophilic moieties at the left-hand phenyl substituents. It was found that a 3′-methyl group is optimal for the compounds to demonstrate strong CSF1R kinase inhibition. When the 3′-methyl group in <b>3ao</b> was removed (<b>3ba</b>) or changed to 2′-position (<b>3bb</b>), the resulting compounds demonstrated 6.8- to 10-fold potency loss. The replacement of 3′-methyl group with the other substituents, e.g., 3′-methoxyl (<b>3bd</b>), 3′-F (<b>3be</b>), 3-Cl (<b>3bf</b>), 3′ CF<sub>3</sub> (<b>3bg</b>), 3′-ethyl (<b>3bh</b>), or 3′-isopropyl (<b>3bi</b>), caused obvious potency loss ranged from 2.9- to 16-fold. Not surprisingly, a replacement of the solvent exposing <i>N</i>-methylpiperazine moiety in compound <b>3ao</b> with a less hydrophilic moiety, such as 1-piperdinyl (<b>3bj</b>), <i>N</i>-morpholino (<b>3bk</b>), or 1-(4-acetylpiperazinyl) (<b>3bl</b>) group, caused an approximately 13- to 20-fold potency loss. However, the 1-(4-methylpiperazinyl) group (<b>3ao</b>) could be replaced by other solvent accessibly terminal hydrophilic groups, e.g., 4-methyl-1,4-diazepan-1-yl (<b>3bm</b>), 4-(dimethylamino)piperidin-1-yl (<b>3bn</b>), 7-methyl-2,7-diazaspiro[4.4]nonan-2-yl (<b>3bo</b>), 9-methyl-3,9-diazaspiro[5.5]undecan-3-yl (<b>3bp</b>), 7-methyl-2, 7-diazaspiro[3.5]nonan-2-yl (<b>3bq</b>), <i>cis</i>-5-methylhexahydropyrrolo[3, 4-<i>c</i>]pyrrol-2(1<i>H</i>)-yl (<b>3br</b>), 2-(dimethylamino)ethyl)(methyl)amino (<b>3bs</b>), without obviously affecting the CSF1R inhibitory potency and the target selectivity (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).<named-content content-type="anchor" rid="tbl4" type="simple"></named-content> N-Demethylation is one of the common metabolic pathways for <i>N</i>-methylpiperazine containing drug, and introduction of steric hindrance is a feasible strategy to block the demethylation process.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Compounds with 3,4-dimethylpiperazin-1-yl (<b>3bt</b>) or <i>cis</i>-3,4,5-trimethylpiperazin-1-yl (<b>3bu</b>) substituent were then designed and synthesized based on this consideration. However, both compounds <b>3bt</b> and <b>3bu</b> exhibited 3- to 4-fold decreased potency compared with the parent molecule <b>3ao</b>. Encouragingly, when the <i>N</i>-methyl group in <b>3ao</b> was replaced with an <i>N</i>-oxetayl fragment, the resulting compound <b>3bv</b> displayed comparable CSF1R inhibitory potency and target selectivity to the parent molecule. The 3-methyl-4-(4-(oxetan-3-yl)piperazin-1-phenyl substituted analogue of <b>3aq</b> was also designed and synthesized (<b>3bw</b>) to display high CSF1R inhibitory potency with an IC<sub>50</sub> value of 3.0 nM and an approximate 120-fold target selectivity over EGFR. Further PK investigation suggested <b>3bw</b> exhibited improved PK parameters in SD rats comparing with original lead compounds <b>3ao</b> and <b>3aq</b>. This compound demonstrated good plasma exposure with AUC<sub>(0–∞)</sub> value of 6462 (μg/L)·h, high maximum plasma concentration with <i>C</i><sub>max</sub> value of 2515 μg/L, 44.4% oral bioavailability, respectively, after a 25 mg/kg oral administration.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro CSF1R Kinase Inhibitory Activities of Inhibitors <b>3ba</b>–<b>bw</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">CSF1R and EGFR<sup>WT</sup> kinase inhibition was determined by using a FRET-based Z′-Lyte assay according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The data are mean values from at least three independent experiments, and the variations are less than 20%.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Profile of Compounds <b>3ao</b>, <b>3aq</b>, and <b>3bw</b> in Rats<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>(0–∞)</sub> ((μg/L)·h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (μg/L)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">CLz (L h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3ao</b></td><td class="colsep0 rowsep0" align="left">po (25 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">1630</td><td class="colsep0 rowsep0" align="char" char=".">396</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">17.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">iv (5 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">1902</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">2.64</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3aq</b></td><td class="colsep0 rowsep0" align="left">po (25 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">5311</td><td class="colsep0 rowsep0" align="char" char=".">988</td><td class="colsep0 rowsep0" align="char" char=".">1.89</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">38.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">iv (5 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">2768</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.48</td><td class="colsep0 rowsep0" align="char" char=".">1.84</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3bw</b></td><td class="colsep0 rowsep0" align="left">po (25 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">6462</td><td class="colsep0 rowsep0" align="char" char=".">2515</td><td class="colsep0 rowsep0" align="char" char=".">1.08</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">44.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">iv (5 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">2911</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1.08</td><td class="colsep0 rowsep0" align="char" char=".">1.73</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">SD rats (male, three animals per group) weighing 190–230 g were used for the study.</p></div></div></div><div class="NLM_p">Inhibitory activity of <b>3bw</b> against the other members of the type III growth factor receptor family, i.e., FLT-3, KIT, and PDGFRα and PDGFRβ, was also evaluated utilizing our in-house kinase assays. It was shown that compound <b>3bw</b> suppressed the kinase functions of FLT-3, KIT, PDGFRα, and PDGFRβ with IC<sub>50</sub> values of 37, 30, 74, 106.2 nM, respectively, which were approximately 10- to 35-fold less potent to its inhibition against CSF1R. The 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidine scaffold in <b>3bw</b> has been successfully applied to the development of reversible and irreversible fibroblast growth factor receptor (FGFR) inhibitors.<a onclick="showRef(event, 'ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42">(40−42)</a> Therefore, the potential “off-target” inhibition of <b>3bw</b> against FGFRs was also determined. Not surprisingly, <b>3bw</b> also potently inhibited FGFR1/2/3/4 with IC<sub>50</sub> values of 10, 27, 40.2, and 166.9 nM, respectively. To further validate the target selectivity of <b>3bw</b>, a kinase selectivity profiling study was conducted against a panel of 250 nonmutant kinases by utilizing the Nanosyn screening platform (Nanosyn, Santa Clara, CA).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> It was shown that <b>3bw</b> showed 98.4% competition rate with CSF1R at 100 nM and displayed reasonable target selectivity with <i>S</i>(35) and <i>S</i>(10) scores of 0.14 and 0.06, respectively (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_001.pdf" class="ext-link">Supporting Information Table S3</a>). In addition to FGFRs, <b>3bw</b> also exhibited obvious inhibition (inhibition rate >90% at 100 nM) against several cancer related kinases including Abelson kinase 1 (ABL1), BMX nonreceptor tyrosine kinase (BMX), ephrin type-A receptor 1 (EPH-A1), EPH-A8, kinase insert domain receptor (KDR), Lck/Yes tyrosine kinase A (LYNA), LYNB and proto-oncogene tyrosine-protein kinase receptor Ret (RET), etc. Notably, although some of these kinases (e.g., FGFR, ABL1, and KDR) have been well validated as molecular targets for anticancer drug discovery,<a onclick="showRef(event, 'ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46">(44−46)</a> strong inhibition against the “off targets” may cause some potential toxicity concerns for the further development of this compound.</div><div class="NLM_p">In view of its strong potency, reasonable target selectivity, and good PK properties, <b>3bw</b> was selected as a representative molecule for further biological investigation. We first investigated the suppressing effect of <b>3bw</b> against CSF1R signal pathway in RAW264.7 cells which harbor high level of the kinase (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). It was shown that <b>3bw</b> dose-dependently inhibited the activation of CSF1R and the downstream target Akt. The compound demonstrated 50% inhibition against the CSF1R activation at an approximate concentration of 80 nM and almost totally abrogated the signal at 2.0 μM after a 6 h treatment.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>3bw</b> dose dependently inhibited phosphorylation of CSF1R and its downstream signaling pathway in RAW264.7 cells. (A) Compound <b>3bw</b> inhibited phosphorylation of CSF1R and its downstream signaling pathway in RAW264.7 cells as determined by Western blot analysis. (B) Immunoblot quantification of p-CSF1R and p-AKT. All bands were quantified and normalized by GAPDH. The data are expressed as the mean ± SEM from at least three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CSF-1-mediated macrophage infiltration contributes greatly to the clinical drug resistance against both targeted therapies and chemotherapy in prostate cancer (PCa) patients.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> CSF1R inhibitor <b>1</b> has been reported to overcome castration-resistance against an androgen receptor (AR) antagonist MDV3100 through blocking TAM influx.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Therefore, the potential suppressing effect of compound <b>3bw</b> against macrophages migration was investigated by using a well-established transwell assay (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The LNCaP prostate cancer cells were treated with 10 μM anti-androgen agent MDV3100 (MDV), or vehicle control (NC), and incubated in 10% FBS 1640 medium for 48 h. The treated medium (CM) was collected and then placed into the lower chamber of transwell plates. The number of RAW264.7 cells that migrated to the other side of the filter membrane was quantified. It was shown that compound <b>3bw</b> dose-dependently inhibited the migration of macrophage cells. Treatment of <b>3bw</b> at 0.625, 1.25, 2.5, or 5.0 μM for 24 h inhibited macrophages invasion by ∼44.5%, ∼ 52.7%, ∼60.6%, or ∼90.7%, respectively (<i>P</i> < 0.05, compared to the PCa CM treatment; <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibitory effect of compound <b>3bw</b> on LNCaP-MDV-CM-mediated macrophage migration. (A) Illustration of the in vitro macrophages migration model. (B) Compound <b>3bw</b> suppressed macrophage migration induced by the PCa cells CM. (C) Quantified results of B. The data are expressed as the mean ± SD (<i>n</i> = 3) and are representative of the results obtained from three independent experiments. Statistical significance relative to untreated is indicated: (∗) <i>p</i> < 0.05, (∗∗) <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CSF1R kinase is one of the key players for the protumorigenic properties of TAMs.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The potential immunotherapeutic effect of <b>3bw</b> was then determined by measuring its capability to suppress the release of protumorigenic cytokines of macrophages. It was found that compound <b>3bw</b> dose-dependently suppressed the production of arginase 1 (ARG1), interleukin 10 (IL10), matrix metallopeptidase 9 (MMP9), and vascular endothelial growth factor A (VEGFA), etc. in RAW264.7 macrophages as determined by quantitative real-time polymerase chain reaction (qRT-PCR) assays, suggesting its promising antitumor potential (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>3bw</b> reduced mRNA levels of ARG1, IL10, MMP9, and VEGFA in a dose-dependent manner in RAW264.7 cells. Each bar represents the mean ± SE of 3–5 independent experiments. Statistical significance relative to untreated is indicated: (∗) <i>p</i> < 0.05, (∗∗) <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antitumor potential of <b>3bw</b> was further examined by a binary prostate tumor cell–macrophage coculture system (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). It was shown that stimulation of the cocultured macrophages significantly enhanced the growth of LNCaP prostate cancer cells. After a 48 h treatment, <b>3bw</b> demonstrated dose-dependent abrogation on the cancer cell growth enhancement of RAW264.7 macrophages and apparently inhibited the proliferation of LNCaP cells by ∼63.4%, ∼70.0%, ∼85.0%, or ∼94.6%, at concentrations of 0.016, 0.08, 0.40, and 2.0 μM, respectively (<i>P</i> < 0.05, compared to the LNCaP alone; <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). These results collectively suggest the promising potential of compound <b>3bw</b> to serve as a lead compound for drug discovery.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Antiproliferation effects of <b>3bw</b> in LNCaP cells. (A) <b>3bw</b> inhibited the proliferation of LNCaP cells induced by RAW264.7. (B) Quantified results of (A). The data are expressed as the mean ± SD (<i>n</i> = 3) and are representative of the results obtained from three independent experiments. Statistical significance relative to untreated is indicated: (∗) <i>p</i> < 0.05, (∗∗) <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31331" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31331" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, a series of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidines were designed and synthesized as new CSF1R inhibitors. One of the most promising compounds, <b>3bw</b>, strongly inhibited the CSF1R kinase activity with an IC<sub>50</sub> value of 3.0 nM and dose-dependently suppressed the activation of CSF1R downstream signals in RAW264.7 macrophages. In addition, <b>3bw</b> demonstrated reasonable pharmacokinetic properties in rats and exhibited promising antitumor effects in blocking macrophage infiltration and abrogating the protumorigenic influences of macrophages. Compound <b>3bw</b> may serve as a new lead compound for antitumor drug discovery. Further structural optimization and in vivo antitumor efficacy of <b>3bw</b> investigation are underway, and the results will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54834" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54834" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> General Methods for Chemistry</h3><div class="NLM_p last">All reagents and solvents used were purchased from commercial sources and were of analytical grade. Flash chromatography was performed using 300 mesh silica gel. All reactions were monitored by thin-layer chromatography (TLC), using silica gel plates with fluorescence F254 and ultraviolet (UV) light visualization. <sup>1</sup>H NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 MHz or a Bruker AV-500 spectrometer at 500 MHz. <sup>13</sup>C NMR spectra were recorded on a Bruker AV-500 spectrometer at 125 MHz. Coupling constants (<i>J</i>) are expressed in hertz (Hz). Chemical shifts (δ) of NMR are reported in parts per million (ppm) units relative to an internal standard (TMS). Low resolution ESI-MS data were recorded on an Agilent 1200 HPLC-MSD mass spectrometer and high resolution ESI-MS data on an Applied Biosystems Q-STAR Elite ESI-LC–MS/MS mass spectrometer. Purity of all of the final compounds was determined by reverse-phase high performance liquid chromatography (HPLC) analysis to be >95%. HPLC instrument: Dionex Summit HPLC (column, Diamonsil C18, 5.0 μm, 4.6 mm × 250 mm (Dikma Technologies); detector, PDA-100 photodiode array; injector, ASI-100 autoinjector; pump, p-680A). A flow rate of 1.0 mL/min was used with mobile phase of MeOH in H<sub>2</sub>O with 0.1% modifier (ammonia, v/v).</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> (<i>S</i>)-3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3a</b>)</h3><div class="NLM_p last"><i>General Procedure for Syntheses of <b>3a</b>–<b>k</b>, <b>3m</b>, <b>3aa</b>–<b>aq</b>, <b>3ba</b>–<b>bw</b>.</i> DIEA (98 μL, 0.56 mmol) and propanoic acid (25 μL, 0.337 mmol) were added to a solution of HATU (128 mg, 0.337 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at rt. After stirring for 10 min, <b>13a</b> (150 mg, 0.28 mmol) was added to the resulting mixture, and then the mixture was stirred at room temperature for 0.5 h. The resulting solution was poured into H<sub>2</sub>O and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with 10% aqueous NaHCO<sub>3</sub>, brine and dried with Na<sub>2</sub>SO<sub>4</sub>. The resultant crude material was purified by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH, 40:1:0.4) to give <b>3a</b> (white solid, 132 mg, yield 80%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −10.169 (<i>c</i> 0.118, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.50 (t, <i>J</i> = 6.8 Hz, 1H), 7.48–7.30 (m, 5H), 7.09 (s, 0.6H), 7.02–7.00 (m, 1.4H), 5.59–5.57 (m, 1H), 4.65–4.61 (m, 1H), 4.51–4.48 (m, 1H), 4.02–3.91(m, 2H), 3.75–3.73 (m, 1H), 3.49–3.42 (m, 1H), 2.93–2.91 (m, 4H), 2.78–2.74 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 3H), 2.30–2.21 (m, 5H), 2.19–2.16 (m, 1H), 1.14 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.6, 159.5, 153.8, 153.7, 152.6, 147.5, 147.4, 139.2, 134.4, 134.3, 133.6, 132.8, 130.8, 129.8, 129.6, 129.5, 128.3, 123.1, 119.7, 118.5, 103.1, 55.8, 52.8, 52.1, 51.2, 47.7, 47.1, 46.3, 45.8, 44.6, 29.0, 28.0, 27.4, 26.7, 18.1, 9.1. HRMS (ESI) for C<sub>31</sub>H<sub>37</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 589.2801. Found: 589.2805. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 9.29 min, 96.44% purity.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> (<i>S</i>)-1-(1-Acetylpyrrolidin-3-yl)-3-(2-chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3b</b>)</h3><div class="NLM_p last">White solid (yield 82%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −21.818 (<i>c</i> 0.110, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.50 (t, <i>J</i> = 6.0 Hz, 1H), 7.37–7.32 (m, 5H), 7.09 (s, 0.6H), 7.02–7.01 (m, 1.4H), 5.59–5.56 (m, 1H), 4.65–4.60 (m, 1H), 4.51–4.46 (m, 1H), 4.20 (s, 0.2H), 4.08–4.03 (m, 0.8H), 3.98–3.91 (m, 1H), 3.79–3.72 (m, 1H), 3.52–3.40 (m, 1H), 2.93 (br s, 4H), 2.79–2.75 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 3H), 2.30 (s, 3H), 2.19–2.15 (m, 1H), 2.02 (s, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 169.5, 169.2, 159.6, 159.5, 153.8, 153.7, 147.6, 139.1, 134.4, 134.3, 133.6, 132.8, 130.8, 129.6, 129.5, 130.8, 129.6, 129.5, 128.3, 123.2, 119.7, 118.6, 103.1, 55.8, 55.7, 52.7, 52.1, 52.0, 51.3, 48.4, 47.1, 46.3, 44.5, 33.3, 32.1, 31.6, 31.4, 30.4, 29.8, 29.5, 26.9, 22.8, 22.7, 22.6, 20.6, 18.1, 18.0. HRMS (ESI) for C<sub>30</sub>H<sub>35</sub>ClN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 575.2644. Found: 575.2648. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.57 min, 98.78% purity.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> (<i>S</i>)-3-(2-Chlorophenyl)-1-(1-isobutyrylpyrrolidin-3-yl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3c</b>)</h3><div class="NLM_p last">White solid (yield 80%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −34.545 (<i>c</i> 0.110, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.52–7.49 (m, 1H), 7.36–7.30 (m, 5H), 7.07 (s, 0.6H), 7.03–7.00 (m, 1H), 6.96 (s, 0.4H), 5.60–5.50 (m, 1H), 4.65–4.61 (m, 1H), 4.60–4.48 (m, 1H), 4.11–4.08 (m, 0.7H), 3,97–3.91 (m, 1.3H), 3.88–3.79 (m, 1H), 3.57–3.45 (m, 0.4H), 3.43–3.40 (m, 0.6H), 2.93–2.91 (m, 4H), 2.78–2.61 (m, 1H), 2.59–2.57 (m, 5H), 2.36 (s, 3H), 2.30 (s, 3H), 2.19–2.17 (m, 1H), 1.14–1.09 (m, 4H), 1.08–1.06 (m, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 176.0, 159.5, 153.8, 153.7, 147.5, 139.2, 134.3, 133.6, 130.8, 129.6, 129.5, 128.3, 123.0, 119.7, 118.5, 103.2, 55.8, 52.9, 52.1, 52.0, 51.5, 47.6, 47.1, 46.3, 44.8, 32.7, 31.9, 29.8, 26.6, 20.6, 19.3, 19.2, 19.0, 18.1, 18.0. HRMS (ESI) for C<sub>32</sub>H<sub>39</sub>ClN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 603.2957. Found: 603.2957. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 12.07 min, 97.79% purity.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> (<i>S</i>)-1-(1-Butyrylpyrrolidin-3-yl)-3-(2-chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3d</b>)</h3><div class="NLM_p last">White solid (yield 81%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −16.049 (<i>c</i> 0.162, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.01 (s, 0.6H), 7.99 (s, 0.4H), 7.51–7.49 (m, 1H), 7.35–7.34 (m, 5H), 7.21 (s, 0.6H), 7.11 (s, 0.4H), 7.01–6.99 (m, 1H), 5.57–5.56 (m, 1H), 4.63–4.60 (m, 1H), 4.50–4.47 (m, 1H), 4.06–3.92 (m, 2H), 3.76–3.74 (m, 1H), 3.50–3.38 (m, 1H), 2.91 (br s, 4H), 2.79–2.76 (m, 1H), 2.57 (br s, 4H), 2.35 (s, 3H), 2.29 (s, 3H), 2.25–2.21 (m, 2H), 2.19–2.12 (m, 1H), 1.67–1.64 (m, 2H), 0.93–0.92 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.1, 171.7, 159.6, 159.5, 153.8, 153.6, 152.7, 147.5, 139.1, 134.3, 133.5, 132.8, 130.7, 129.8, 129.6, 129.5, 128.3, 123.1, 119.6, 118.7, 118.5, 103.0, 55.8, 55.7, 52.8, 52.0, 51.2, 47.7, 47.0, 46.3, 44.5, 36.9, 36.2, 29.8, 26.6, 18.4, 18.3, 18.0, 14.2, 9.1. HRMS (ESI) for C<sub>32</sub>H<sub>39</sub>ClN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 603.2957. Found: 603.2919. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.33 min, 97.93% purity.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> (<i>S</i>)-3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-(3-methylbutanoyl)pyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3e</b>)</h3><div class="NLM_p last">White solid (yield 80%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −33.333 (<i>c</i> 0.138, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.52–7.48 (m, 1H), 7.35–7.32 (m, 5H), 7.11 (s, 0.6H), 7.02–6.99 (m, 1.4H), 5.57–5.54 (m, 1H), 4.64–4.61 (m, 1H), 4.50–4.45 (m, 1H), 4.09–3.91 (m, 2H), 3.77–3.76 (m, 1H), 3.53–3.40 (m, 1H), 2.92 (br s, 4H), 2.79–2.75 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 3H), 2.30 (s, 3H), 2.15–2.11 (m, 4H), 0.95 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 171.6, 171.3, 159.6, 159.5, 153.8, 153.7, 147.5, 139.2, 134.3, 133.6, 130.8, 129.6, 129.4, 128.3, 128.2, 123.1, 119.7, 118.5, 103.1, 55.8, 52.8, 52.1, 52.0, 51.2, 47.8, 47.1, 46.3, 46.0, 44.5, 43.9, 43.2, 29.8, 26.6, 25.6, 25.5, 22.9, 22.8, 18.1, 18.0. HRMS (ESI) for C<sub>33</sub>H<sub>41</sub>ClN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 617.3114. Found: 617.3111. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.64 min, 97.76% purity.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> (<i>S</i>)-3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-pivaloylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3f</b>)</h3><div class="NLM_p last">White solid (yield 84%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −11.667 (<i>c</i> 0.240, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.01 (s, 1H), 7.50 (d, <i>J</i> = 8.0 Hz, 1H), 7.37–7.29 (m, 5H), 7.11 (s, 1H), 7.00 (d, <i>J</i> = 8.8 Hz, 1H), 5.53–5.49 (m, 1H), 4.62 (d, <i>J</i> = 13.6 Hz, 1H), 4.48 (d, <i>J</i> = 13.6 Hz, 1H), 4.12–4.11 (m, 1H), 4.00–3.98 (m, 2H), 3.56–3.55 (m, 1H), 2.92 (t, <i>J</i> = 4.4 Hz, 4H), 2.71–2.70 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 3H), 2.30 (s, 3H), 2.19–2.14 (m, 1H), 1.23 (s, 9H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ176.7, 159.5, 157.6, 153.7, 152.7, 147.4, 139.2, 134.4, 133.5, 134.4, 133.5, 132.9, 132.8, 130.7, 129.7, 129.5, 128.3, 123.0, 119.7, 118.5, 103.1, 55.8, 52.0, 48.7, 47.1, 47.0, 46.3, 39.1, 32.0, 29.8, 29.7, 29.5, 27.7, 22.8, 18.1, 14.2. HRMS (ESI) for C<sub>33</sub>H<sub>41</sub>ClN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 617.3114. Found: 617.3116. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 14.12 min, 98.96% purity.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (<i>S</i>)-3-(2-Chlorophenyl)-1-(1-(cyclopropanecarbonyl)pyrrolidin-3-yl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3g</b>)</h3><div class="NLM_p last">White solid (yield 75%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −41.667 (<i>c</i> 0.072, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.52–7.49 (m, 1H), 7.36–7.33 (m, 5H), 7.11 (s, 0.6H), 7.02–6.97 (m, 1.4H), 5.63 (t, J = 8.4 Hz, 1H), 4.64 (d, J = 13.6 Hz, 1H), 4.50 (d, J = 13.6 Hz, 1H), 4.25–4.22 (m, 0.6H), 4.00–3.96 (m, 2.4H), 3.72–3.70 (m, 0.4H), 3.48–3.40 (m, 0.6H), 2.93 (br s, 4H), 2.79–2.78 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 3H), 2.30 (s, 3H), 2.20–2.18 (m, 1H), 1.66–1.65 (m, 0.4H), 1.58–1.57 (m, 0.6H), 1.00–0.99 (m, 2H), 0.88–0.86 (m, 1H), 0.75–0.71 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.5, 172.1, 159.6, 159.5, 157.4, 153.8, 152.8, 147.4, 139.2, 134.4, 133.6, 132.8, 130.8, 129.8, 129.6, 120.3, 123.2, 123.1, 123.0, 119.7, 118.7, 118.6, 118.4, 103.1, 55.8, 52.8, 52.1, 52.0, 47.1, 46.3, 45.0, 29.8, 26.8, 18.1, 18.0, 12.8, 12.1, 7.6, 7.5, 7.4. HRMS (ESI) for C<sub>32</sub>H<sub>37</sub>ClN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 601.2801. Found: 601.2798. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 10.11 min, 98.3% purity.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (<i>S</i>)-3-(2-Chlorophenyl)-1-(1-(cyclopentanecarbonyl)pyrrolidin-3-yl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3h</b>)</h3><div class="NLM_p last">White solid (yield 90%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −24.490 (<i>c</i> 0.098, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.50–7.49 (m, 1H), 7.36–7.35 (m, 5H), 7.17 (s, 0.6H), 7.06–7.00 (m, 1.4H), 5.57–5.56 (m, 1H), 4.61–4.60 (m, 1H), 4.51–4.47 (m, 1H), 4.23–4.22 (m, 0.1H), 4.09–4.08 (m, 0.6H), 3.93–3.82 (m, 2H), 3.65–3.57 (m, 0.1H), 3.44–3.43 (m, 0.3H), 3.11–3.10 (m, 0.7H), 3.15–3.12 (m, 0.2H), 2.94 (br s, 4H), 2.79–2.72 (m, 1H), 2.70 (br s, 4H), 2.40 (s, 3H), 2.29 (br s, 4H), 2.17–2.15 (m, 1H), 1.54–1.52 (m, 3H), 1.42–1.40 (m, 1H), 1.28–1.25 (m, 4H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 175.3, 175.0, 159.5, 159.4, 157.4, 153.8, 153.6, 152.7, 147.3, 147.2, 139.2, 134.6, 134.4, 133.6, 132.6, 130.8, 129.8, 129.6, 129.5, 128.3, 123.1, 119.7, 118.6, 103.1, 55.8, 55.7, 52.8, 52.0, 51.9, 51.2, 47.7, 47.1, 46.2, 46.1, 45.8, 44.8, 43.4, 42.6, 33.3, 32.0, 31.6, 31.4, 30.3, 30.1, 29.9, 29.8, 29.5, 26.6, 26.3, 25.2, 23.2, 22.8, 18.6, 18.2, 9.1. HRMS (ESI) for C<sub>30</sub>H<sub>36</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 629.3270. Found: 629.3088. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 16.39 min, 96.77% purity.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (<i>S</i>)-3-(2-Chlorophenyl)-1-(1-(cyclohexanecarbonyl)pyrrolidin-3-yl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3i</b>)</h3><div class="NLM_p last">White solid (yield 85%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −39.130 (<i>c</i> 0.092, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.50 (t, J = 7.2 Hz, 1H), 7.35–7.32 (m, 5H), 7.14 (s, 0.7H), 7.02–6.99 (m, 1.3H), 5.56–5.55 (m, 1H), 4.64–4.61 (m, 1H), 4.51–4.47 (m, 1H), 4.20–4.21 (m, 0.1H), 4.11–4.07 (m, 0.9H), 3.91–3.81 (m, 1.6H), 3.64–3.61 (m, 0.6H), 3.56–3.40 (m, 0.4H), 3.09–3.08 (m, 0.4H), 2.93 (br s, 4H), 2.79–2.74 (m, 1H), 2.60 (br s, 4H), 2.37 (s, 3H), 2.29 (s, 3H), 2.17–2.16 (m, 2H), 1.49–1.42 (m, 2H), 1.39–1.28 (m, 2H), 1.25–1.21 (m, 6H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 175.2, 174.8, 159.5, 159.4, 157.4, 153.8, 153.6, 152.7, 147.3, 147.2, 139.2, 134.6, 134.4, 133.6, 132.8, 130.8, 129.8, 129.6, 129.5, 128.3, 123.1, 119.7, 118.6, 103.1, 103.0, 55.8, 54.9, 52.9, 52.0, 51.9, 51.1, 47.5, 47.1, 46.2, 46.1, 45.7, 44.7, 43.1, 42.3, 32.0, 31.6, 31.4, 30.3, 29.8, 29.5, 29.1, 29.0, 28.8, 26.6, 26.0, 25.2, 23.2, 22.8, 18.6, 18.0, 9.1. HRMS (ESI) for C<sub>30</sub>H<sub>36</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 643.3270. Found: 643.3203. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 19.80 min, 98.22% purity.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>S</i>)-3-(2-Chlorophenyl)-1-(1-(2-hydroxyacetyl)pyrrolidin-3-yl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3j</b>)</h3><div class="NLM_p last">White solid (yield 82%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −21.311 (<i>c</i> 0.122, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.02 (s, 1H), 7.52–7.50 (m, 1H), 7.35–7.32 (m, 5H), 7.03–7.01 (m, 2H), 5.60 (q, <i>J</i> = 8.8 Hz, 1H), 4.64–4.60 (m, 1H), 4.50–4.47 (m, 1H), 4.09 (s, 1H), 4.03–3.94 (m, 2H), 3.64 (s, 1H), 3.56–3.51 (m, 2H), 3.38–3.36 (m, 1H), 2.93 (br s, 4H), 2.75–2.73 (m, 1H), 2.65 (br s, 4H), 2.41 (s, 3H), 2.29 (s, 3H), 2.25–2.22 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 170.3, 170.0, 159.6, 157.3, 153.9, 153.8, 152.5, 147.7, 139.0, 134.2, 133.5, 132.8, 130.8, 129.7, 129.6, 129.5, 128.3, 123.4, 119.6, 118.9, 102.9, 60.7, 60.4, 55.7, 52.4, 52.0, 51.9, 50.6, 47.1, 46.3, 44.9, 31.5, 31.4, 30.3, 29.8, 26.3, 20.6, 18.1, 18.0. HRMS (ESI) for C<sub>30</sub>H<sub>35</sub>ClN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 591.2593. Found: 591.2597. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.09 min, 98.57% purity.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (<i>S</i>)-3-(2-Chlorophenyl)-1-(1-(2-(dimethylamino)acetyl)pyrrolidin-3-yl)-7-((3-methy l-4-(4-methylpiperazin-1-yl)phenyl)amino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3k</b>)</h3><div class="NLM_p last">White solid (yield 79%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −26.415 (<i>c</i> 0.106, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.02 (s, 0.6H), 7.99 (s, 0.4H), 7.52–7.49 (m, 1H), 7.37–7.30 (m, 5H), 7.10 (s, 0.4H), 7.06 (s, 0.6H), 7.03–7.00 (m, 1H), 5.59–5.57 (m, 1H), 4.66–4.61 (m, 1H), 4.59–4.48 (m, 1H), 4.21–4.20 (m, 0.2H), 4.07–4.02 (m, 0.8H), 3.95–3.93 (m, 1.5H), 3. 89–3.85 (m, 0.5H), 3.61–3.59 (m, 0.4H), 3.49–3.46 (m, 0.6H), 3.11–3.06 (m, 1.4H), 3.05–3.01 (m, 0.6H), 2.98–2.93 (m, 4H), 2.76–2.1 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 3H), 2.31 (s, 6H), 2.30 (s, 3H), 2.19–2.15 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 168.7, 168.3, 159.5, 159.4, 157.3, 153.7, 153.5, 152.5, 152.4, 147.3, 139.0, 134.4, 134.3, 133.3, 132.6, 132.5, 130.6, 130.5, 129.6, 129.5, 129.4, 129.3, 128.1, 123.3, 123.1, 119.4, 118.7, 118.4, 102.8, 62.4, 62.3, 62.1, 55.6, 55.5, 52.7, 51.9, 51.8, 50.8, 46.9, 46.2, 46.1, 45.8, 45.7, 45.6, 45.5, 44.7, 26.2, 26.1, 18.0, 17.9. HRMS (ESI) for C<sub>32</sub>H<sub>40</sub>ClN<sub>9</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 618.3066. Found: 618.3069. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 11.42 min, 96.13% purity.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<i>S</i>)-3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3l</b>)</h3><div class="NLM_p last"><i>N</i>,<i>N</i>-Diisopropylethylamine (49 μL, 0.28 mmol) and iodopropane (27 μL, 0.28 mmol) were added to a solution of <b>13a</b> (100 mg, 0.19 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (10 mL) with stirring at 0 °C. The reaction was allowed to warm to room temperature, and then, after stirring for 4 h, the reaction mixture was poured into a solution of 10% aqueous NaHCO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was separated, washed with 10% aqueous NaHCO<sub>3</sub> and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resultant crude material was purified by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH, 40:1:0.4) to give <b>3n</b> (60 mg, yield 56%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −27.027 (<i>c</i> 0.074, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99 (s, 1H), 7.51–7.44 (m, 3H), 7.36–7.30 (m, 4H), 7.05 (d, J = 8.8 Hz, 1H), 5.69 (m, 1H), 4.66–4.4.42 (m, 2H), 3.52–3.43 (m, 1H), 3.16–3.15 (m, 3H), 2.94–2.91 (m, 4H), 2.73–2.70 (m, 1H), 2.58 (br s, 4H), 2,43–2.41 (m, 1H), 2.35 (s, 3H), 2.31 (s, 3H), 1.67 (q, <i>J</i> = 8.0 Hz, 2H), 1.41–1.33 (m, 2H), 0.94 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 159.6, 157.6, 153.6, 152.6, 147.3, 139.2, 134.5, 133.6, 133.0, 132.8, 130.8, 129.6, 129.5, 128.4, 128.4, 123.1, 119.9, 118.6, 102.8, 57.9, 55.9, 55.1, 54.9, 53.9, 52.0, 51.3, 47.2, 46.3, 29.8, 28.5, 28.4, 20.9, 19.2, 18.1, 14.2, 11.9. HRMS (ESI) for C<sub>31</sub>H<sub>39</sub>ClN<sub>8</sub>O [M + H]<sup>+</sup>, calcd: 575.3008. Found: 575.3017. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 27.27 min, 97.44% purity.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>R</i>)-3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3m</b>)</h3><div class="NLM_p last">White solid (yield 87%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> +14.736 (<i>c</i> 0.095, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, a mixture of rotamers) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.52–7.49 (m, 1H), 7.37–7.34 (m, 5H), 7.04–7.00 (m, 1.6H), 6.94 (s, 0.4H), 5.60–5.53 (m, 1H), 4.65–4.61 (m, 1H), 4.51–4.45 (m, 1H), 4.08–3.88 (m, 2H), 3.78–3.70 (m, 1H), 3.52–3.41 (m, 1H), 2.94–2.92 (m, 4H), 2.78–2.74 (m, 1H), 2.60 (br s, 4H), 2.37 (s, 3H), 2.30 (s, 3H), 2.27–2.21 (m, 2H), 2.19–2.14 (m, 1H), 1.12 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 162.8, 160.8, 159.6, 159.5, 157.3, 153.9, 153.7, 152.7, 147.6, 147.5, 135.5, 134.3, 133.6, 130.9, 130.7, 130.6, 123.3, 123.2, 123.1, 119.7, 118.8, 118.7, 118.6, 118.2, 118.0, 115.6, 115.4, 102.9, 55.8, 55.7, 528, 52.1, 52.0, 51.2, 47.6, 47.2, 46.3, 44.6, 28.0, 27.4, 26.7, 18.1, 18.0, 9.1. HRMS (ESI) for C<sub>31</sub>H<sub>37</sub>ClN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 589.2801. Found: 589.2804. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 11.93 min, 98.56% purity.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>S</i>)-3-(2-Fluorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3aa</b>)</h3><div class="NLM_p last">White solid (yield 84%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −12.766 (<i>c</i> 0.094, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.36–7.32 (m, 4H), 7.23–7.17 (m, 2H), 7.03–7.00 (m, 1.7H), 6.92 (s, 0.3H), 5.59–5.50 (m, 1H), 4.59–4.57 (m, 2H), 4.07–3.92 (m, 2H), 3.75–3.71 (m, 1H), 3.50–3.41 (m, 1H), 2.95–2.93 (m, 4H), 2.81–2.74 (m, 1H), 2.61 (br s, 4H), 2.38 (s, 3H), 2.30 (s, 3H), 2.23 (q, <i>J</i> = 7.6 Hz, 2H), 2.19–2.16 (m, 1H), 1.14 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.6, 159.5, 159.1, 157.8, 157.4, 157.1, 153.8, 153.6, 152.9, 152.6, 147.5, 147.4, 134.4, 134.3, 133.5, 129.5, 129.4, 129.3, 128.8, 128.6, 124.9, 123.3, 123.1, 119.7, 118.7, 118.5, 117.0, 116.9, 103.2, 103.1, 55.8, 55.7, 53.0, 51.9, 51.4, 47.6, 47.2, 47.1, 46.3, 45.7, 44.6, 28.7, 28.0, 27.4, 26.6, 18.1, 18.0, 9.2. HRMS (ESI) for C<sub>31</sub>H<sub>37</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 573.3096. Found: 573.3113. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.61 min, 98.59% purity.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>S</i>)-7-((3-Methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3-(<i>o</i>-tolyl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3ab</b>)</h3><div class="NLM_p last">White solid (yield 85%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −19.149 (<i>c</i> 0.094, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01 (s, 0.6H), 7.99 (s, 0.4H), 7.35–7.32 (m, 2H), 7.31–7.27 (m, 4H), 7.02–7.01 (m, 1.6H), 6.92 (s, 0.4H), 5.57–5.54 (m, 1H), 4.66–4.63 (m, 1H), 4.43–4.39 (m, 1H), 4.08–3.96 (m, 1.7H), 3.76–3.71 (m, 1.3H), 3.50–3.39 (m, 2H), 2.95 (br s, 4H), 2.78–2.74 (m, 1H), 2.62 (br s, 4H), 2.39 (s, 3H), 2.30 (s, 3H), 2.28–2.23 (m, 5H), 2.15–2.13 (m, 1H), 1.12 (t, <i>J</i> = 8.0 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.6, 159.5, 157.9, 157.6, 153.6, 153.5, 152.6, 147.5, 147.4, 140.8, 140.7, 135.9, 135.7, 135.6, 134.4, 134.3, 133.6, 131.4, 128.3, 128.2, 127.5, 127.4, 127.0, 126.9, 126.8, 126.7, 123.2, 123.1, 119.7, 118.6, 118.5, 103.2, 55.8, 52.8, 52.7, 52.1, 52.0, 51.1, 47.6, 47.4, 46.3, 45.7, 44.6, 44.5, 29.0, 28.8, 28.1, 28.0, 27.4, 26.7, 26.6, 18.1, 18.0, 17.9, 17.8, 9.1. HRMS (ESI) for C<sub>32</sub>H<sub>40</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 569.3347. Found: 569.3352. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 10.88 min, 97.36% purity.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>S</i>)-3-(3-Fluorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3ac</b>)</h3><div class="NLM_p last">White solid (yield 81%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −11.475 (<i>c</i> 0.122, MeOH). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.03 (s, 0.6H), 8.02 (s, 0.4H), 7.38–7.35 (m, 3H), 7.32 (s, 0.6H), 7.14–7.06 (m, 2H), 7.01–6.97 (m, 2.4H), 5.51 (q, <i>J</i> = 8.5 Hz, 1H), 4.65–4.58 (m, 2H), 4.07–4.03 (m, 0.6H), 3.96–3.94 (m, 1.4H), 3.73 (t, <i>J</i> = 9.0 Hz, 1H), 3.49–3.40 (m, 1H), 2.92 (br s, 4H), 2.83–2.74 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 3H), 2.30 (s, 3H), 2.25–2.24 (m, 2H), 2.23–2.21 (m, 1H), 1.14 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.5, 163.9, 161.9, 159.7, 159.6, 157.6, 157.2, 153.8, 153.6, 153.2, 152.9, 147.6, 147.5, 143.5, 143.4, 134.3, 134.2, 133.6, 130.4, 130.3, 130.2, 123.3, 123.2, 123.1, 120.8, 119.7, 118.7, 118.6, 113.9, 113.7, 113.5, 112.9, 112.8, 103.1, 55.8, 53.1, 52.1, 52.0, 51.5, 47.6, 47.1, 47.0, 46.3, 45.7, 44.6, 28.7, 28.0, 27.4, 26.6, 18.1, 18.0, 9.2. HRMS (ESI) for C<sub>31</sub>H<sub>37</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 573.3096. Found: 573.3098. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 10.82 min, 98.45% purity.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>S</i>)-3-(4-Fluorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3ad</b>)</h3><div class="NLM_p last">White solid (yield 87%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −14.286 (<i>c</i> 0.070, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.35–7.27 (m, 4H), 7.13–7.07 (m, 2.6H), 7.01–6.99 (m, 1.4H), 5.56–5.50 (m, 1H), 4.60–4.58 (m, 2H), 4.06–4.02 (m, 0.6H), 3.95–3.92 (m, 1.4H), 3.74–3.69 (m, 1H), 3.49–3.41 (m, 1H), 2.93–2.91 (m, 4H), 2.80–2.75 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 3H), 2.29 (s, 3H), 2.23 (q, <i>J</i> = 7.2 Hz, 2H), 1.94–1.92 (m, 1H), 1.14 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 162.2, 160.2, 159.6, 159.5, 157.6, 157.3, 153.7, 153.6, 153.5, 153.1, 147.6, 147.5, 138.1, 134.4, 134.3, 127.5, 127.4, 127.3, 127.2, 123.3, 123.1, 119.7, 118.7, 118.6, 116.3, 116.2, 116.1, 116.0, 103.1, 55.8, 53.1, 52.1, 52.0, 51.5, 47.6, 47.1, 47.0, 46.3, 45.7, 44.6, 28.7, 28.1, 27.4, 26.6, 18.1, 18.0, 14.2, 9.2. HRMS (ESI) for C<sub>31</sub>H<sub>37</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 573.3096. Found: 573.3078. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.84 min, 97.92% purity.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>S</i>)-3-(3-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3ae</b>)</h3><div class="NLM_p last">White solid (yield 89%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −14.063 (<i>c</i> 0.128, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (s, 0.6H), 8.01 (s, 0.4H), 7.34–7.32 (m, 4H), 7.25–7.23 (m, 2H), 7.14 (s, 0.5H), 7.01–6.99 (m, 1.5H), 5.55–5.47 (m, 1H), 4.65–4.56 (m, 2H), 4.07–4.01 (m, 0.6H), 3.95–3.92 (m, 1.4H), 3.75–3.70 (m, 1H), 3.51–3.39 (m, 1H), 2.92 (br s, 4H), 2.84–2.73 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 3H), 2.29 (s, 3H), 2.24 (q, <i>J</i> = 7.2 Hz, 2H), 2.18–2.15 (m, 1H), 1.16 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.6, 159.5, 157.5, 157.2, 153.8, 153.3, 153.2, 152.9, 147.6, 147.5, 143.1, 143.0, 134.8, 134.7, 134.3, 134.2, 133.6, 130.2, 130.1, 127.0, 126.9, 125.6, 123.6, 123.5, 123.2, 123.1, 119.7, 118.7, 118.5, 103.1, 103.0, 55.8, 53.1, 52.1, 52.0, 51.5, 47.6, 47.1, 47.0, 46.3, 45.7, 44.6, 28.7, 28.1, 27.4, 26.6, 18.1, 18.0, 9.2. HRMS (ESI) for C<sub>31</sub>H<sub>37</sub>ClN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 589.2801. Found: 589.2802. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 9.53 min, 97.38% purity.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>S</i>)-3-(4-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3af</b>)</h3><div class="NLM_p last">White solid (yield 82%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −14.583 (<i>c</i> 0.096, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04 (s, 0.6H), 8.02 (s, 0.4H), 7.39–7.33 (m, 5H), 7.03–7.01 (m, 1.6H), 6.93 (s, 0.4H), 7.06–7.00 (m, 1.3H), 5.52 (q, <i>J</i> = 8.0 Hz, 1H), 4.65–4.62 (m, 2H), 4.04–3.94 (m, 1H), 3.77–3.67 (m, 1H), 3.52–3.48 (m, 1H), 2.97 (br s, 4H), 2.77–2.74 (m, 1H), 2.67 (br s, 4H), 2.42 (s, 3H), 2.30 (s, 3H), 2.27–2.23 (m, 3H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.5, 159.6, 159.5, 157.7, 157.6, 157.3, 153.6, 153.3, 153.0, 147.6, 147.5, 140.5, 134.3, 134.2, 133.6, 132.4, 132.3, 129.4, 129.3, 126.7, 126.6, 123.3, 123.1, 119.6, 118.7, 118.6, 103.0, 55.8, 53.1, 52.1, 52.0, 51.5, 47.6, 47.1, 47.0, 46.3, 45.7, 44.6, 28.7, 28.1, 27.4, 26.6, 18.1, 18.0, 9.2. HRMS (ESI) for C<sub>31</sub>H<sub>37</sub>ClN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 589.2801. Found: 589.2804. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 13.49 min, 99.12% purity.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>S</i>)-7-((3-Methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3-(<i>m</i>-tolyl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3ag</b>)</h3><div class="NLM_p last">White solid (yield 88%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −16.000 (<i>c</i> 0.100, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01 (s, 0.6H), 7.99 (s, 0.4H), 7.35–7.27 (m, 3H), 7.15–7.09 (m, 4H), 7.00 (d, <i>J</i> = 9.2 Hz, 1H), 5.54–5.49 (m, 1H), 4.61–4.59 (m, 2H), 4.09–4.04 (m, 0.6H), 3.96–3.93 (m, 1.4H), 3.74–3.70 (m, 1H), 3.44–3.41 (m, 1H), 2.93–2.92 (m, 4H), 2.91–2.75 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 6H), 2.32 (s, 3H), 2.30 (s, 3H), 2.27 (q, <i>J</i> = 5.2 Hz, 2H), 2.23–2.21 (m, 1H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.5, 157.8, 157.4, 153.6, 153.4, 153.1, 147.5, 142.0, 139.4, 134.4, 133.5, 129.1, 127.8, 127.1, 126.2, 126.1, 123.2, 123.0, 119.7, 118.7, 118.5, 103.4, 55.8, 53.0, 52.1, 52.0, 47.3, 46.3, 44.6, 29.8, 28.7, 28.1, 27.4, 26.6, 21.5, 18.1, 9.2. HRMS (ESI) for C<sub>32</sub>H<sub>40</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 569.3347. Found: 569.3352. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 11.43 min, 96.13% purity.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>S</i>)-7-((3-Methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3-(<i>p</i>-tolyl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3ah</b>)</h3><div class="NLM_p last">White solid (yield 78%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −19.672 (<i>c</i> 0.122, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00 (s, 0.6H), 7.98 (s, 0.4H), 7.34–7.31 (m, 2H), 7.22–7.16 (m, 4.7H), 7.12 (s, 0.3H), 7.00–6.99 (m, 1H), 5.54–5.50 (m, 1H), 4.61–4.58 (m, 2H), 4.08–4.04 (m, 0.6H), 3.95–3.91 (m, 1.4H), 3.73–3.69 (m, 1H), 3.46–3.40 (m, 1H), 2.93–2.91 (m, 4H), 2.80–2.74 (m, 1H), 2.57 (br s, 4H), 2.36 (s, 6H), 2.29 (s, 3H), 2.24 (q, <i>J</i> = 7.6 Hz, 2H), 2.21–2.18 (m, 1H), 1.13 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.7, 172.4, 159.6, 159.5, 157.7, 157.4, 153.6, 153.4, 153.1, 147.4, 147.4, 140.5, 139.6, 139.5, 136.9, 136.7, 134.5, 134.4, 133.6, 129.9, 129.8, 125.3, 125.2, 123.2, 123.1, 119.6, 118.7, 118.6, 103.4, 103.3, 55.8, 52.9, 52.1, 52.0, 51.5, 47.6, 47.3, 47.2, 46.3, 45.7, 44.6, 32.1, 29.8, 29.5, 28.7, 28.1, 27.4, 26.6, 22.8, 21.1, 18.1, 18.0, 9.2. HRMS (ESI) for C<sub>32</sub>H<sub>40</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd: 569.3347. Found: 569.3352. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 11.66 min, 98.72% purity.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>S</i>)-3-(2-Methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3ai</b>)</h3><div class="NLM_p last">White solid (yield 81%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −10.000 (<i>c</i> 0.140, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (s, 0.6H), 7.96 (s, 0.4H), 7.35–7.29 (m, 3H), 7.25–7.22 (m, 1H), 7.01–6.98 (m, 3.7H), 6.91 (s, 0.3H), 5.59–5.53 (m, 1H), 4.62–4.60 (m, 2H), 4.08–4.03 (m, 0.5H), 3.96–3.92 (m, 1.5H), 3.85–3.84 (m, 3H), 3.74–3.69 (m, 1H), 3.49–3.44 (m, 1H), 2.93–2.91 (m, 4H), 2.80–2.77 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 3H), 2.30 (s, 3H), 2.26 (q, <i>J</i> = 8.0 Hz, 2H), 2.23–2.21 (m, 1H), 1.13 (t, <i>J</i> = 8.0 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.4, 155.3, 153.5, 153.3, 153.2, 152.9, 147.4, 147.3, 134.6, 134.5, 133.6, 130.3, 129.4, 129.3, 128.9, 123.1, 123.0, 121.3, 119.7, 118.6, 118.5, 112.4, 103.8, 55.9, 55.8, 52.8, 52.1, 52.0, 51.2, 47.6, 47.4, 46.3, 45.8, 44.6, 28.8, 28.1, 28.0, 27.4, 26.7, 26.6, 18.1, 18.0, 9.2. HRMS (ESI) for C<sub>32</sub>H<sub>40</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 585.3296. Found: 585.3293. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.54 min, 99.99% purity.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>S</i>)-3-(3-Methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3aj</b>)</h3><div class="NLM_p last">White solid (yield 84%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −13.000 (<i>c</i> 0.200, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.35–7.28 (m, 3H), 7.05–6.99 (m, 1.7H), 6.95 (s, 0.3H), 6.89–6.83 (m, 3H), 5.56–5.47 (m, 1H), 4.65–4.56 (m, 2H), 4.08–4.04 (m, 0.7H), 3.96–3.94 (m, 1.3H), 3.82 (s, 3H), 3.75–3.70 (m, 1H), 3.49–3.39 (m, 1H), 2.93 (t, <i>J</i> = 4.4 Hz, 4H), 2.80–2.75 (m, 1H), 2.60 (br s, 4H), 2.36 (s, 3H), 2.30 (s, 3H), 2.25 (q, <i>J</i> = 7.2 Hz, 2H), 2.22–2.21 (m, 1H), 1.14 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 160.4, 160.3, 159.6, 159.5, 157.8, 157.4, 153.6, 153.5, 153.3, 153.1, 147.5, 147.4, 143.2, 134.4, 134.3, 133.6, 130.0, 129.9, 123.2, 123.1, 119.7, 118.7, 118.5, 117.7, 112.6, 112.5, 111.7, 111.6, 103.4, 55.8, 55.6, 53.0, 52.1, 52.0, 51.5, 47.6, 47.3, 46.3, 45.7, 44.6, 28.7, 28.1, 27.4, 26.6, 18.1, 18.0, 9.2. HRMS (ESI) for C<sub>32</sub>H<sub>40</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 585.3296. Found: 585.3298. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 9.34 min, 99.42% purity.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (<i>S</i>)-3-(4-Methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3ak</b>)</h3><div class="NLM_p last">White solid (yield 85%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −11.494 (<i>c</i> 0.174, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01 (s, 0.6H), 7.99 (s, 0.4H), 7.34–7.32 (m, 2H), 7.24–7.21 (m, 2H), 7.02–6.99 (m, 2H), 6.95–6.92 (m, 2H), 5.57–5.49 (m, 1H), 4.59–4.57 (m, 2H), 4.06–4.04 (m, 0.6H), 3.95–3.93 (m, 1.4H), 3.81 (s, 3H), 3.73–3.71 (m, 0.6H), 3.46–3.43 (m, 1.6H), 2.93–2.91 (m, 4H), 2.82–2.77 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 3H), 2.30 (s, 3H), 2.24 (q, <i>J</i> = 7.6 Hz, 2H), 2.16–2.15 (m, 1H), 1.14 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.6, 159.5, 158.4, 158.3, 157.8, 157.4, 153.6, 153.4, 153.3, 147.5, 147.4, 134.9, 134.5, 134.4, 133.6, 126.9, 126.8, 123.2, 123.1, 119.6, 118.7, 118.5, 114.7, 103.4, 55.8, 55.7, 52.9, 52.1, 52.0, 51.3, 47.6, 47.2, 46.3, 45.8, 44.6, 28.7, 28.1, 27.4, 26.6, 18.1, 18.0, 9.2. HRMS (ESI) for C<sub>32</sub>H<sub>40</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 585.3296. Found: 585.3300. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 10.48 min, 97.65% purity.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>S</i>)-3-(3-(Difluoromethoxy)phenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3al</b>)</h3><div class="NLM_p last">White solid (yield 89%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −18.750 (<i>c</i> 0.096, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04 (s, 0.6H), 8.03 (s, 0.4H), 7.43–7.32 (m, 3H), 7.20–7.19 (m, 1H), 7.18–7.17 (m, 0.8H), 7.12–6.93 (m, 2.2H), 6.92 (s, 0.3H), 6.72 (s, 0.2H), 6.53 (s, 0.4H), 6.35 (s, 0.1H), 5.53–5.49 (m, 1H), 4.67–4.62 (m, 2H), 4.07–3.93 (m, 2H), 3.76–3.74 (m, 1H), 3.50–3.45 (m, 1H), 2.93–2.91 (m, 4H), 2.80–2.76 (m, 1H), 2.59 (br s, 4H), 2.36 (s, 3H), 2.31 (s, 3H), 2.30–2.28 (m, 2H), 2.26–2.22 (m, 1H), 1.15 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.7, 159.6, 159.6, 157.6, 157.2, 153.8, 153.6, 153.3, 153.0, 151.6, 147.6, 147.5, 143.4, 134.4, 134.3, 133.6, 130.3, 130.2, 123.3, 123.2, 122.2, 122.1, 119.7, 118.7, 118.6, 117.7, 117.6, 116.9, 116.8, 115.9, 113.8, 103.1, 55.8, 53.2, 52.1, 52.0, 51.6, 47.6, 47.1, 47.0, 46.3, 45.7, 44.6, 29.8, 28.7, 28.1, 27.4, 26.6, 18.1, 18.0, 9.2. HRMS (ESI) for C<sub>32</sub>H<sub>38</sub>F<sub>2</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 621.3108. Found: 621.3105. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 10.34 min, 99.71% purity.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>S</i>)-7-((3-Methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3-(3-(trifluoromethoxy)phenyl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1H) -one (<b>3am</b>)</h3><div class="NLM_p last">White solid (yield 86%). [α]<sub class="stack">D</sub><sup class="stack">20</sup>-7.895 (<i>c</i> 0.152, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.05 (s, 0.6H), 8.04 (s, 0.4H), 7.46–7.41 (m, 1H), 7.37–7.34 (m, 2H), 7.33–7.29 (m, 1H), 7.21–7.18 (m, 1H), 7.15–7.13 (m, 1H), 7.08 (s, 0.6H), 7.02–6.98 (m, 1.4H), 5.53–5.49 (m, 1H), 4.68–4.63 (m, 2H), 4.05–4.04 (m, 0.6H), 3.96–3.93 (m, 1.4H), 3.76–3.74 (m, 1H), 3.49–3.47 (m, 1H), 2.98–2.96 (m, 4H), 2.76–2.74 (m, 1H), 2.69 (br s, 4H), 2.45 (s, 3H), 2.32 (s, 3H), 2.24 (q, <i>J</i> = 7.2 Hz, 2H), 2.21–2.20 (m, 1H), 1.12 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.6, 172.3, 159.6, 159.5, 157.5, 157.1, 153.8, 153.6, 153.2, 152.9, 149.5, 147.2, 143.3, 143.2, 134.6, 134.4, 133.5, 130.2, 130.1, 123.5, 123.4, 123.2, 121.5, 119.6, 119.5, 118.9, 118.7, 118.6, 118.0, 117.4, 103.1, 103.0, 55.7, 53.1, 51.6, 51.5, 47.5, 47.1, 46.9, 46.0, 45.7, 44.5, 28.6, 28.0, 27.3, 26.5, 18.0, 17.9, 9.1. HRMS (ESI) for C<sub>32</sub>H<sub>37</sub>F<sub>3</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 639.3014. Found: 639.3020. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 11.14 min, 96.01% purity.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>S</i>)-3-(2-Fluoro-3-methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3an</b>)</h3><div class="NLM_p last">White solid (yield 87%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −17.308 (<i>c</i> 0.104, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00 (s, 0.6H), 7.98 (s, 0.4H), 7.35–7.33 (m, 2H), 7.22 (s, 0.6H), 7.11–7.09 (m, 1.4H), 7.00–6.89 (m, 3H), 5.58–5.51 (m, 1H), 4.57–4.52 (m, 2H), 4.06–4.02 (m, 0.7H), 3.99–3.90 (m, 4.3H), 3.74–3.70 (m, 1H), 3.51–3.39 (m, 1H), 2.92 (br s, 4H), 2.78–2.73 (m, 1H), 2.58 (br s, 4H), 2.36 (s, 3H), 2.28–2.24 (m, 5H), 2.22–2.20 (m, 1H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.6, 159.5, 157.8, 157.4, 153.7, 153.6, 152.8, 152.5, 149.5, 149.0, 148.9, 147.5, 147.4, 134.4, 134.3, 133.5, 130.1, 124.2, 124.1, 123.2, 123.1, 119.9, 119.7, 118.7, 118.5, 112.9, 103.2, 103.1, 56.7, 55.8, 52.9, 52.1, 52.0, 51.3, 47.6, 47.2, 46.3, 45.7, 44.6, 29.8, 28.8, 27.4, 26.6, 18.1, 18.0, 9.1. HRMS (ESI) for C<sub>32</sub>H<sub>39</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 603.3202. Found: 603.3197. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.95 min, 98.91% purity.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3ao</b>)</h3><div class="NLM_p last">White solid (yield 88%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −22.222 (<i>c</i> 0.100, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00 (s, 0.6H), 7.98 (s, 0.4H), 7.35–7.31 (m, 2H), 7.27 (s, 0.7H), 7.16 (s, 0.3H), 7.08–7.06 (m, 1H), 7.00–6.98 (m, 1H), 6.84–6.80 (m, 2H), 5.58–5.49 (m, 1H), 4.60–4.55 (m, 2H), 4.06–4.02 (m, 0.6H), 3.96–3.92 (m, 1.4H), 3.78–3.70 (m, 4H), 3.49–3.38 (m, 1H), 2.93–2.91 (m, 4H), 2.82–2.73 (m, 1H), 2.59 (br s, 4H), 2.36 (s, 3H), 2.28–2.25 (m, 5H), 2.24–2.22 (m, 1H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.6, 159.5, 157.7, 157.4, 153.7, 153.6, 153.4, 152.8, 152.6, 151.5, 147.5, 147.4, 134.4, 134.3, 133.5, 129.7, 129.5, 123.2, 123.1, 119.6, 118.7, 118.5, 117.2, 117.0, 114.6, 114.5, 114.4, 114.3, 113.7, 113.6, 103.2, 103.1, 56.0, 55.8, 53.0, 52.1, 52.0, 51.3, 47.6, 47.2, 47.1, 46.3, 45.7, 44.6, 29.8, 28.7, 28.0, 27.4, 26.6, 18.1, 18.0, 9.1. HRMS (ESI) for C<sub>32</sub>H<sub>39</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 603.3202. Found: 603.3195. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 10.23 min, 99.24% purity.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>S</i>)-3-(2-Chloro-3-methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3ap</b>)</h3><div class="NLM_p last">White solid (yield 89%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −22.973 (<i>c</i> 0.148, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (s, 0.6H), 8.01 (s, 0.4H), 7.39–7.29 (m, 3.3H), 7.03 (s, 0.7H), 7.00–6.97 (m, 3H), 5.60–5.52 (m, 1H), 4.66–4.63 (m, 1H), 4.51–4.48 (m, 1H), 3.98–3.94 (m, 5H), 3.77–3.75 (m, 1H), 3.47–3.38 (m, 1H), 2.96–2.94 (m, 4H), 2.78–2.76 (m, 1H), 2.62 (br s, 4H), 2.39 (s, 3H), 2.32–2.25 (m, 5H), 2.24–2.20 (m, 1H), 1.12 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.5, 159.4, 157.8, 156.6, 153.8, 153.7, 147.5, 140.5, 134.4, 133.6, 128.1, 123.3, 123.2, 121.0, 119.7, 118.6, 111.9, 103.1, 56.8, 55.8, 52.8, 52.1, 52.0, 51.2, 51.0, 47.6, 47.0, 46.3, 44.6, 29.1, 28.1, 27.4, 26.7, 18.1, 9.2. HRMS (ESI) for C<sub>32</sub>H<sub>39</sub>ClN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 619.2906. Found: 619.2885. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 10.65 min, 97.52% purity.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>S</i>)-3-(2-Chloro-5-methoxyphenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3aq</b>)</h3><div class="NLM_p last">White solid (yield 83%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −41.071 (<i>c</i> 0.112, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.40–7.32 (m, 3H), 7.03–6.99 (m, 1.6H), 6.89 (s, 0.4H), 6.88–6.85 (m, 2H), 5.58–5.49 (m, 1H), 4.64–4.60 (m, 1H), 4.49–4.46 (m, 1H), 4.03–3.99 (m, 2H), 3.80 (s, 1H), 3.75–3.73 (m, 1H), 3.49–3.42 (m, 1H), 2.94–2.92 (m, 4H), 2.78–2.73 (m, 1H), 2.59 (br s, 4H), 2.37 (s, 3H), 2.30 (s, 3H), 2.26 (q, <i>J</i> = 7.6 Hz, 2H), 2.22–2.21 (m, 1H), 1.12 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.6, 172.4, 159.6, 159.4, 157.7, 157.4, 153.7, 153.6, 152.5, 152.3, 152.1, 147.4, 147.2, 139.6, 134.4, 134.3, 133.4, 130.9, 124.1, 123.8, 123.2, 123.1, 119.5, 118.6, 118.5, 115.6, 115.3, 114.9, 114.8, 102.9, 55.8, 55.7, 52.7, 52.0, 51.9, 51.0, 47.5, 47.0, 46.2, 45.7, 44.5, 28.9, 28.7, 28.0, 27.3, 26.6, 18.1, 18.0, 9.1. HRMS (ESI) for C<sub>32</sub>H<sub>39</sub>ClN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 619.2906. Found: 619.2902. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 12.56 min, 97.72% purity.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3ba</b>)</h3><div class="NLM_p last">White solid (yield 82%). [α]<sub class="stack">D</sub><sup class="stack">20</sup>+8.333 (<i>c</i> 0.072, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99 (s, 0.6H), 7.97 (s, 0.4H), 7.39–7.37 (m, 2H), 7.15 (s, 0.6H), 7.11–7.03 (m, 1.4H), 6.90–6.88 (m, 2H), 6.87–6.83 (m, 2H), 5.47 (q, <i>J</i> = 8.5 Hz, 1H), 4.60–4.51 (m, 2H), 4.09–4.05 (m, 0.6H), 3.92–3.91 (m, 1.4H), 3.78 (s, 3H), 3.71–3.66 (m, 1H), 3.54–3.52 (m, 1H), 3.42–3.37 (m, 1H), 3.19 (br s, 4H), 2.79–2.77 (m, 1H), 2.60 (br s, 4H), 2.36 (s, 3H), 2.24 (q, <i>J</i> = 7.2 Hz, 2H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.6, 172.4, 159.8, 159.7, 157.6, 157.2, 156.1, 153.7, 153.5, 153.4, 152.9, 152.6, 151.4, 147.8, 147.7, 134.5, 134.4, 129.6, 129.5, 122.3, 121.8, 117.1, 116.9, 116.7, 116.5, 114.5, 114.4, 114.3, 113.7, 113.6, 102.8, 65.8, 55.9, 55.2, 55.1, 52.8, 51.2, 49.6, 49.4, 47.1, 47.0, 46.1, 46.0, 45.6, 44.4, 42.0, 30.2, 29.7, 29.2, 28.4, 27.9, 27.3, 26.2, 23.4, 23.1, 14.1, 11.1, 9.1. HRMS (ESI) for C<sub>31</sub>H<sub>37</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 589.3045. Found: 589.3040. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.12 min, 97.35% purity.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((2-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bb</b>)</h3><div class="NLM_p last">White solid (yield 80%). [α]<sub class="stack">D</sub><sup class="stack">20</sup>+8.108 (<i>c</i> 0.074, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.97 (s, 0.6H), 7.96 (s, 0.4H), 7.44–7.39 (m, 1H), 7.09–7.08 (m, 1H), 6.83–6.78 (m, 4H), 6.61 (s, 0.6H), 6.53 (s, 0.4H), 5.46–5.39 (m, 1H), 4.59–4.49 (m, 2H), 4.01–3.97 (m, 0.5H), 3.87–3.85 (m, 1H), 3.79 (s, 3H), 3.63–3.61 (m, 1H), 3.54 (s, 0.5H), 3.39–3.36 (m, 1H), 3.20 (br s, 4H), 2.72–2.70 (m, 1H), 2.60 (br s, 4H), 2.36 (s, 3H), 2.27 (s, 3H), 2.26–2.20 (m, 3H), 1.12 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.5, 172.4, 160.8, 160.7, 157.7, 157.5, 156.2, 153.9, 153.8, 153.0, 153.0, 152.8, 152.5, 151.5, 149.2, 133.6, 133.0, 129.7, 129.2, 128.9, 126.4, 125.9, 118.7, 117.2, 117.0, 114.5, 114.4, 114.3, 114.2, 113.7, 113.6, 102.7, 56.0, 55.3, 55.2, 52.7, 51.1, 49.4, 49.2, 47.2, 47.0, 46.7, 46.2, 46.1, 45.4, 44.3, 28.2, 28.0, 27.2, 26.1, 18.7, 9.2, 9.1. HRMS (ESI) for C<sub>32</sub>H<sub>39</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 603.3202. Found: 603.3202. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.36 min, 96.26% purity.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bc</b>)</h3><div class="NLM_p last">White solid (yield 83%). [α]<sub class="stack">D</sub><sup class="stack">20</sup>+9.836 (<i>c</i> 0.122, MeOH). 8.01–7.99 (m, 2H), 7.41–7.40 (m, 0.6H), 7.30–7.29 (m, 0.4H), 7.08–7.05 (m, 1H), 6.83–6.80 (m, 2H), 6.54–6.49 (m, 2H), 5.58–5.53 (m, 1H), 4.59–4.51 (m, 2H), 4.16–4.12 (m, 1H), 4.00–3.96 (m, 4H), 3.88–3.68 (m, 4H), 3.48–3.44 (m, 1H), 3.18 (br s, 4H), 2.91 (s, 0.5H), 2.89 (s, 0.5H), 2.59 (br s, 4H), 2.35 (s, 3H), 2.27 (q, <i>J</i> = 7.5 Hz, 2H), 2.14–2.11 (m, 1H), 1.12 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.7, 172.4, 160.0, 159.4, 157.6, 157.4, 156.2, 153.8, 153.6, 153.5, 153.0, 152.7, 151.5, 150.0, 147.9, 147.8, 129.7, 129.6, 123.7, 121.5, 120.9, 120.4, 117.2, 117.0, 114.6, 114.5, 114.4, 114.3, 113.7, 113.6, 108.1, 107.9, 102.9, 102.8, 100.6, 100.3, 56.0, 55.8, 55.3, 55.2, 52.9, 51.2, 50.1, 49.9, 47.3, 47.2, 46.8, 46.2, 45.8, 44.3, 32.0, 30.3, 29.7, 29.0, 28.4, 28.1, 27.7, 15.2, 9.1. HRMS (ESI) for C<sub>32</sub>H<sub>39</sub>FN<sub>8</sub>O<sub>4</sub> [M + H]<sup>+</sup>, calcd: 619.3151. Found: 619.3144. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.58 min, 97.14% purity.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2 (1<i>H</i>)-one (<b>3bd</b>)</h3><div class="NLM_p last">White solid (yield 87%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −15.190 (<i>c</i> 0.158, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (s, 0.6H), 8.01 (s, 0.4H), 7.18–7.15 (m, 0.6H), 7.12–7.06 (m, 3H), 6.98 (s, 0.4H), 6.91–6.90 (m, 1H), 6.85–6.83 (m, 2H), 5.70–5.60 (m, 1H), 4.61–4.52 (m, 2H), 4.04–3.92(m, 2H), 3.87 (s, 3H), 3.78 (s, 3H), 3.76–3.71 (m, 1H), 3.50–3.38 (m, 2H), 3.11 (br s, 4H), 2.80–2.75 (m, 1H), 2.69 (br s, 4H), 2.40 (s, 3H), 2.28 (t, <i>J</i> = 7.6 Hz, 2H), 1.13 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.5, 159.6, 159.4, 157.7, 157.3, 156.2, 153.7, 153.6, 153.5, 152.9, 152.7, 152.5, 151.6, 137.4, 137.3, 134.6, 129.7, 129.5, 118.5, 117.2, 117.0, 114.6, 114.5, 114.4, 113.8, 113.7, 112.9, 112.5, 105.7, 104.8, 103.3, 56.0, 55.7, 55.6, 55.5, 52.9, 51.2, 50.9, 50.8, 47.9, 47.2, 47.1, 46.2, 45.7, 44.7, 32.0, 31.6, 30.3, 29.8, 29.5, 28.7, 28.1, 27.4, 26.7, 15.1, 9.0. HRMS (ESI) for C<sub>32</sub>H<sub>39</sub>FN<sub>8</sub>O<sub>4</sub> [M + H]<sup>+</sup>, calcd: 619.3151. Found: 619.3095. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.64 min, 99.09% purity.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>S</i>)-7-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3be</b>)</h3><div class="NLM_p last">White solid (yield 86%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −10.938 (<i>c</i> 0.128, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04 (s, 0.6H), 8.02 (s, 0.4H), 7.55–7.54 (m, 0.5H), 7.51–7.50 (m, 0.5H), 7.19–7.07 (m, 3H), 6.93–6.89 (m, 1H), 6.85–6.83 (m, 2H), 5.60–5.45 (m, 1H), 4.62–4.54 (m, 2H), 4.05–3.91 (m, 2H), 3.79–3.73 (m, 4H), 3.53–3.37 (m, 1H), 3.11 (br s, 4H), 2.84–2.73 (m, 1H), 2.63 (br s, 4H), 2.37 (s, 3H), 2.27 (t, <i>J</i> = 7.6 Hz, 3H), 2.22–2.17 (m, 1H), 1.13 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 173.0, 172.6, 159.2, 159.1, 157.8, 157.4, 153.6, 153.5, 153.4, 152.8, 152.6, 151.5, 135.7, 135.6, 129.6, 129.5, 119.4, 119.3, 119.2, 119.1, 117.2, 117.0, 115.7, 114.6, 114.5, 114.4, 114.3, 113.7, 113.6, 108.9, 108.8, 108.7, 108.6, 103.7, 103.6, 56.0, 55.3, 53.1, 51.6, 50.9, 47.9, 47.2, 47.0, 46.2, 45.7, 44.8, 32.0, 31.6, 30.3, 29.8, 28.5, 28.1, 27.4, 26.7, 18.2, 18.1, 15.1, 9.1. HRMS (ESI) for C<sub>31</sub>H<sub>36</sub>F<sub>2</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 607.2951. Found: 607.2947. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.72 min, 98.92% purity.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (<i>S</i>)-7-((3-Chloro-4-(4-methylpiperazin-1-yl)phenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bf</b>)</h3><div class="NLM_p last">White solid (yield 80%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −25.758 (<i>c</i> 0.132, MeOH). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.05 (s, 0.6H), 8.03 (s, 0.4H), 7.84–7.83 (m, 1H), 7.38–7.37 (m, 0.7H), 7.28–7.27 (m, 1.3H), 7.13–7.09 (m, 1H), 7.04–7.02 (m, 1H), 6.86–6.80 (m, 2H), 5.59–5.50 (m, 1H), 4.60–4.57 (m, 2H), 4.06–3.95 (m, 2H), 3.81–3.80 (m, 4H), 3.54–3.43 (m, 1H), 3.07 (br s, 4H), 2.81–2.79 (m, 1H), 2.64 (br s, 4H), 2.38 (s, 3H), 2.32–2.22 (m, 3H), 1.13 (t, <i>J</i> = 5.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.9, 172.5, 159.2, 159.1, 157.9, 157.5, 156.2, 156.1, 153.7, 153.6, 153.5, 152.8, 152.4, 151.5, 144.8, 144.7, 135.2, 135.0, 129.6, 129.5, 129.1, 122.3, 122.2, 120.7, 120.6, 119.2, 119.1, 117.2, 117.0, 114.6, 114.5, 114.4, 114.3, 113.8, 113.7, 103.8, 103.7, 56.0, 55.4, 53.1, 51.6, 51.5, 51.4, 47.8, 47.2, 47.0, 46.2, 45.7, 44.6, 32.0, 31.6, 30.3, 29.8, 29.5, 28.7, 28.1, 27.4, 26.7, 18.8, 18.2, 18.1, 9.1. HRMS (ESI) for C<sub>31</sub>H<sub>36</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 623.2656. Found: 623.2653. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 10.95 min, 97.73% purity.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bg</b>)</h3><div class="NLM_p last">White solid (yield 88%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −20.588 (<i>c</i> 0.068, MeOH). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.05 (s, 0.6H), 8.03 (s, 0.4H), 8.00 (s, 1H), 7.64–7.63 (m, 0.4H), 7.58–7.56 (m, 0.4H), 7.54–7.53 (m, 0.6H), 7.52–7.49 (m, 1.6H), 7.10–7.08 (m, 1H), 6.84–6.83 (m, 2H), 5.60–5.50 (m, 1H), 4.60–4.58 (m, 2H), 4.23–4.22 (m, 0.2H), 4.00–3.98 (m, 1.2H), 3.94–3.92 (m, 0.6H), 3.78–3.77 (m, 4H), 3.51–3.41 (m, 1H), 2.93 (br s, 4H), 2.80–2.70 (m, 0.5H), 2.68–2.66 (m, 0.5H), 2.57 (br s, 4H), 2.36 (s, 3H), 2.30–2.24 (m, 3H), 1.13 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 173.0, 172.6, 159.1, 159.0, 157.7, 157.5, 153.7, 156.2, 153.7, 153.6, 153.5, 152.7, 152.3, 151.6, 147.4, 147.3, 136.3, 129.5, 127.9, 125.0, 124.9, 124.1, 123.6, 123.5, 118.3, 117.2, 117.0, 114.7, 114.6, 114.5, 114.4, 113.8, 113.7, 103.2, 104.1, 80.2, 65.8, 56.0, 55.6, 53.6, 53.1, 51.6, 48.2, 47.2, 46.3, 45.7, 44.8, 33.3, 32.1, 31.8, 31.6, 31.4, 30.4, 29.8, 29.5, 28.7, 28.1, 27.4, 26.9, 26.8, 26.6, 18.2, 18.1, 9.1. HRMS (ESI) for C<sub>32</sub>H<sub>36</sub>F<sub>4</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 657.2919. Found: 657.2919. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 12.57 min, 98.79% purity.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (<i>S</i>)-7-((3-Ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bh</b>)</h3><div class="NLM_p last">White solid (yield 89%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −14.063 (<i>c</i> 0.128, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (m, 0.6H), 8.01 (s, 0.4H), 7.41–7.32 (m, 2H), 7.10–7.07 (m, 2.6H), 6.96 (m, 0.4H), 6.85–6.84 (m, 2H), 5.61–5.55 (m, 1H), 4.58–4.56 (m, 2H), 4.08–3.92 (m, 2H), 3.79–3.65 (m, 4H), 3.50–3.41 (m, 1H), 2.92 (br s, 4H), 2.78–2.75 (m, 1H), 2.70 (q, <i>J</i> = 6.4 Hz, 2H), 2.60 (br s, 4H), 2.37 (s, 3H), 2.28 (q, <i>J</i> = 7.2 Hz, 2H), 2.24–2.22 (m, 1H), 1.24 (t, <i>J</i> = 6.4 Hz, 3H), 1.12 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.5, 159.4, 157.4, 156.2, 153.7, 153.6, 152.8, 152.5, 151.5, 147.0, 146.9, 140.3, 135.2, 135.1, 129.6, 129.5, 121.0, 120.9, 118.5, 118.4, 117.2, 117.0, 114.4, 114.3, 113.7, 113.6, 103.1, 56.0, 55.9, 55.8, 52.9, 52.8, 52.7, 51.3, 47.6, 47.2, 46.2, 46.1, 45.7, 44.6, 28.7, 28.0, 27.4, 26.6, 23.7, 19.1, 15.0, 13.8, 9.1. HRMS (ESI) for C<sub>33</sub>H<sub>41</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 617.3358. Found: 617.3347. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 13.64 min, 96.90% purity.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-isopropyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bi</b>)</h3><div class="NLM_p last">White solid (yield 83%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −21.429 (<i>c</i> 0.140, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (m, 0.6H), 8.00 (s, 0.4H), 7.44–7.28 (m, 3H), 7.11–7.06 (m, 2H), 6.85–6.81 (m, 2H), 5.63–5.59 (m, 1H), 4.60–4.57 (m, 2H), 4.07–3.98 (m, 1H), 3.95–3.86 (m, 2H), 3.78–3.72 (m, 4H), 3.49–3.40 (m, 2H), 2.97 (br s, 4H), 2.86–2.74 (m, 4H), 2.37 (s, 3H), 2.33–2.23 (m, 2H), 2.22–2.21 (m, 1H), 1.21 (d, <i>J</i> = 2.4 Hz, 6H), 1.12 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.7, 159.3, 157.6, 153.7, 156.1, 153.6, 153.2, 152.7, 152.4, 151.3, 145.5, 145.4, 145.1, 136.3, 136.2, 129.5, 129.4, 121.3, 121.2, 118.3, 118.1, 118.0, 117.0, 114.7, 114.4, 113.5, 103.1, 103.0, 55.9, 55.4, 52.5, 52.1, 51.1, 47.4, 47.3, 47.0, 45.7, 45.2, 45.1, 44.5, 28.6, 27.9, 27.2, 26.9, 26.4, 24.0, 23.9, 9.1, 9.0. HRMS (ESI) for C<sub>34</sub>H<sub>43</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 631.3515. Found: 631.3481. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 14.76 min, 98.01% purity.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(piperidin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bj</b>)</h3><div class="NLM_p last">White solid (yield 85%). [α]<sub class="stack">D</sub><sup class="stack">20</sup>-6.154 (<i>c</i> 0.260, MeOH). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.00 (s, 0.6H), 7.97 (s, 0.4H), 7.36–7.28 (m, 3H), 7.09 (s, 0.2H), 7.07–7.06 (m, 0.8H), 6.98–6.96 (m, 1H), 6.83–6.82 (m, 2H), 5.57–5.49 (m, 1H), 4.56–4.55 (m, 2H), 4.06–4.04 (m, 0.5H), 3.94–3.91 (m, 1.5H), 3.78 (s, 3H), 3.77–3.72 (m, 1H), 3.50–3.38 (m, 1H), 2.81–2.77 (m, 5H), 2.37–2.30 (m, 0.3H), 2.29 (s, 3H), 2.24 (q, <i>J</i> = 7.0 Hz, 2H), 2.19–2.15 (m, 0.7H), 1.71–1.69 (m, 4H), 1.56–1.55 (m, 2H), 1.13 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 159.5, 159.4, 157.7, 157.5, 156.1, 153.5, 153.4, 153.2, 152.8, 152.5, 151.5, 149.0, 148.9, 133.8, 133.7, 133.5, 133.4, 129.6, 129.4, 129.3, 123.3, 123.0, 119.4, 118.7, 118.4, 117.4, 116.9, 115.6, 114.5, 114.4, 114.3, 113.7, 113.6, 56.0, 53.7, 53.6, 52.9, 51.3, 47.3, 47.1, 45.6, 44.7, 38.7, 29.7, 28.6, 27.9, 27.3, 26.7, 26. 4, 24.5, 24.4, 18.0, 17.9, 9.3, 9.0. HRMS (ESI) for C<sub>32</sub>H<sub>38</sub>FN<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 588.3093. Found: 588.3037. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 11.44 min, 96.03% purity.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-morpholinophenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bk</b>)</h3><div class="NLM_p last">White solid (yield 86%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −17.143 (<i>c</i> 0.140, MeOH). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.01 (s, 0.6H), 7.99 (s, 0.4H), 7.38–7.31 (m, 2.7H), 7.09–7.07 (m, 0.3H), 7.06–7.05 (m, 1H), 7.00–6.97 (m, 1H), 6.84–6.81 (m, 2H), 5.57–5.51 (m, 1H), 4.57–4.55 (m, 2H), 4.07–4.03 (m, 0.6H), 3.96–3.92 (m, 1.4H), 3.85–3.83 (m, 4H), 3.78–3.77 (m, 3H), 3.74–3.72 (m, 1H), 3.43–3.41 (m, 1H), 2.89–2.87 (m, 4H), 2.79–2.77 (m, 1H), 2.31 (s, 3H), 2.28 (q, <i>J</i> = 12.0 Hz, 2H), 2.23–2.21 (m, 1H), 1.13 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.4, 159.5, 159.4, 157.7, 157.4, 156.1, 153.6, 153.5, 153.4, 152.8, 152.5, 151.5, 147.2, 147.0, 134.7, 134.6, 133.5, 129.9, 129.5, 123.2, 123.1, 119.5, 118.6, 118.5, 117.1, 117.0, 114.6, 114.5, 114.4, 114.3, 113.7, 113.6, 103.2, 103.1, 67.5, 56.0, 52.9, 52.6, 52.5, 51.3, 47.4, 47.2, 45.7, 44.5, 28.7, 28.0, 27.4, 26.5, 18.1, 18.0, 9.1. HRMS (ESI) for C<sub>31</sub>H<sub>36</sub>FN<sub>7</sub>O<sub>4</sub> [M + H]<sup>+</sup>, calcd: 590.2886. Found: 590.2884. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 9.38 min, 96.49% purity.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (<i>S</i>)-7-((4-(4-Acetylpiperazin-1-yl)-3-methylphenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bl</b>)</h3><div class="NLM_p last">White solid (yield 89%). [α]<sub class="stack">D</sub><sup class="stack">20</sup>-6.316 (<i>c</i> 0.190, MeOH). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.01 (s, 0.6H), 8.00 (s, 0.4H), 7.37–7.29 (m, 2H), 7.28 (s, 0.5H), 7.22 (s, 0.5H), 7.09–7.07 (m, 1H), 6.97–6.95 (m, 1H), 6.84–6.80 (m, 2H), 5.58–5.55 (m, 1H), 4.57–4.54 (m, 2H), 4.06–4.04 (m, 0.6H), 3.93–3.92 (m, 1.4H), 3.78–3.71 (m, 6H), 3.60–3.58 (m, 2H), 3.56–3.54 (m, 1H), 3.13–3.11 (m, 2H), 2.78–2.59 (m, 3H), 2.32–2.30 (m, 3H), 2.28–2.21 (m, 3H), 2.21 (s, 3H), 1.13 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.8, 172.4, 169.3, 159.6, 159.5, 157.7, 157.3, 156.1, 153.7, 153.5, 153.4, 152.8, 152.5, 151.4, 148.0, 147.9, 134.1, 134.0, 133.5, 133.4, 129.6, 129.5, 123.2, 123.0, 119.4, 118.6, 118.3, 117.1, 116.9, 115.7, 114.5, 114.4, 114.3, 114.2, 113.7, 113.6, 102.9, 62.3, 62.2, 56.0, 52.9, 52.1, 51.3, 47.3, 47.1, 45.6, 44.5, 41.8, 29.2, 28.6, 27.9, 27.3, 26.4, 21.4, 18.0, 9.1. HRMS (ESI) for C<sub>33</sub>H<sub>39</sub>FN<sub>8</sub>O<sub>4</sub> [M + H]<sup>+</sup>, calcd: 631.3151. Found: 631.3134. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 16.96 min, 98.90% purity.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(4-methyl-1,4-diazepan-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2 (1<i>H</i>)-one (<b>3bm</b>)</h3><div class="NLM_p last">White solid (yield 84%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −23.684 (<i>c</i> 0.076, MeOH). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.01 (s, 0.6H), 7.99 (s, 0.4H), 7.32–7.29 (m, 2H), 7.19–7.18 (m, 0.6H), 7.09–7.07 (m, 1.4H), 7.03–7.01 (m, 1H), 6.84–6.82 (m, 2H), 5.58–5.54 (m, 1H), 4.57–4.54 (m, 2H), 4.05–3.96 (m, 0.6H), 3.94–3.92 (m, 1.4H), 3.80 (s, 3H), 3.78–3.72 (m, 1H), 3.69–3.54 (m, 1H), 3.19–3.17 (m, 2H), 3.15–3.12 (m, 2H), 2.79–2.72 (m, 5H), 2.41 (s, 3H), 2.30 (s, 3H), 2.29–2.21 (m, 3H), 1.99–1.93 (m, 2H), 1.13 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.4, 159.6, 159.5, 157.7, 157.4, 153.6, 153.4, 152.8, 149.9, 149.8, 133.9, 133.8, 133.5, 129.6, 129.5, 123.1, 123.0, 121.4, 121.1, 118.7, 118.5, 117.1, 117.0, 114.4, 114.3, 113.7, 113.6, 103.1, 103.0, 57.0, 56.0, 55.2, 55.0, 54.5, 54.4, 52.9, 51.3, 47.4, 47.2, 47.1,47.0, 45.7, 44.5, 29.8, 28.7, 28.4, 28.3, 28.0, 27.4, 26.5, 19.0, 18.9, 9.1. HRMS (ESI) for C<sub>33</sub>H<sub>41</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 617.3358. Found: 617.3343. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 25.42 min, 99.41% purity.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (<i>S</i>)-7-((4-(4-(Dimethylamino)piperidin-1-yl)-3-methylphenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bn</b>)</h3><div class="NLM_p last">White solid (yield 77%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −13.636 (<i>c</i> 0.176, MeOH). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.00 (s, 0.6H), 7.98 (s, 0.4H), 7.37–7.36 (m, 0.6H), 7.35–7.30 (m, 1.4H), 7.28–7.27 (m, 0.8H), 7.09–7.07 (m, 1.2H), 6.97–6.95 (m, 1H), 6.86–6.82 (m, 2H), 5.56–5.51 (m, 1H), 4.56–4.54 (m, 2H), 4.06–4.04 (m, 0.6H), 3.93–3.91 (m, 1.4H), 3.78–3.71 (m, 4H), 3.46–3.44 (m, 1H), 3.13–3.11 (m, 2H), 2.81–2.77 (m, 1H), 2.64–2.59 (m, 2H), 2.32 (s, 6H), 2.30–2.24 (m, 2H), 2.23–2.21 (m, 1H), 1.92–1.89 (m, 2H), 1.67–1.65 (m, 2H), 1.31–1.13 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.4, 159.5, 159.4, 157.7, 157.5, 156.1, 153.5, 153.4, 153.3, 152.8, 152.5, 151.5, 149.0, 148.9, 133.8, 133.7, 133.5, 133.4, 129.6, 129.4, 123.3, 123.0, 119.4, 118.7, 118.4, 117.1, 116.9, 115.7, 114.6, 114.5, 114.4, 114.3, 113.7, 113.6, 102.8, 56.0, 53,7, 53.6, 52.9, 51.3, 47.3, 47.1, 45.7, 44.5, 38.7, 29.7, 28.6, 28.0, 27.3, 26.7, 26.4, 24.5, 24.4, 18.0, 17.9, 9.3, 9.1. HRMS (ESI) for C<sub>34</sub>H<sub>43</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 631.3515. Found: 631.3478. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 19.95 min, 96.89% purity.</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)phenyl)amino)-1-((<i>S</i>)-1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bo</b>)</h3><div class="NLM_p last">White solid (yield 76%). [α]<sub class="stack">D</sub><sup class="stack">20</sup>-9.615 (<i>c</i> 0.104, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00 (s, 0.6H), 7.98 (s, 0.4H), 7.23–7.20 (m, 2H), 7.10–6.93 (m, 1H), 6.85–6.80 (m, 4H), 5.58–5.51 (m, 1H), 4.57–4.55 (m, 2H), 4.06–3.91 (m, 2H), 3.79–3.71 (m, 4H), 3.49–3.42 (m, 1H), 3.27–3.10 (m, 4H), 2.65–2.63 (m, 1H), 2.53–2.51 (m, 4H), 2.36 (s, 3H), 2.30 (s, 3H), 2. 28–2.23 (m, 3H), 2.00–1.90 (m, 4H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.3, 159.8, 157.4, 156.1, 153.8, 153.6, 152.9, 145.7, 131.6, 129.3, 124.7, 124.5, 119.2, 118.9, 117.1, 117.0, 115.9, 115.8, 114.4, 113.7, 113.6, 102.7, 68.1, 68.0, 63.9, 63.8, 56.3, 56.0, 52.9, 51.3, 50.7, 50.6, 48.6, 47.5, 47.2, 47.1, 45.7, 44.4, 38.9, 37.8, 37.7, 37.6, 28.7, 28.0, 27.4, 26.4, 20.6, 20.5, 9.1. HRMS (ESI) for C<sub>35</sub>H<sub>43</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 643.3515. Found: 643.3512. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 19.29 min, 97.11% purity.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(9-methyl-3,9-diazaspiro[5.5]undecan-3-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bp</b>)</h3><div class="NLM_p last">White solid (yield 78%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −15.789 (<i>c</i> 0.076, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01 (s, 0.6H), 7.99 (s, 0.4H), 7.38–7.30 (m, 2H), 7.10–6.95 (m, 3H), 6.85–6.82 (m, 2H), 5.56–5.52 (m, 1H), 4.58–4.55 (m, 2H), 4.06–3.92 (m, 2H), 3.79–3.72 (m, 4H), 3.47–3.45 (m, 1H), 2.82–2.80 (m, 5H), 2.39–2.32(m, 4H), 2.29–2.21 (m, 9H), 1.62–1.61 (m, 8H), 1.12 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.3, 159.6, 159.5, 157.7, 157.4, 156.1, 153.7, 153.6, 153.6, 152.8, 152.5, 148.4, 148.3, 134.0, 133.9, 133.4, 133.3, 123.3, 123.0, 119.3, 118.6, 118.3, 117.1, 117.0, 114.4, 114.3, 113.7, 113.6, 103.0, 102.9, 56.0, 52.9, 51.4, 51.3, 48.2, 48.1, 47.4, 47.2, 47.1, 46.4, 45.6, 44.5, 36.1, 28.7, 28.6, 28.0, 27.3, 26.5, 18.0, 17.9, 9.1. HRMS (ESI) for C<sub>37</sub>H<sub>47</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 671.3828. Found: 671.3833. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 34.80 min, 99.86% purity.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bq</b>)</h3><div class="NLM_p last">White solid (yield 89%). [α]<sub class="stack">D</sub><sup class="stack">20</sup>-4.819 (<i>c</i> 0.166, MeOH). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.01 (s, 0.6H), 7.99 (s, 0.4H), 7.36–7.30 (m, 2H), 7.12–7.10 (m, 1H), 7.08–6.91 (m, 2H), 6.83–6.83 (m, 2H), 5.58–5.51 (m, 1H), 4.58–4.55 (m, 2H), 4.07–3.92 (m, 2H), 3.79–3.71 (m, 4H), 3.49–3.42 (m, 1H), 3.09–3.08 (m, 4H), 2.79–2.75 (m, 5H), 2.36 (s, 3H), 2. 92–2.16 (m, 6H), 1.89–1.86 (m, 4H), 1.12 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.3, 159.6, 159.5, 157.7, 157.4, 156.1, 153.7, 153.6, 153.5, 152.8, 152.6, 151.5, 148.2, 134.1, 133.6, 129.6, 123.2, 122.9, 119.5, 118.6, 118.3, 117.2, 117.0, 114.4, 113.7, 113.6, 103.0, 66.6, 56.0, 52.9, 51.3, 49.8, 47.5, 47.2, 46.4, 45.7, 44.5, 37.0, 33.9, 28.7, 28.0, 27.4, 26.5, 18.0, 9.1. HRMS (ESI) for C<sub>35</sub>H<sub>43</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 643.3515. Found: 643.3516. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 27.79 min, 96.23% purity.</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-((3a<i>R</i>,6a<i>S</i>)-5-methylhexahydropyrrolo[3,4-<i>c</i>]pyrrol-2(1<i>H</i>)-yl)phenyl)amino)-1-((<i>S</i>)-1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3br</b>)</h3><div class="NLM_p last">White solid (yield 79%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −10.000 (<i>c</i> 0.140, MeOH). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.01 (s, 0.6H), 7.99 (s, 0.4H), 7.32–7.25 (m, 2H), 7.09–6.93 (m, 3H), 6.83–6.82 (m, 2H), 5.57–5.51 (m, 1H), 4.57–4.55 (m, 2H), 4.07–3.92 (m, 2H), 3.79–3.71 (m, 4H), 3.47–3.41 (m, 1H), 2.98–2.77 (m, 9H), 2.35 (s, 3H), 2.31 (s, 3H), 2.28–2.15 (m, 5H), 1.13 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.3, 159.6, 159.5, 157.7, 157.4, 156.1, 156.0, 153.7, 153.6, 152.8, 152.5, 151.5, 144.2, 133.6, 133.5, 132.3, 129.6, 129.5, 123.6, 123.4, 118.7, 118.5, 117.1, 117.0, 114.4, 114.3, 113.7, 113.6, 102.9, 62.5, 62.4, 56.5, 56.4, 56.3, 56.0, 52.9, 51.3, 47.3, 47.2, 45.7, 44.4, 42.5, 41.8, 28.7, 28.0, 27.4, 26.4, 19.3, 19.2, 9.1. HRMS (ESI) for C<sub>34</sub>H<sub>41</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 629.3358. Found: 629.3356. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 20.56 min, 99.45% purity.</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (<i>S</i>)-7-((4-((2-(Dimethylamino)ethyl)(methyl)amino)-3-methylphenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bs</b>)</h3><div class="NLM_p last">White solid (yield 88%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −18.519 (<i>c</i> 0.108, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.39–7.37 (m, 0.7H), 7.33–7.32 (m, 1.3H), 7.10–7.06 (m, 2.6H), 7.04–7.03 (m, 0.4H), 6.85–6.83 (m, 2H), 5.57–5.53 (m, 1H), 4.57–4.56 (m, 2H), 4.05–3.93 (m, 2H), 3.79–3.72 (m, 4H), 3.55–3.45 (m, 2H), 3.03–2.99 (m, 2H), 2.79–2.77 (m, 1H), 2.68 (s, 3H), 2.48–2.44 (m, 2H), 2.30 (s, 3H), 2.26–2.25 (m, 8H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.4, 159.5, 159.4, 157.3, 156.1, 153.6, 153.5, 152.8, 147.8, 134.3, 134.1, 129.6, 129.5, 122.9, 122.8, 120.5, 118.4, 118.2, 117.1, 116.9, 114.4, 114.3, 113.7, 113.6, 103.0, 65.1, 57.5, 57.4, 55.9, 54.6, 54.6, 52.8, 51.3, 47.4, 47.2, 47.1, 45.8, 45.7, 45.6, 44.5, 42.9, 42.7, 42.1, 30.2, 29.7, 28.2, 28.7, 28.0, 27.3, 26.4, 23.4, 23.1, 18.4, 18.3, 14.1, 11.1, 9.1. HRMS (ESI) for C<sub>32</sub>H<sub>41</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 605.3358. Found: 605.3356. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 14.95 min, 99.79% purity.</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 7-((4-((<i>S</i>)-3,4-Dimethylpiperazin-1-yl)-3-methylphenyl)amino)-3-(2-fluoro-5-methoxyphenyl)-1-((<i>S</i>)-1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bt</b>)</h3><div class="NLM_p last">White solid (yield 86%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00 (s, 0.6H), 7.98 (s, 0.4H), 7.33–7.31 (m, 2.5H), 7.18–7.17 (m, 0.5H), 7.10–7.08 (m, 1H), 7.06–6.98 (m, 1H), 6.83–6.82 (m, 2H), 5.55–5.52 (m, 1H), 4.56–4.54 (m, 2H), 4.05–4.01 (m, 0.6H), 3.95–3.91 (m, 1.4H), 3.77–3.69 (m, 4H), 3.45–3.40 (m, 1H), 2.98–2.95 (m, 4H), 2.91–2.86 (m, 1H), 2.78–2.72 (m, 3H), 2.56 (s, 3H), 2.50 (s, 3H), 2.47–2.20 (m, 3H), 1.12 (m, 6H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.7, 172.4, 159.5, 159.4, 157.6, 157.3, 156.0, 153.6, 153.5, 153.4, 152.7, 152.5, 147.1, 134.4, 134.3, 133.3, 129.5, 129.4, 129.3, 123.2, 123.1, 123.0, 119.4, 118.6, 118.5, 118.4, 117.0, 116.9, 115.7, 114.3, 114.2, 113.6, 113.5, 102.9, 59.2, 59.1, 58.2, 55.9, 52.8, 52.2, 52.1, 51.2, 47.4, 47.1, 45.6, 44.4, 42.6, 42.5, 28.6, 27.9, 27.3, 26.4, 18.0, 17.9, 9.0. HRMS (ESI) for C<sub>33</sub>H<sub>41</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 617.3358. Found: 617.3344. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 6.9 min, 99.24% purity. HRMS (ESI) for C<sub>33</sub>H<sub>41</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 617.3358. Found: 617.3344. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 6.9 min, 99.24% purity.</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-((3<i>R</i>,5<i>S</i>)-3,4,5-trimethylpiperazin-1-yl)phenyl)amino)-1-((<i>S</i>)-1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bu</b>)</h3><div class="NLM_p last">White solid (yield 88%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −26.684 (<i>c</i> 0.076, MeOH). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.01 (s, 0.6H), 7.99 (s, 0.4H), 7.32–7.27 (m, 2H), 7.18–7.17 (m, 0.6H), 7.11–7.10 (m, 0.4H), 7.08–7.05 (m, 1H), 6.96–6.94 (m, 1H), 6.84–6.83 (m, 2H), 5.57–5.52 (m, 1H), 4.59–4.55 (m, 2H), 4.05–4.02 (m, 0.7H), 3.95–3.91 (m, 1.3H), 3.88 (s, 3H), 3.78–3.72 (m, 1H), 3.50–3.40 (m, 1H), 2.95–2.94 (m, 2H), 2.79–2.78 (m, 2H), 2.77–2.73 (m, 4H), 2.46 (s, 3H), 2.30 (s, 3H), 2.28–2.13 (m, 2H), 1.28–1.25 (m, 6H), 1.13 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.6, 159.5, 157.7, 157.4, 156.1, 153.7, 153.6, 153.4, 152.8, 152.6, 151.5, 146.5, 146.4, 134.8, 134.6, 133.5, 133.4, 129.6, 129.5, 123.1, 123.0, 119.5, 118.7, 118.5, 117.1, 117.0, 114.4, 114.3, 113.7, 113.6, 103. 1, 56.0, 52.9, 51.3, 47.5, 47.3, 47.2, 45.7, 44.6, 29.8, 28.7, 28.0, 27.4, 26.5, 18.1, 18.0, 17.5, 17.4, 9.2, 9.1. HRMS (ESI) for C<sub>34</sub>H<sub>43</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>, calcd: 631.3515. Found: 631.3513. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 15.06 min, 98.49% purity.</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (<i>S</i>)-3-(2-Fluoro-5-methoxyphenyl)-7-((3-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bv</b>)</h3><div class="NLM_p last">White solid (yield 84%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −14.063 (<i>c</i> 0.128, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (s, 0.6H), 8.00 (s, 0.4H), 7.37–7.34 (m, 2H), 7.11–7.10 (m, 1.7H), 7.08–7.00 (m, 1.3H), 6.85–6.82 (m, 2H), 5.56–5.52 (m, 1H), 4.71–4.70 (m, 4H), 4.68–4.55 (m, 2H), 4.05–4.00 (m, 0.6H), 3.94–3.92 (m, 1.4H), 3.79–3.72 (m, 4H), 3.60–3.58 (m, 1H), 3.57–3.56 (m, 1H), 2.96–2.94 (m, 4H), 2.79–2.78 (m, 1H), 2.50 (br s, 4H), 2.28–2.25 (m, 5H), 2.29–2.21 (m, 1H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.3, 159.5, 159.4, 157.7, 157.3, 156.1, 156.0, 153.7, 153.5, 153.4, 152.8, 152.5, 151.4, 147.2, 147.0, 134.5, 133.4, 129.6, 129.5, 123.1, 123.0, 119.6, 118.6, 118.5, 117.1, 116.9, 114.3, 114.2, 113.7, 113.6, 103.0, 59.3, 55.9, 52.9, 51.6, 51.5, 51.3, 50.2, 47.4, 47.1, 45.6, 44.4, 28.6, 28.0, 27.3, 26.4, 18.0, 17.9, 9.1. HRMS (ESI) for C<sub>34</sub>H<sub>41</sub>FN<sub>8</sub>O<sub>4</sub> [M + H]<sup>+</sup>, calcd: 645.3308. Found: 645.3316. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 7.99 min, 96.27% purity.</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (<i>S</i>)-3-(2-Chloro-5-methoxyphenyl)-7-((3-methyl-4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)amino)-1-(1-propionylpyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>3bw</b>)</h3><div class="NLM_p last">White solid (yield 88%). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −46.000 (<i>c</i> 0.100, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01 (s, 0.6H), 8.00 (s, 0.4H), 7.38–7.32 (m, 3H), 7.20–7.19 (m, 0.6H), 7.03–7.02 (m, 0.4H), 7.00–6.98 (m, 1H), 6.89–6.83 (m, 2H), 5.58–5.56 (m, 1H), 4.71–4.60 (m, 5H), 4.49–4.45 (m, 1H), 4.05–3.90 (m, 2H), 3.80 (s, 3H), 3.79–3.74 (m, 1H), 3.71–3.69 (m, 1H), 3.60–3.40 (m, 1H), 2.96–2.94 (m, 4H), 2.79–2.78 (m, 1H), 2.49 (br s, 4H), 2.28–2.25 (m, 5H), 2.29–2.21 (m, 1H), 1.13 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 172.6, 172.3, 159.5, 159.4, 159.3, 153.7, 153.6, 147.2, 139.6, 134.6, 134.5, 133.5, 130.9, 123.9, 123.1, 119.7, 118.5, 115.3, 115.2, 115.0, 114.9, 103.0, 59.4, 55.8, 52.8, 51.7, 51.6, 51.1, 50.2, 47.5, 47.0, 45.8, 44.5, 29.8, 28.0, 27.4, 26.6, 18.0, 17.9, 9.1. HRMS (ESI) for C<sub>34</sub>H<sub>41</sub>ClN<sub>8</sub>O<sub>4</sub> [M + H]<sup>+</sup>, calcd: 661.3012. Found: 661.2989. HPLC analysis: MeOH–H<sub>2</sub>O (85:15), 8.44 min, 99.74% purity.</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> (<i>S</i>)-<i>tert</i>-Butyl-3-((5-formyl-2-(methylthio)pyrimidin-4-yl)amino)pyrrolidine-1-carboxylate (<b>6a</b>)</h3><div class="NLM_p last">Compound <b>5a</b> (22.0 g, 118.2 mmol) and potassium carbonate (29.64 g, 214.8 mmol) were added to a solution of <b>4a</b> (24.98 g, 107.4 mmol) in DMF (50 mL). The resulting solution was stirred at 60 °C overnight. After cooling to room temperature, ice–water (500 mL) was added to the reaction mixture. The precipitate was filtered, and the filter cake was rinsed with additional cold water and then dried in a vacuum oven to give <b>6a</b> (white solid, 30.4 g, yield 74%), which was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.63 (s, 1H), 8.34 (s, 1H), 4.72 (s, <i>J</i> = 2.4 Hz, 1H), 4.31 (q, <i>J</i> = 7.2 Hz, 2H), 3.77–3.73 (m, 1H), 3.49–3.48 (m, 2H), 3.36–3.34 (m, 0.5H), 3.23–3.22 (m, 0.5H), 2.52 (s, 3H), 2.30–2.21 (m, 1H), 1.94–1.93 (m, 1H), 1.45 (s, 9H), 1.36 (t, <i>J</i> = 7.2 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i> 383.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (<i>S</i>)-<i>tert</i>-Butyl-3-((5-(hydroxymethyl)-2-(methylthio)pyrimidin-4-yl)amino)pyrrolidine-1-carboxylate (<b>7a</b>)</h3><div class="NLM_p last">A suspension of LiAlH<sub>4</sub> (6.04 g, 158.3 mmol) in anhydrous THF (50 mL) was added dropwise to a solution of <b>6a</b> (30.4 g, 79.15 mmol) in anhydrous THF (200 mL) under stirring for 0.5 h at −40 °C. The reaction mixture was stirred until the temperature was slowly warmed to 0 °C, and then 6 mL of water was added to decompose unreacted LiAlH<sub>4</sub>. Then, a further 18 mL of water was added to the reaction mixture followed by 15% aqueous NaOH (6 mL). The resulting mixture was stirred for 10 min at room temperature and filtered through a pad of Celite. The Celite was washed with THF, and the washes were combined and then concentrated in vacuo. The concentrated mixture was poured into water and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was separated, washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>. The crude material was purified by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH stepwise elution, 40:1 to 20:1) to give <b>6a</b> (white solid, 13 g, yield 48%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.74 (s, 1H), 6,02 (s, 1H), 4.68 (d, <i>J</i> = 5.6 Hz, 1H), 4.52 (s, 2H), 3.72–3.71 (m, 1H), 3.46–3.45 (m, 2H), 3.27–3.21 (m, 1H), 2.50 (s, 3H), 2.25–2.23 (m, 1H), 1.92–1.91 (m, 1H), 1.46 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 341.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (<i>S</i>)-<i>tert</i>-Butyl-3-((5-formyl-2-(methylthio)pyrimidin-4-yl)amino)pyrrolidine-1-carboxylate (<b>8a</b>)</h3><div class="NLM_p last">MnO<sub>2</sub> (16.6 g, 191.10 mmol) was added to a solution of <b>7a</b> (13 g, 38.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (100 mL). The mixture was stirred at room temperature overnight. The mixture was filtered and the filtrate was concentrated in vacuo and further purified by flash chromatography on silica gel (SiO<sub>2</sub>, petroleum ether/EtOAc stepwise elution, 3:1 to 1:1) to give <b>8a</b> (white solid, 11.2 g, yield 87%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.78 (s, 1H), 8.64 (s, 1H), 8.30 (s, 1H), 4.72 (s, 1H), 3.73–3.72 (m, 1H), 3.47–3.46 (m, 2H), 3.73–3.72 (m, 0.5H), 3.34–3.21 (m, 0.5H), 2.52 (s, 3H), 2.26–2.23 (m, 1H), 1.97–1.96 (m, 1H), 1.44 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 339.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> (<i>S</i>)-<i>tert</i>-Butyl-3-((5-(((2-chlorophenyl)amino)methyl)-2-(methylthio)pyrimidin-4-yl)amino)pyrrolidine-1-carboxylate (<b>9a</b>)</h3><div class="NLM_p last">2-Chloroaniline (1.51 g, 11.84 mmol) and AcOH (0.1 mL) were added at room temperature to a solution of <b>8a</b> (2.0 g, 5.92 mmol) in toluene (50 mL). After the amine was converted completely to the imine as determined by TLC, NaBH<sub>4</sub> (1.119 g, 29.6 mmol) was added to the reaction mixture at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 4 h. The resulting mixture was concentrated in vacuo, partitioned between CH<sub>2</sub>Cl<sub>2</sub> and saturated NaHCO<sub>3</sub>. The organic layer was separated, and washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>. The resulting crude material was subjected to flash column chromatography (SiO<sub>2</sub>, petroleum ether/EtOAc, 3:1) to give <b>9a</b> (white solid, 1.86 g, yield 70%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.96 (s, 1H), 7.30 (d, <i>J</i> = 7.6 Hz, 1H), 7.21–7.17 (m, 1H), 6.81–6.77 (m, 2H), 5.98 (s, 1H), 4.71–4.64 (m, 1H), 4.20–4.10 (m, 3H), 3.72–3.70 (m, 1H), 3.43–3.42 (m, 1H), 3.31–3.30 (m, 0.5H), 3.15–3.14 (m, 0.5H), 2.52 (s, 3H), 2.23–2.15 (m, 1H), 1.84–1.83 (m, 1H), 1.43 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 450.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> (<i>S</i>)-<i>tert</i>-Butyl-3-(3-(2-chlorophenyl)-7-(methylthio)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)pyrrolidine-1-carboxylate (<b>10a</b>)</h3><div class="NLM_p last">DIEA (2.2 mL, 12.42 mmol) and triphosgene (0.49 g, 1.66 mmol) were added to a solution of <b>9a</b> (1.86 g, 4.14 mmol) in CH<sub>2</sub>Cl<sub>2</sub> at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 0.5 h. The mixture was poured into a solution of 10% aqueous NaHCO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2.</sub> The organic layer was washed with 10% aqueous NaHCO<sub>3</sub>, brine, and dried with Na<sub>2</sub>SO<sub>4</sub>. Then the organic phase was concentrated in vacuo to give <b>10a</b> (yellow oil, 1.90 g, yield 97%), which was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.11 (s, 1H), 7.50 (d, <i>J</i> = 7.2 Hz, 1H), 7.36–7.31 (m, 3H), 5.59–5.54 (m, 1H), 4.70–4.66 (m, 1H), 4.56–4.51 (m, 1H), 3.88–3.83 (m, 1H), 3.72–3.67 (m, 2H), 3.44–3.39 (m, 1H), 2.77–2.71 (m, 1H), 2.54 (s, 3H), 2.15–2.14 (m, 1H), 1.45 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 476.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> (<i>S</i>)-<i>tert</i>-Butyl-3-(3-(2-chlorophenyl)-7-(methylsulfonyl)-2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)pyrrolidine-1-carboxylate (<b>11a</b>)</h3><div class="NLM_p last">m-CPBA (1.74 g, 8.66 mmol) was added to a solution of <b>10a</b> (1.9 g, 4.33 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (50 mL) at 0 °C under argon. The reaction mixture was allowed to warm to room temperature and stirred for 4 h. The solution was diluted with CH<sub>2</sub>Cl<sub>2</sub> and then treated with 50% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>/NaHCO<sub>3</sub> solution. The organic layer was separated, washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The resulting crude material was subjected to flash column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH stepwise elution, 40:1 to 20:1) to give <b>11a</b> (white solid, 1.71g, yield 78%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.44 (s, 1H), 7.53 (d, <i>J</i> = 6.0 Hz, 1H), 7.39–7.38 (m, 3H), 5.64–5.59 (m, 1H), 4.87–4.82 (m, 1H), 4.72–4.67 (m, 1H), 3.80–3.79 (m, 3H), 3.78–3.74 (m, 1H), 3.33 (s, 3H), 2.68–2.67 (m, 1H), 2.25–2.24 (m, 1H), 1.45 (s, 9H). MS (ESI) <i>m</i>/<i>z</i> 507.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> (<i>S</i>)-3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-1-(pyrrolidin-3-yl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-2(1<i>H</i>)-one (<b>13a</b>)</h3><div class="NLM_p last">2-Methyl-4-(4-methylpiperazin-1-yl)aniline (172 mg, 0.84 mmol) was added to a solution of <b>11a</b> (3 27 mg, 0.64 mmol) in 2-butyl alcohol (5 mL), followed by trifluoroacetic acid (62 μL, 0.84 mmol). The reaction mixture was stirred for 18 h at 110 °C in a sealed tube. The reaction mixture was cooled to room temperature and concentrated in vacuo to give crude product <b>12a</b> which was used in the next step without further characterization. Then trifluoroacetic acid (2 mL) was added to a solution of <b>12a</b> in CH<sub>2</sub>Cl<sub>2</sub> (5 mL), and the resulting mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and basified with saturated aqueous NaHCO<sub>3</sub> to pH = 9. The organic layer was separated and washed with 10% aqueous NaHCO<sub>3</sub>, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and then concentrated in vacuo. The resultant crude material was purified by column chromatography (SiO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH, 40:1:0.4) to give <b>13a</b> (white solid, 150 mg, yield 44% for twosteps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (s, 1H), 7.51 (d, <i>J</i> = 7.2 Hz, 1H), 7.42 (s, 1H), 7.37–7.31 (m, 4H), 7.10 (s, 1H), 7.04–7.02 (m, 1H), 5.49–5.47 (m, 1H), 4.73–4.66 (m, 1H), 4.50–4.45 (m, 1H), 3.30–3.27 (m, 2H), 3.09–3.04 (m, 1H), 2.94–2.92 (m, 4H), 2.74–2.69 (m, 1H), 2.67–2.65 (m, 4H), 2.36 (s, 3H), 2.32 (s, 3H), 1.89–1.88 (m, 2H). MS (ESI) <i>m</i>/<i>z</i> 533.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Reagents and Antibodies</h3><div class="NLM_p last">The compound was dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich) at a concentration of 10 mmol/L and stored at −20 °C. Primary antibodies against CSF1R (3152), phosphor-CSF1R (Tyr723, 3151), glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 2118), and anti-rabbit or anti-mouse IgG horseradish peroxidase (HRP)-linked secondary antibodies were purchased from Cell Signaling Technology (CST, Boston, MA, USA). Primary antibodies against akt (AKT, SC8312), phosphor-AKT (SC16646R) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). MDV3100 was purchased from ACROS Organic Company, and CSF1R protein, EGFR protein, and the Z′-Lyte kinase assay kit were purchased from Invitrogen.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Cell Lines</h3><div class="NLM_p last">The murine macrophage RAW264.7 (RAW) cells (ATCC) were cultured in DMEM, while LNCaP (ATCC) cells were cultured in RPMI 1640 medium. Both media were supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin (P/S). The cells were maintained at 37 °C in 5% CO<sub>2</sub> incubator.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> In Vitro Kinase Enzyme Assay</h3><div class="NLM_p last">CSF1R, EGFR, and the Z′-Lyte kinase assay kit were purchased from Invitrogen. The experiments were performed according to the instructions of the manufacturer. The concentrations of kinases were determined by optimization experiments and the respective concentrations were the following: EGFR (PV3872, Invitrogen), 0.287 μg/μL; CSF1R (PV3249, Invitrogen) 0.055 μg/μL. First, the compounds were diluted 3-fold from 10<sup>–10</sup> M to 1 × 10<sup>–4</sup> M in DMSO and a 400 μM compound solution was prepared (4 μL of compound dissolved in 96 μL of water). Second, a 100 μM ATP solution in 1.33× kinase buffer was prepared. Third, a kinase/peptide mixture containing 2× kinase and 4 μM Tyr4 peptide (Invitrogen, PV3193) was prepared right before use. Kinase/peptide mixture was prepared by diluting Z′-LYTE Tyr4 peptide (Invitrogen, PV3193) and kinase in 1× kinase buffer, and 0.2 μM Tyr4 phospho-peptide solution was made by adding Z′-LYTE Tyr4 phospho-peptide to 1× kinase buffer. The final 10 μL reaction consists of 0.002 ng of kinase, 2 μM Tyr4 peptide in 1× kinase buffer. For each assay, 10 μL kinase reactions was made at first (including 2.5 μL compound solution, 5 μL kinase/peptide mixture, and 2.5 μL ATP solution). Mixed the plate thoroughly and incubated for 1 h at room temperature. Then 5 μL development solution was added to each well and the plate was incubated for 1 h at room temperature; the non-phospho-peptides were cleaved at this time. In the end, 5 μL of stop reagent was loaded to stop the reaction. For the control setting, 5 μL of phospho-peptide solution instead of kinase–peptide mixture was used as 100% phosphorylation control. 2.5 μL of 1.33× kinase buffer instead of ATP solution was used as 100% inhibition control, and 2.5 μL of 4% DMSO instead of compound solution was used as the 0% inhibitor control. The plate was measured on an EnVision multilabel reader (PerkinElmer). Curve fitting and data presentations were performed using GraphPad Prism, version 5.0. Every experiment was repeated at least three times.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Computational Study</h3><div class="NLM_p last">All procedures were performed in Maestro 9.9 (Schrodinger LLC). The crystal structures of CSF1R and EGFR protein were taken from the PDB (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK">3DPK</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VJO">3VJO</a>). The protein was processed using the “Protein Preparation Wizard” workflow in Maestro 9.9 (Schrodinger LLC) to add bond orders and to add hydrogens. All heteroatom residues and crystal water molecules beyond 5 Å from heteroatom group were removed. Inhibitors were built in the LigPrep module using the OPLS-2005 force field. Glide module was used as the docking program. The grid-enclosing box was placed on the centroid of the binding ligand in the optimized crystal structure as described above, and a scaling factor of 1.0 was set to van der Waals (vdW) radius of those receptor atoms with partial atomic charges of less than 0.25. Standard precision (SP) approach of Glide was adopted to dock <b>2</b> into CSF1R and EGFR with the default parameters, and the top-ranking pose was selected for energy minimization using Prime MM-GBSA, under the solvation model of VSGB.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Western Blot Assay</h3><div class="NLM_p last">RAW264.7 macrophage cells were seeded into six-well plates and incubated overnight and then treated with or without different concentrations of compounds <b>3bw</b> for 6 h and then stimulated with or without CSF-1 (50 ng/mL) for 20 min. Cell samples were then lysed in 1× SDS lysis buffer (CST recommended). After being sonicated and boiled, the supernatant of cell lysate was used for Western blot analysis. Cell lysates were loaded to 8–12% SDS–PAGE and separated by electrophoresis. Separated proteins were then electrically transferred to polyvinylidene difluoride membranes (Millipore), which were blocked with 5% bovine serum albumin/TBST for 1 h and then hybridized with specific primary antibodies. The bands were visualized using a SuperSignal West Dura Extended Duration Substrate kit (Thermo Scientific, USA) after hybridization with a HRP-conjugated secondary antibody and then quantified by ImageJ software (1.51j8, National Institutes of Health, USA).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> In Vitro Migration Assay</h3><div class="NLM_p last">Cell migration assays were evaluated in transwell chambers (BD Falcon). First, (2–4) × 10<sup>5</sup> RAW264.7 macrophage cells (200 μL) were added in the hanging cell culture insert (BD Falcon: 353097) without FBS. A total of 800 μL of the conditioned media from LNCaP cells treated with 10 μM MDV3100 or DMSO vehicle was added in the lower chamber. After incubation for 24 h at 37 °C, migrated cells were immediately fixed in 100% methanol and stained with 0.25% crystal violet, and the cells that had not migrated from the top surface of the filters were removed with cotton. Migrated cells were quantitated by counting cells in six randomly selected fields on each filter under a microscope at 200× magnification and graphed as the mean of three independent experiments. To block CSF1 signaling, four doses of <b>3bw</b> of 0.625, 1.25, 2.5, and 5.0 μM were added to the top chamber, and macrophage cells in the hanging insert were incubated for 24 h. The migrating cells were counted as described above. The experiments shown are representative of three independent experiments.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Real-Time RT-PCR</h3><div class="NLM_p last">RAW264.7 macrophage cells were treated with <b>3bw</b> of 0.08, 0.4, and 2.0 μM or DMSO vehicle for 48 h. Total RNA was extracted using TRIzol (Takara, Japan) according to TRIzol protocol. One microgram of total RNA was used for complementary DNA synthesis using a cDNA reverse transcription kit (Takara, Japan). Real-time PCR was performed in triplicate using gene-specific primers on a Stratagene Bio-Rad CFX 3.1 real-time PCR systems (Bio-Rad Laboratories) machine. The mRNA expression levels were normalized to GAPDH. All analysis was performed using Microsoft Excel 2010 and GraphPad Prism 5 software. The experiment was performed three times and in triplicate. The gene-specific primers are listed in <a href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_001.pdf" class="ext-link">Supporting Information Table 1</a>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> In Vitro Coculture Assay</h3><div class="NLM_p last">Cell coculture assays were evaluated in transwell chambers (BD Falcon). First, (2–4) × 10<sup>5</sup> LNCaP cells were seeded in the lower chamber (BD Falcon: 353502). After incubation for 2 h at 37 °C, (1–2) × 10<sup>6</sup> RAW264.7 cells were seeded in the 0.4 μm hanging cell culture insert (BD Falcon: 353090). After coculture for 48 h at 37 °C, the top chamber was removed, and the images of the bottom LNCaP cells were captured by bright-field microscopy (CKX41; Olympus), and three images fields were randomly chosen. Also, the LNCaP cells was digested and counted by cell counting kit 8 (CCK8, CK04, Dojindo Laboratories, Japan). To block CSF1 signaling, four doses of <b>3bw</b> of 0.016, 0.08, 0.4, and 2.0 μM were added to the top chamber, and cells were cocultured for 48 h. The LNCaP cells were counted as described above. All analysis was performed using Microsoft Excel 2010 and GraphPad Prism 5 software. The experiment was performed three times and in triplicate.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Determination of Pharmacokinetic Parameters in Rats</h3><div class="NLM_p last">All animal studies were performed according to the protocols and guidelines of the institutional care and use committee. The 4- to 6-week-old male Sprague-Dawley rats were purchased from the Shanghai Laboratory Animal Research Center (Shanghai, China). All the procedures related to animal handling, care, and treatment in this article were performed in compliance with Agreement of the Ethics Committee on Laboratory Animal Care and the Guidelines for the Care and Use of Laboratory Animals in Shanghai, China. Rats were housed at an ambient temperature of 21–23 °C with 50–60% relative humidity and 12 h/12 h light/dark cycle. Rats were fed with pelleted rat chow and reverse osmosis (RO) water at libitum. After adaptation for 1 week the rats (180–220 g) were dosed with the test compounds intravenously (iv) at 5 mg/kg and by oral gavage (po) at 25 mg/kg. The compound was dissolved in a vehicle of 2% DMSO, 4% EtOH, 4% castor oil, and 90% H<sub>2</sub>O. Blood samples (0.3 mL) were then obtained via orbital sinus puncture at 2 min, 10 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 21 h, 24 h, 30 h, 36 h, 48 h, and 72 h time points and collected into heparinized tubes. Blood samples were centrifuged for cell removal, and the plasma supernatant was then transferred to a clean vial and subsequently stored at −20 °C prior to analysis. Test compound concentrations were determined by LC/MS using propranolol as an internal standard. Pharmacokinetic parameters were calculated using DAS 2.0 software.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i82"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01612" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01612" class="ext-link">10.1021/acs.jmedchem.7b01612</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H NMR and <sup>13</sup>C NMR for final compounds, biological data, and assay details (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Compound characterization checklist (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_002.xls" class="ext-link">XLS</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_001.pdf">jm7b01612_si_001.pdf (9.56 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_002.xls">jm7b01612_si_002.xls (102.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_003.csv">jm7b01612_si_003.csv (5.48 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01612" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45140" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45140" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyun Lu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#167a636e6f24262720567c786338737263387578"><span class="__cf_email__" data-cfemail="e8849d9091dad8d9dea882869dc68d8c9dc68b86">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ke Ding</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of
Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span>; 
    <span class="hlFld-Affiliation affiliation">Guangzhou
City Key Laboratory of Precision Chemical Drug Development, Guangzhou 510632, China</span>; 
    <span class="hlFld-Affiliation affiliation">International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Development, Ministry
of Education (MOE) of People’s Republic of China, Guangzhou 510632, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9016-812X" title="Orcid link">http://orcid.org/0000-0001-9016-812X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1f7b76717840747a5f75716a317a7b6a317c71"><span class="__cf_email__" data-cfemail="0d6964636a5266684d67637823686978236e63">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiuju Xun</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of
Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhang Zhang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinfeng Luo</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of
Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linjiang Tong</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Drug Research, Shanghai Institute
of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Zhangjiang
Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minhao Huang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of
Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhen Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of
Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Zou</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingqiang Liu</span> - <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Life Sciences, Shanghai University, No. 99 Shangda Road, Shanghai 200444, China</span>; 
    <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Drug Research, Shanghai Institute
of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Zhangjiang
Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Xu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of
Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3601-0246" title="Orcid link">http://orcid.org/0000-0003-3601-0246</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hua Xie</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Drug Research, Shanghai Institute
of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Zhangjiang
Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zheng-Chao Tu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of
Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Q.X. and Z.Z. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d50e5647-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i84">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52848" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52848" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors appreciate the financial support from National Natural Science Foundation of China (Grants 21572230, 81425021, and 81673285), Guangdong Province (Grants 2014TQ01R341, 2015A030306042, 2015A030312014, 2016A050502041 and Nanyue-Baijie Award), Guangzhou City (Grant 201508030036), and Jinan University.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">CSF1R</td><td class="NLM_def"><p class="first last">colony stimulating factor 1 receptor</p></td></tr><tr><td class="NLM_term">TAM</td><td class="NLM_def"><p class="first last">tumor-associated macrophage</p></td></tr><tr><td class="NLM_term">TME</td><td class="NLM_def"><p class="first last">tumor microenvironment</p></td></tr><tr><td class="NLM_term">PGE2</td><td class="NLM_def"><p class="first last">prostaglandin E2</p></td></tr><tr><td class="NLM_term">TGFβ</td><td class="NLM_def"><p class="first last">transforming growth factor β</p></td></tr><tr><td class="NLM_term">TREG</td><td class="NLM_def"><p class="first last">T regulatory cell</p></td></tr><tr><td class="NLM_term">CCL22</td><td class="NLM_def"><p class="first last">C–C motif chemokine 22</p></td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">death protein 1</p></td></tr><tr><td class="NLM_term">CTLA-4</td><td class="NLM_def"><p class="first last">cytotoxic T-lymphocyte antigen 4</p></td></tr><tr><td class="NLM_term">HLA-G</td><td class="NLM_def"><p class="first last">human leukocyte antigen G</p></td></tr><tr><td class="NLM_term">FLT-3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase-3</p></td></tr><tr><td class="NLM_term">KIT</td><td class="NLM_def"><p class="first last">stem cell factor receptor</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">PCa</td><td class="NLM_def"><p class="first last">prostate cancer</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half maximal (50%) inhibitory concentration (IC) of a substance</p></td></tr><tr><td class="NLM_term">C</td><td class="NLM_def"><p class="first last">cysteine</p></td></tr><tr><td class="NLM_term">V</td><td class="NLM_def"><p class="first last">valine</p></td></tr><tr><td class="NLM_term">T</td><td class="NLM_def"><p class="first last">threonine</p></td></tr><tr><td class="NLM_term">M</td><td class="NLM_def"><p class="first last">methionine</p></td></tr><tr><td class="NLM_term">D</td><td class="NLM_def"><p class="first last">aspartic acid</p></td></tr><tr><td class="NLM_term">F</td><td class="NLM_def"><p class="first last">phenylalanine</p></td></tr><tr><td class="NLM_term">R</td><td class="NLM_def"><p class="first last">arginine</p></td></tr><tr><td class="NLM_term">E</td><td class="NLM_def"><p class="first last">glutamic acid</p></td></tr><tr><td class="NLM_term">K</td><td class="NLM_def"><p class="first last">lysine</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">ethyldiisopropylamine</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum serum concentration</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under curve</p></td></tr><tr><td class="NLM_term">CLz</td><td class="NLM_def"><p class="first last">clearance rate</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">ABL1</td><td class="NLM_def"><p class="first last">Abelson kinase 1</p></td></tr><tr><td class="NLM_term">BMX</td><td class="NLM_def"><p class="first last">BMX nonreceptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">EPH-A1</td><td class="NLM_def"><p class="first last">ephrin type-A receptor 1</p></td></tr><tr><td class="NLM_term">KDR</td><td class="NLM_def"><p class="first last">kinase insert domain receptor</p></td></tr><tr><td class="NLM_term">LYNA</td><td class="NLM_def"><p class="first last">Lck/Yes tyrosine kinase A</p></td></tr><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">proto-oncogene tyrosine-protein kinase receptor Ret</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous administration</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">oral gavage</p></td></tr><tr><td class="NLM_term">Akt</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">ARG1</td><td class="NLM_def"><p class="first last">arginase 1</p></td></tr><tr><td class="NLM_term">IL10</td><td class="NLM_def"><p class="first last">interleukin 10</p></td></tr><tr><td class="NLM_term">MMP9</td><td class="NLM_def"><p class="first last">matrix metallopeptidase 9</p></td></tr><tr><td class="NLM_term">VEGFA</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor A</p></td></tr><tr><td class="NLM_term">qRT-PCR</td><td class="NLM_def"><p class="first last">quantitative real-time polymerase chain reaction</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">UV</td><td class="NLM_def"><p class="first last">ultraviolet</p></td></tr><tr><td class="NLM_term">ppm</td><td class="NLM_def"><p class="first last">parts per million</p></td></tr><tr><td class="NLM_term">SRB</td><td class="NLM_def"><p class="first last">sulforhodamine B</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 47 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherr, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettenmier, C. W.</span></span> <span> </span><span class="NLM_article-title">Colony-stimulating factor-1 receptor (c-fms)</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1002/jcb.240380305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1002%2Fjcb.240380305" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1988&pages=179-187&author=C.+J.+Sherrauthor=M.+F.+Rousselauthor=C.+W.+Rettenmier&title=Colony-stimulating+factor-1+receptor+%28c-fms%29&doi=10.1002%2Fjcb.240380305"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fjcb.240380305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.240380305%26sid%3Dliteratum%253Aachs%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26aulast%3DRoussel%26aufirst%3DM.%2BF.%26aulast%3DRettenmier%26aufirst%3DC.%2BW.%26atitle%3DColony-stimulating%2520factor-1%2520receptor%2520%2528c-fms%2529%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D1988%26volume%3D38%26spage%3D179%26epage%3D187%26doi%3D10.1002%2Fjcb.240380305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Till, J. H.</span></span> <span> </span><span class="NLM_article-title">Protein tyrosine kinase structure and function</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.69.1.373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1146%2Fannurev.biochem.69.1.373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10966463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1ajtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2000&pages=373-398&author=S.+R.+Hubbardauthor=J.+H.+Till&title=Protein+tyrosine+kinase+structure+and+function&doi=10.1146%2Fannurev.biochem.69.1.373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine kinase structure and function</span></div><div class="casAuthors">Hubbard, Stevan R.; Till, Jeffrey H.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">373-398</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 116 refs.  Tyr-phosphorylation is one of the key covalent modifications that occurs in multicellular organisms as a result of intercellular communication during embryogenesis and maintenance of adult tissues.  The enzymes that carry out this modification are the protein tyrosine kinases (PTKs), which catalyze the transfer of the γ-phosphate of ATP to Tyr residues on protein substrates.  Phosphorylation of Tyr residues modulates enzymic activity and creates binding sites for the recruitment of downstream signaling proteins.  Two classes of PTKs are present in cells: the transmembrane receptor PTKs and the nonreceptor PTKs.  Because PTKs are crit. components of cellular signaling pathways, their catalytic activity is strictly regulated.  Over the past several years, high-resoln. structural studies of PTKs have provided a mol. basis for understanding the mechanisms by which receptor and nonreceptor PTKs are regulated.  This review highlights the important results that have emerged from these structural studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogx8K1IKwbKLVg90H21EOLACvtfcHk0lgzUKCkLe3Ytg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1ajtb0%253D&md5=2aae3e0c121c9e6652be99030af36af1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.69.1.373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.69.1.373%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DTill%26aufirst%3DJ.%2BH.%26atitle%3DProtein%2520tyrosine%2520kinase%2520structure%2520and%2520function%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2000%26volume%3D69%26spage%3D373%26epage%3D398%26doi%3D10.1146%2Fannurev.biochem.69.1.373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothwell, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrschneider, L.</span></span> <span> </span><span class="NLM_article-title">Characterization of the human c-fms gene product and its expression in cells of the monocyte-macrophage lineage</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3458</span>– <span class="NLM_lpage">3466</span>, <span class="refDoi"> DOI: 10.1128/MCB.5.12.3458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1128%2FMCB.5.12.3458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=3018521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADyaL28XivFOhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1985&pages=3458-3466&author=J.+Woolfordauthor=V.+Rothwellauthor=L.+Rohrschneider&title=Characterization+of+the+human+c-fms+gene+product+and+its+expression+in+cells+of+the+monocyte-macrophage+lineage&doi=10.1128%2FMCB.5.12.3458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the human c-fms gene product and its expression in cells of the monocyte-macrophage lineage</span></div><div class="casAuthors">Woolford, Joseph; Rothwell, Victoria; Rohrschneider, Larry</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3458-66</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The McDonough strain of feline sarcoma virus contains an oncogene called v-fms whose ultimate protein product (gp140v-fms) resembles a cell surface growth factor receptor.  To identify and characterize the protein product of the proto-oncogene c-fms, antisera were prepd. to the viral fms sequences and used to detect specific cross-reacting sequences in human choriocarcinoma cells (BeWo) known to express c-fms mRNA.  Both tumor-bearing rat sera and a rabbit antiserum prepd. to a segment of v-fms expressed in Escherichia coli detected a 140-kilodalton (kDa) glycoprotein in the BeWo cells.  Tryptic fingerprint anal. of [35S]methionine-labeled proteins indicated that the viral fms proteins and the 140-kDa BeWo cell protein were highly related.  This 140-kDa glycoprotein contained an assocd. tyrosine kinase activity in vitro and was labeled principally on serine after 32Pi metabolic labeling.  Thus, the 140-kDa protein in BeWo cells is the protein product of the human c-fms proto-oncogene.  This conclusion is supported by the finding that a similar protein is detectable only in other human cells that express c-fms mRNA.  These other human cells include adherent monocytes and the cell line ML-1, which can be induced to differentiate along the monocyte-macrophage pathway.  This is in agreement with current thought that the c-fms proto-oncogene product functions as the colony-stimulating factor-1 receptor specific to this pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyQC6ZdFdrfrVg90H21EOLACvtfcHk0ljhNH_0CQyf9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XivFOhsQ%253D%253D&md5=183f3753f96a5a6165607014a93065d6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1128%2FMCB.5.12.3458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.5.12.3458%26sid%3Dliteratum%253Aachs%26aulast%3DWoolford%26aufirst%3DJ.%26aulast%3DRothwell%26aufirst%3DV.%26aulast%3DRohrschneider%26aufirst%3DL.%26atitle%3DCharacterization%2520of%2520the%2520human%2520c-fms%2520gene%2520product%2520and%2520its%2520expression%2520in%2520cells%2520of%2520the%2520monocyte-macrophage%2520lineage%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1985%26volume%3D5%26spage%3D3458%26epage%3D3466%26doi%3D10.1128%2FMCB.5.12.3458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pixley, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, E. R.</span></span> <span> </span><span class="NLM_article-title">Macrophage proliferation is regulated through CSF-1 receptor tyrosines 544, 559, and 807</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">13694</span>– <span class="NLM_lpage">13704</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.355610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1074%2Fjbc.M112.355610" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=13694-13704&author=W.+Yuauthor=J.+Chenauthor=Y.+Xiongauthor=F.+J.+Pixleyauthor=Y.+G.+Yeungauthor=E.+R.+Stanley&title=Macrophage+proliferation+is+regulated+through+CSF-1+receptor+tyrosines+544%2C+559%2C+and+807&doi=10.1074%2Fjbc.M112.355610"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.355610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.355610%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DPixley%26aufirst%3DF.%2BJ.%26aulast%3DYeung%26aufirst%3DY.%2BG.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DMacrophage%2520proliferation%2520is%2520regulated%2520through%2520CSF-1%2520receptor%2520tyrosines%2520544%252C%2520559%252C%2520and%2520807%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D13694%26epage%3D13704%26doi%3D10.1074%2Fjbc.M112.355610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hume, D. A.</span></span> <span> </span><span class="NLM_article-title">CSF-1 as a regulator of macrophage activation and immune responses</span>. <i>Arch. Immunol. Ther. Exp.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=12894871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvFOrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2003&pages=169-177&author=M.+J.+Sweetauthor=D.+A.+Hume&title=CSF-1+as+a+regulator+of+macrophage+activation+and+immune+responses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CSF-1 as a regulator of macrophage activation and immune responses</span></div><div class="casAuthors">Sweet, Matthew J.; Hume, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Archivum Immunologiae et Therapiae Experimentalis</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-177</span>CODEN:
                <span class="NLM_cas:coden">AITEAT</span>;
        ISSN:<span class="NLM_cas:issn">0004-069X</span>.
    
            (<span class="NLM_cas:orgname">Ossolineum Publishing House</span>)
        </div><div class="casAbstract">A review.  Macrophage activation is a key determinant of susceptibility and pathol. in a variety of inflammatory diseases.  The extent of macrophage activation is tightly regulated by a no. of pro-inflammatory cytokines (e.g. IFN-γ, IL-2, GM-CSF, IL-3) and anti-inflammatory cytokines (e.g. IL-4, IL-10, TGF-β).  Macrophage colony-stimulating factor (CSF-1/M-CSF) is a key differentiation, growth and survival factor for monocytes/macrophages and osteoclasts.  The role of this factor in regulating macrophage activation is often overlooked.  This review summarizes the current understanding of the effects of CSF-1 on the activation state of mature macrophages and its role in regulating immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUPBgBJCtxHrVg90H21EOLACvtfcHk0ljhNH_0CQyf9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvFOrtLk%253D&md5=40807f0f5023ba8c6ac7cd53cbe813b3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSweet%26aufirst%3DM.%2BJ.%26aulast%3DHume%26aufirst%3DD.%2BA.%26atitle%3DCSF-1%2520as%2520a%2520regulator%2520of%2520macrophage%2520activation%2520and%2520immune%2520responses%26jtitle%3DArch.%2520Immunol.%2520Ther.%2520Exp.%26date%3D2003%26volume%3D51%26spage%3D169%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherr, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettenmier, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, M. F.</span></span> <span> </span><span class="NLM_article-title">Macrophage colony-stimulating factor, CSF-1, and its proto-oncogene-encoded receptor</span>. <i>Cold Spring Harbor Symp. Quant. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1101/SQB.1988.053.01.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1101%2FSQB.1988.053.01.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=2855492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADyaK3cXls12rsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1988&pages=521-530&author=C.+J.+Sherrauthor=C.+W.+Rettenmierauthor=M.+F.+Roussel&title=Macrophage+colony-stimulating+factor%2C+CSF-1%2C+and+its+proto-oncogene-encoded+receptor&doi=10.1101%2FSQB.1988.053.01.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage colony-stimulating factor, CSF-1, and its proto-oncogene-encoded receptor</span></div><div class="casAuthors">Sherr, C. J.; Rettenmier, C. W.; Roussel, M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Symposia on Quantitative Biology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">Mol. Biol. Signal Transduction, Pt. 1</span>),
    <span class="NLM_cas:pages">521-30</span>CODEN:
                <span class="NLM_cas:coden">CSHSAZ</span>;
        ISSN:<span class="NLM_cas:issn">0091-7451</span>.
    </div><div class="casAbstract">A review with ∼100 refs.  The CSF-1 receptor is the product of the c-fms proto-oncogene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNptdlBxxGtbVg90H21EOLACvtfcHk0ljPlZfp8H1bHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXls12rsLs%253D&md5=3bb763b62cd24ff85ea8a88ad046ee95</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1101%2FSQB.1988.053.01.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252FSQB.1988.053.01.060%26sid%3Dliteratum%253Aachs%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26aulast%3DRettenmier%26aufirst%3DC.%2BW.%26aulast%3DRoussel%26aufirst%3DM.%2BF.%26atitle%3DMacrophage%2520colony-stimulating%2520factor%252C%2520CSF-1%252C%2520and%2520its%2520proto-oncogene-encoded%2520receptor%26jtitle%3DCold%2520Spring%2520Harbor%2520Symp.%2520Quant.%2520Biol.%26date%3D1988%26volume%3D53%26spage%3D521%26epage%3D530%26doi%3D10.1101%2FSQB.1988.053.01.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chitu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, E. R.</span></span> <span> </span><span class="NLM_article-title">Colony-stimulating factor-1 in immunity and inflammation</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.coi.2005.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.coi.2005.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=16337366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2006&pages=39-48&author=V.+Chituauthor=E.+R.+Stanley&title=Colony-stimulating+factor-1+in+immunity+and+inflammation&doi=10.1016%2Fj.coi.2005.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Colony-stimulating factor-1 in immunity and inflammation</span></div><div class="casAuthors">Chitu, Violeta; Stanley, E. Richard</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-48</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Colony-stimulating factor-1 (CSF-1, also known as macrophage-CSF) is the primary regulator of the survival, proliferation, differentiation and function of mononuclear phagocytes.  Studies that involve CSF-1-deficient mice demonstrate that there is a variable requirement for CSF-1 in the development of individual mononuclear phagocyte populations.  However, these cells uniformly express the CSF-1 receptor, and their morphol., phagocytosis and responsiveness to infectious and non-infectious stimuli is regulated by CSF-1.  CSF-1 plays important roles in innate immunity, cancer and inflammatory diseases, including systemic lupus erythematosus, arthritis, atherosclerosis and obesity.  In several conditions, activation of macrophages involves a CSF-1 autocrine loop.  In addn., secreted and cell-surface isoforms of CSF-1 can have differential effects in inflammation and immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDWBfpwAK0KbVg90H21EOLACvtfcHk0ljPlZfp8H1bHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOgsg%253D%253D&md5=c1734f38620b1689c7560514a7760189</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2005.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2005.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DChitu%26aufirst%3DV.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DColony-stimulating%2520factor-1%2520in%2520immunity%2520and%2520inflammation%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2006%26volume%3D18%26spage%3D39%26epage%3D48%26doi%3D10.1016%2Fj.coi.2005.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pixley, F. J.</span></span> <span> </span><span class="NLM_article-title">Macrophage migration and its regulation by CSF-1</span>. <i>Int. J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">501962</span>, <span class="refDoi"> DOI: 10.1155/2012/501962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1155%2F2012%2F501962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=22505929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A280%3ADC%252BC38rltlWnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=501962&author=F.+J.+Pixley&title=Macrophage+migration+and+its+regulation+by+CSF-1&doi=10.1155%2F2012%2F501962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage Migration and Its Regulation by CSF-1</span></div><div class="casAuthors">Pixley Fiona J</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cell biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">501962</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Macrophages are terminally differentiated cells of the mononuclear phagocytic lineage and develop under the stimulus of their primary growth and differentiation factor, CSF-1.  Although they differentiate into heterogeneous populations, depending upon their tissue of residence, motility is an important aspect of their function.  To facilitate their migration through tissues, macrophages express a unique range of adhesion and cytoskeletal proteins.  Notably, macrophages do not form large, stable adhesions or actin stress fibers but rely on small, short lived point contacts, focal complexes and podosomes for traction.  Thus, macrophages are built to respond rapidly to migratory stimuli.  As well as triggering growth and differentiation, CSF-1 is also a chemokine that regulates macrophage migration via activation the CSF-1 receptor tyrosine kinase.  CSF-1R autophosphorylation of several intracellular tyrosine residues leads to association and activation of many downstream signaling molecules.  However, phosphorylation of just one residue, Y721, mediates association of PI3K with the receptor to activate the major motility signaling pathways in macrophages.  Dissection of these pathways will identify drug targets for the inhibition of diseases in which macrophages contribute to adverse outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3GaptlusG3dy3lHz94U-GfW6udTcc2eY1QqI60pQSNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rltlWnsQ%253D%253D&md5=4d85c088f146e975e1ee547260f717fd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1155%2F2012%2F501962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F501962%26sid%3Dliteratum%253Aachs%26aulast%3DPixley%26aufirst%3DF.%2BJ.%26atitle%3DMacrophage%2520migration%2520and%2520its%2520regulation%2520by%2520CSF-1%26jtitle%3DInt.%2520J.%2520Cell%2520Biol.%26date%3D2012%26volume%3D2012%26spage%3D501962%26doi%3D10.1155%2F2012%2F501962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitu, V.</span></span> <span> </span><span class="NLM_article-title">CSF-1 receptor signaling in myeloid cells</span>. <i>Cold Spring Harbor Perspect. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">a021857</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a021857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1101%2Fcshperspect.a021857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=24890514" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=a021857&author=E.+R.+Stanleyauthor=V.+Chitu&title=CSF-1+receptor+signaling+in+myeloid+cells&doi=10.1101%2Fcshperspect.a021857"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a021857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a021857%26sid%3Dliteratum%253Aachs%26aulast%3DStanley%26aufirst%3DE.%2BR.%26aulast%3DChitu%26aufirst%3DV.%26atitle%3DCSF-1%2520receptor%2520signaling%2520in%2520myeloid%2520cells%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Biol.%26date%3D2014%26volume%3D6%26spage%3Da021857%26doi%3D10.1101%2Fcshperspect.a021857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. W.</span></span> <span> </span><span class="NLM_article-title">Tumor-associated macrophages: from mechanisms to therapy</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2014.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.immuni.2014.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=25035953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOrsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=49-61&author=R.+Noyauthor=J.+W.+Pollard&title=Tumor-associated+macrophages%3A+from+mechanisms+to+therapy&doi=10.1016%2Fj.immuni.2014.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-Associated Macrophages: From Mechanisms to Therapy</span></div><div class="casAuthors">Noy, Roy; Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-61</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The tumor microenvironment is a complex ecol. of cells that evolves with and provides support to tumor cells during the transition to malignancy.  Among the innate and adaptive immune cells recruited to the tumor site, macrophages are particularly abundant and are present at all stages of tumor progression.  Clin. studies and exptl. mouse models indicate that these macrophages generally play a protumoral role.  In the primary tumor, macrophages can stimulate angiogenesis and enhance tumor cell invasion, motility, and intravasation.  During metastasis, monocytes and/or macrophages prime the premetastatic site and promote tumor cell extravasation, survival, and persistent growth.  Macrophages are also immunosuppressive, preventing tumor cell attack by natural killer and T cells during tumor progression and after recovery from chemo- or immunotherapy.  Therapeutic success in targeting these protumoral roles in preclin. models and in early clin. trials suggests that macrophages are attractive targets as part of combination therapy in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbrnEPk0kD97Vg90H21EOLACvtfcHk0ljf-HijhBJtYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOrsLvL&md5=23ffcaefccbfc01237956857607e4066</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2014.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2014.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DNoy%26aufirst%3DR.%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DTumor-associated%2520macrophages%253A%2520from%2520mechanisms%2520to%2520therapy%26jtitle%3DImmunity%26date%3D2014%26volume%3D41%26spage%3D49%26epage%3D61%26doi%3D10.1016%2Fj.immuni.2014.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostuni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochvill, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natoli, G.</span></span> <span> </span><span class="NLM_article-title">Macrophages and cancer: from mechanisms to therapeutic implications</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1016/j.it.2015.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.it.2015.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=25770924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslCksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=229-239&author=R.+Ostuniauthor=F.+Kratochvillauthor=P.+J.+Murrayauthor=G.+Natoli&title=Macrophages+and+cancer%3A+from+mechanisms+to+therapeutic+implications&doi=10.1016%2Fj.it.2015.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophages and cancer: from mechanisms to therapeutic implications</span></div><div class="casAuthors">Ostuni, Renato; Kratochvill, Franz; Murray, Peter J.; Natoli, Gioacchino</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">229-239</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Infiltration by immune cells is a hallmark of most forms of malignancy.  In this context, tumor-assocd. macrophages (TAMs) represent key regulators of the complex interplay between the immune system and cancer.  We discuss evidence indicating that in many settings TAMs fuel, rather than limit, tumor progression, and neg. impact on responses to therapy.  We discuss how the unique functional properties of TAMs are shaped by tumor-derived signals, placing TAM development in the context of the broader understanding of the cellular and mol. mechanisms controlling macrophage origin, differentiation, and maintenance in tissues.  Finally, we provide examples of how a mol. understanding of the relationships between TAMs and the tumor microenvironment may lead to improved cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJFig-CHupnrVg90H21EOLACvtfcHk0lja7iJ9sd4HnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslCksbk%253D&md5=2e9c1992f8b7564205b3820eb0fe1d78</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2015.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2015.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DOstuni%26aufirst%3DR.%26aulast%3DKratochvill%26aufirst%3DF.%26aulast%3DMurray%26aufirst%3DP.%2BJ.%26aulast%3DNatoli%26aufirst%3DG.%26atitle%3DMacrophages%2520and%2520cancer%253A%2520from%2520mechanisms%2520to%2520therapeutic%2520implications%26jtitle%3DTrends%2520Immunol.%26date%3D2015%26volume%3D36%26spage%3D229%26epage%3D239%26doi%3D10.1016%2Fj.it.2015.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsley, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germain, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevach, E. M.</span></span> <span> </span><span class="NLM_article-title">IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">1224</span>– <span class="NLM_lpage">1234</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=1993&pages=1224-1234&author=L.+Dingauthor=P.+S.+Linsleyauthor=L.+Y.+Huangauthor=R.+N.+Germainauthor=E.+M.+Shevach&title=IL-10+inhibits+macrophage+costimulatory+activity+by+selectively+inhibiting+the+up-regulation+of+B7+expression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DL.%26aulast%3DLinsley%26aufirst%3DP.%2BS.%26aulast%3DHuang%26aufirst%3DL.%2BY.%26aulast%3DGermain%26aufirst%3DR.%2BN.%26aulast%3DShevach%26aufirst%3DE.%2BM.%26atitle%3DIL-10%2520inhibits%2520macrophage%2520costimulatory%2520activity%2520by%2520selectively%2520inhibiting%2520the%2520up-regulation%2520of%2520B7%2520expression%26jtitle%3DJ.%2520Immunol.%26date%3D1993%26volume%3D151%26spage%3D1224%26epage%3D1234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M. O.</span></span> <span> </span><span class="NLM_article-title">TGF-β: guardian of T cell function</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">3973</span>– <span class="NLM_lpage">3979</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1301843</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.4049%2Fjimmunol.1301843" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=3973-3979&author=S.+A.+Ohauthor=M.+O.+Li&title=TGF-%CE%B2%3A+guardian+of+T+cell+function&doi=10.4049%2Fjimmunol.1301843"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301843%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DM.%2BO.%26atitle%3DTGF-%25CE%25B2%253A%2520guardian%2520of%2520T%2520cell%2520function%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D3973%26epage%3D3979%26doi%3D10.4049%2Fjimmunol.1301843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coukos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evdemon-Hogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conejo-Garcia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryczek, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disis, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span> <span> </span><span class="NLM_article-title">Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1038/nm1093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1038%2Fnm1093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=15322536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFSkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=942-949&author=T.+J.+Curielauthor=G.+Coukosauthor=L.+Zouauthor=X.+Alvarezauthor=P.+Chengauthor=P.+Mottramauthor=M.+Evdemon-Hoganauthor=J.+R.+Conejo-Garciaauthor=L.+Zhangauthor=M.+Burowauthor=Y.+Zhuauthor=S.+Weiauthor=I.+Kryczekauthor=B.+Danielauthor=A.+Gordonauthor=L.+Myersauthor=A.+Lacknerauthor=M.+L.+Disisauthor=K.+L.+Knutsonauthor=L.+Chenauthor=W.+Zou&title=Specific+recruitment+of+regulatory+T+cells+in+ovarian+carcinoma+fosters+immune+privilege+and+predicts+reduced+survival&doi=10.1038%2Fnm1093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</span></div><div class="casAuthors">Curiel, Tyler J.; Coukos, George; Zou, Linhua; Alvarez, Xavier; Cheng, Pui; Mottram, Peter; Evdemon-Hogan, Melina; Conejo-Garcia, Jose R.; Zhang, Lin; Burow, Matthew; Zhu, Yun; Wei, Shuang; Kryczek, Ilona; Daniel, Ben; Gordon, Alan; Myers, Leann; Lackner, Andrew; Disis, Mary L.; Knutson, Keith L.; Chen, Lieping; Zou, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">942-949</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Regulatory T (Treg) cells mediate homeostatic peripheral tolerance by suppressing autoreactive T cells.  Failure of host antitumor immunity may be caused by exaggerated suppression of tumor-assocd. antigen-reactive lymphocytes mediated by Treg cells; however, definitive evidence that Treg cells have an immunopathol. role in human cancer is lacking.  Here the authors show, in detailed studies of CD4+CD25+FOXP3+ Treg cells in 104 individuals affected with ovarian carcinoma, that human tumor Treg cells suppress tumor-specific T cell immunity and contribute to growth of human tumors in vivo.  The authors also show that tumor Treg cells are assocd. with a high death hazard and reduced survival.  Human Treg cells preferentially move to and accumulate in tumors and ascites, but rarely enter draining lymph nodes in later cancer stages.  Tumor cells and microenvironmental macrophages produce the chemokine CCL22, which mediates trafficking of Treg cells to the tumor.  This specific recruitment of Treg cells represents a mechanism by which tumors may foster immune privilege.  Thus, blocking Treg cell migration or function may help to defeat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUuPjm7zZim7Vg90H21EOLACvtfcHk0lja7iJ9sd4HnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFSkt7g%253D&md5=eaf598e6096d6e92381c1b26f4b2fe91</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnm1093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1093%26sid%3Dliteratum%253Aachs%26aulast%3DCuriel%26aufirst%3DT.%2BJ.%26aulast%3DCoukos%26aufirst%3DG.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DAlvarez%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DP.%26aulast%3DMottram%26aufirst%3DP.%26aulast%3DEvdemon-Hogan%26aufirst%3DM.%26aulast%3DConejo-Garcia%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBurow%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DKryczek%26aufirst%3DI.%26aulast%3DDaniel%26aufirst%3DB.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DMyers%26aufirst%3DL.%26aulast%3DLackner%26aufirst%3DA.%26aulast%3DDisis%26aufirst%3DM.%2BL.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DW.%26atitle%3DSpecific%2520recruitment%2520of%2520regulatory%2520T%2520cells%2520in%2520ovarian%2520carcinoma%2520fosters%2520immune%2520privilege%2520and%2520predicts%2520reduced%2520survival%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D942%26epage%3D949%26doi%3D10.1038%2Fnm1093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phamduy, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span> <span> </span><span class="NLM_article-title">Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2007.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.immuni.2007.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=17629517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=111-122&author=M.+J.+Butteauthor=M.+E.+Keirauthor=T.+B.+Phamduyauthor=A.+H.+Sharpeauthor=G.+J.+Freeman&title=Programmed+death-1+ligand+1+interacts+specifically+with+the+B7-1+costimulatory+molecule+to+inhibit+T+cell+responses&doi=10.1016%2Fj.immuni.2007.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed Death-1 Ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</span></div><div class="casAuthors">Butte, Manish J.; Keir, Mary E.; Phamduy, Theresa B.; Sharpe, Arlene H.; Freeman, Gordon J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-122</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Pathways in the B7:CD28 family of costimulatory mols. regulate T cell activation and tolerance.  B7-dependent responses in Cd28-/- Ctla4-/- T cells together with reports of stimulatory and inhibitory functions for Programmed Death-1 Ligand 1 or 2 mols. (PD-L1 or PD-L2) have suggested addnl. receptors for these B7 family members.  The authors show that B7-1 and PD-L1 interacted with affinity intermediate to that of B7-1:CD28 and B7-1:CTLA-4.  The PD-L1:B7-1 interface overlapped with the B7-1:CTLA-4 and PD-L1:PD-1 (Programmed Death-1) interfaces.  T cell activation and cytokine prodn. were inhibited by the interaction of B7-1 with PD-L1.  The responses of PD-1-deficient vs. PD-1,B7-1 double-deficient T cells to PD-L1 and of CD28,CTLA-4 double-deficient vs. CD28,CTLA-4,PD-L1 triple-deficient T cells to B7-1 demonstrated that PD-L1 and B7-1 interact specifically to inhibit T cell activation.  The authors' findings point to a substantial bidirectional inhibitory interaction between B7-1 and PD-L1 and add an addnl. dimension to immunoregulatory functions of the B7:CD28 family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMR5dpv_Vr5LVg90H21EOLACvtfcHk0li2lM-sbqw60g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFeqtrk%253D&md5=8fabef0e1244a1d356378867d92a248e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2007.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2007.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DButte%26aufirst%3DM.%2BJ.%26aulast%3DKeir%26aufirst%3DM.%2BE.%26aulast%3DPhamduy%26aufirst%3DT.%2BB.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26atitle%3DProgrammed%2520death-1%2520ligand%25201%2520interacts%2520specifically%2520with%2520the%2520B7-1%2520costimulatory%2520molecule%2520to%2520inhibit%2520T%2520cell%2520responses%26jtitle%3DImmunity%26date%3D2007%26volume%3D27%26spage%3D111%26epage%3D122%26doi%3D10.1016%2Fj.immuni.2007.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daurkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eruslanov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffs, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosser, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieweg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusmartsev, S.</span></span> <span> </span><span class="NLM_article-title">Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">6400</span>– <span class="NLM_lpage">6409</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F0008-5472.CAN-11-1261" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=6400-6409&author=I.+Daurkinauthor=E.+Eruslanovauthor=T.+Stoffsauthor=G.+Q.+Perrinauthor=C.+Algoodauthor=S.+M.+Gilbertauthor=C.+J.+Rosserauthor=L.-M.+Suauthor=J.+Viewegauthor=S.+Kusmartsev&title=Tumor-associated+macrophages+mediate+immunosuppression+in+the+renal+cancer+microenvironment+by+activating+the+15-lipoxygenase-2+pathway&doi=10.1158%2F0008-5472.CAN-11-1261"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1261%26sid%3Dliteratum%253Aachs%26aulast%3DDaurkin%26aufirst%3DI.%26aulast%3DEruslanov%26aufirst%3DE.%26aulast%3DStoffs%26aufirst%3DT.%26aulast%3DPerrin%26aufirst%3DG.%2BQ.%26aulast%3DAlgood%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DS.%2BM.%26aulast%3DRosser%26aufirst%3DC.%2BJ.%26aulast%3DSu%26aufirst%3DL.-M.%26aulast%3DVieweg%26aufirst%3DJ.%26aulast%3DKusmartsev%26aufirst%3DS.%26atitle%3DTumor-associated%2520macrophages%2520mediate%2520immunosuppression%2520in%2520the%2520renal%2520cancer%2520microenvironment%2520by%2520activating%2520the%252015-lipoxygenase-2%2520pathway%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D6400%26epage%3D6409%26doi%3D10.1158%2F0008-5472.CAN-11-1261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latchman, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">Negative co-receptors on lymphocytes</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1016/S0952-7915(02)00341-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2FS0952-7915%2802%2900341-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=11973140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVeitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2002&pages=391-396&author=R.+J.+Greenwaldauthor=Y.+E.+Latchmanauthor=A.+H.+Sharpe&title=Negative+co-receptors+on+lymphocytes&doi=10.1016%2FS0952-7915%2802%2900341-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Negative co-receptors on lymphocytes</span></div><div class="casAuthors">Greenwald, Rebecca J.; Latchman, Yvette E.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">391-396</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The past year has seen significant advances in the authors' understanding of crit. roles of neg. immunoregulatory signals delivered through the B7-CD28 superfamily in regulating T cell activation and tolerance.  Structural data on CTLA-4 have provided novel insights into the inhibitory functions of CTLA-4.  Initial characterization of the PD-1-PD-1-ligand pathway has revealed that this pathway can down-regulate TCR- and CD28-mediated signals.  Recent studies indicate that ICOS exerts distinct effects at different phases of an immune response: ICOS can inhibit as well as stimulate T cell responses.  Recent studies show that signals through CTLA-4, ICOS and PD-1 provide crit. neg. signals for regulatory T cell activation and tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLLfsqd8NdiLVg90H21EOLACvtfcHk0ljU7M_mdIpfPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVeitLY%253D&md5=03f53ff49c0590c58800d68c9c054e73</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2802%2900341-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252802%252900341-2%26sid%3Dliteratum%253Aachs%26aulast%3DGreenwald%26aufirst%3DR.%2BJ.%26aulast%3DLatchman%26aufirst%3DY.%2BE.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DNegative%2520co-receptors%2520on%2520lymphocytes%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2002%26volume%3D14%26spage%3D391%26epage%3D396%26doi%3D10.1016%2FS0952-7915%2802%2900341-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y. Q.</span></span> <span> </span><span class="NLM_article-title">Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e50946</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0050946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1371%2Fjournal.pone.0050946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=23284651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e50946&author=Q.+W.+Zhangauthor=L.+Liuauthor=C.+Y.+Gongauthor=H.+S.+Shiauthor=Y.+H.+Zengauthor=X.+Z.+Wangauthor=Y.+W.+Zhaoauthor=Y.+Q.+Wei&title=Prognostic+significance+of+tumor-associated+macrophages+in+solid+tumor%3A+a+meta-analysis+of+the+literature&doi=10.1371%2Fjournal.pone.0050946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature</span></div><div class="casAuthors">Zhang, Qiong-Wen; Liu, Lei; Gong, Chang-Yang; Shi, Hua-Shan; Zeng, Yun-Hui; Wang, Xiao-Ze; Zhao, Yu-Wei; Wei, Yu-Quan</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e50946</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Purpose: Tumor assocd. macrophages (TAMs) are considered with the capacity to have both neg. and pos. effects on tumor growth.  The prognostic value of TAM for survival in patients with solid tumor remains controversial.  Exptl. Design: We conducted a meta-anal. of 55 studies (n = 8,692 patients) that evaluated the correlation between TAM (detected by immunohistochem.) and clin. staging, overall survival (OS) and disease free survival (DFS).  The impact of M1 and M2 type TAM (n = 5) on survival was also examd.  Results: High d. of TAM was significantly assocd. with late clin. staging in patients with breast cancer [risk ratio (RR) = 1.20 (95% confidence interval (CI), 1.14-1.28)] and bladder cancer [RR = 3.30 (95% CI, 1.56-6.96)] and with early clin. staging in patients with ovarian cancer [RR = 0.52 (95% CI, 0.35-0.77)].  Neg. effects of TAM on OS was shown in patients with gastric cancer [RR = 1.64 (95% CI, 1.24-2.16)], breast cancer [RR = 8.62 (95% CI, 3.10-23.95)], bladder cancer [RR = 5.00 (95% CI, 1.98-12.63)], ovarian cancer [RR = 2.55 (95% CI, 1.60-4.06)], oral cancer [RR = 2.03 (95% CI, 1.47-2.80)] and thyroid cancer [RR = 2.72 (95% CI, 1.26-5.86)] and pos. effects was displayed in patients with colorectal cancer [RR = 0.64 (95% CI, 0.43-0.96)].  No significant effect was shown between TAM and DFS.  There was also no significant effect of two phenotypes of TAM on survival.  Conclusions: Although some modest bias cannot be excluded, high d. of TAM seems to be assocd. with worse OS in patients with gastric cancer, urogenital cancer and head and neck cancer, with better OS in patients with colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_X3L2OOPlvLVg90H21EOLACvtfcHk0ljU7M_mdIpfPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVygsg%253D%253D&md5=1052f33d7a701af2fda965a43c4b3221</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0050946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0050946%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%2BW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGong%26aufirst%3DC.%2BY.%26aulast%3DShi%26aufirst%3DH.%2BS.%26aulast%3DZeng%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DX.%2BZ.%26aulast%3DZhao%26aufirst%3DY.%2BW.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26atitle%3DPrognostic%2520significance%2520of%2520tumor-associated%2520macrophages%2520in%2520solid%2520tumor%253A%2520a%2520meta-analysis%2520of%2520the%2520literature%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De50946%26doi%3D10.1371%2Fjournal.pone.0050946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escamilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priceman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span> <span> </span><span class="NLM_article-title">CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2782</span>– <span class="NLM_lpage">2794</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-3981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F0008-5472.CAN-12-3981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=23418320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVShtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=2782-2794&author=J.+Xuauthor=J.+Escamillaauthor=S.+Mokauthor=J.+Davidauthor=S.+Pricemanauthor=B.+Westauthor=G.+Bollagauthor=W.+McBrideauthor=L.+Wu&title=CSF1R+signaling+blockade+stanches+tumor-infiltrating+myeloid+cells+and+improves+the+efficacy+of+radiotherapy+in+prostate+cancer&doi=10.1158%2F0008-5472.CAN-12-3981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer</span></div><div class="casAuthors">Xu, Jingying; Escamilla, Jemima; Mok, Stephen; David, John; Priceman, Saul; West, Brian; Bollag, Gideon; McBride, William; Wu, Lily</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2782-2794</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Radiotherapy is used to treat many types of cancer, but many treated patients relapse with local tumor recurrence.  Tumor-infiltrating myeloid cells (TIM), including CD11b+ (ITGAM)+F4/80 (EMR1)+ tumor-assocd. macrophages (TAM), and CD11b+Gr-1 (LY6G)+ myeloid-derived suppressor cells (MDSC), respond to cancer-related stresses and play crit. roles in promoting tumor angiogenesis, tissue remodeling, and immunosuppression.  In this report, we used a prostate cancer model to investigate the effects of irradn. on TAMs and MDSCs in tumor-bearing animals.  Unexpectedly, when primary tumor sites were irradiated, we obsd. a systemic increase of MDSCs in spleen, lung, lymph nodes, and peripheral blood.  Cytokine anal. showed that the macrophage colony-stimulating factor CSF1 increased by two-fold in irradiated tumors.  Enhanced macrophage migration induced by conditioned media from irradiated tumor cells was completely blocked by a selective inhibitor of CSF1R.  These findings were confirmed in patients with prostate cancer, where serum levels of CSF1 increased after radiotherapy.  Mechanistic investigations revealed the recruitment of the DNA damage-induced kinase ABL1 into cell nuclei where it bound the CSFl gene promoter and enhanced CSFl gene transcription.  When added to radiotherapy, a selective inhibitor of CSF1R suppressed tumor growth more effectively than irradn. alone.  Our results highlight the importance of CSF1/CSF1R signaling in the recruitment of TIMs that can limit the efficacy of radiotherapy.  Furthermore, they suggest that CSF1 inhibitors should be evaluated in clin. trials in combination with radiotherapy as a strategy to improve outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomWESrA4ObubVg90H21EOLACvtfcHk0lgBWdi_rfZmJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVShtb8%253D&md5=6a6ca9efb87ed1c1c8b73aa6f0f042cd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-3981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-3981%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DEscamilla%26aufirst%3DJ.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DDavid%26aufirst%3DJ.%26aulast%3DPriceman%26aufirst%3DS.%26aulast%3DWest%26aufirst%3DB.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DMcBride%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DL.%26atitle%3DCSF1R%2520signaling%2520blockade%2520stanches%2520tumor-infiltrating%2520myeloid%2520cells%2520and%2520improves%2520the%2520efficacy%2520of%2520radiotherapy%2520in%2520prostate%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D2782%26epage%3D2794%26doi%3D10.1158%2F0008-5472.CAN-12-3981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escamilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schokrpur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priceman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moughon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magyar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradet, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span> <span> </span><span class="NLM_article-title">CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">950</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F0008-5472.CAN-14-0992" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=950-962&author=J.+Escamillaauthor=S.+Schokrpurauthor=C.+Liuauthor=S.+J.+Pricemanauthor=D.+Moughonauthor=Z.+Jiangauthor=F.+Pouliotauthor=C.+Magyarauthor=J.+L.+Sungauthor=J.+Xuauthor=G.+Dengauthor=B.+L.+Westauthor=G.+Bollagauthor=Y.+Fradetauthor=L.+Lacombeauthor=M.+E.+Jungauthor=J.+Huangauthor=L.+Wu&title=CSF1+receptor+targeting+in+prostate+cancer+reverses+macrophage-mediated+resistance+to+androgen+blockade+therapy&doi=10.1158%2F0008-5472.CAN-14-0992"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0992%26sid%3Dliteratum%253Aachs%26aulast%3DEscamilla%26aufirst%3DJ.%26aulast%3DSchokrpur%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DPriceman%26aufirst%3DS.%2BJ.%26aulast%3DMoughon%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DPouliot%26aufirst%3DF.%26aulast%3DMagyar%26aufirst%3DC.%26aulast%3DSung%26aufirst%3DJ.%2BL.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DFradet%26aufirst%3DY.%26aulast%3DLacombe%26aufirst%3DL.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%26atitle%3DCSF1%2520receptor%2520targeting%2520in%2520prostate%2520cancer%2520reverses%2520macrophage-mediated%2520resistance%2520to%2520androgen%2520blockade%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D950%26epage%3D962%26doi%3D10.1158%2F0008-5472.CAN-14-0992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pyonteck, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akkari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuhmacher, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevenich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quick, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huse, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teijeiro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedraza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. A.</span></span> <span> </span><span class="NLM_article-title">CSF-1R inhibition alters macrophage polarization and blocks glioma progression</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1264</span>– <span class="NLM_lpage">1272</span>, <span class="refDoi"> DOI: 10.1038/nm.3337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1038%2Fnm.3337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=24056773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2jsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1264-1272&author=S.+M.+Pyonteckauthor=L.+Akkariauthor=A.+J.+Schuhmacherauthor=R.+L.+Bowmanauthor=L.+Sevenichauthor=D.+F.+Quailauthor=O.+C.+Olsonauthor=M.+L.+Quickauthor=J.+T.+Huseauthor=V.+Teijeiroauthor=M.+Settyauthor=C.+S.+Leslieauthor=Y.+Oeiauthor=A.+Pedrazaauthor=J.+Zhangauthor=C.+W.+Brennanauthor=J.+C.+Suttonauthor=E.+C.+Hollandauthor=D.+Danielauthor=J.+A.+Joyce&title=CSF-1R+inhibition+alters+macrophage+polarization+and+blocks+glioma+progression&doi=10.1038%2Fnm.3337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">CSF-1R inhibition alters macrophage polarization and blocks glioma progression</span></div><div class="casAuthors">Pyonteck, Stephanie M.; Akkari, Leila; Schuhmacher, Alberto J.; Bowman, Robert L.; Sevenich, Lisa; Quail, Daniela F.; Olson, Oakley C.; Quick, Marsha L.; Huse, Jason T.; Teijeiro, Virginia; Setty, Manu; Leslie, Christina S.; Oei, Yoko; Pedraza, Alicia; Zhang, Jianan; Brennan, Cameron W.; Sutton, James C.; Holland, Eric C.; Daniel, Dylan; Joyce, Johanna A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1264-1272</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) comprises several mol. subtypes, including proneural GBM.  Most therapeutic approaches targeting glioma cells have failed.  An alternative strategy is to target cells in the glioma microenvironment, such as tumor-assocd. macrophages and microglia (TAMs).  Macrophages depend on colony stimulating factor-1 (CSF-1) for differentiation and survival.  We used an inhibitor of the CSF-1 receptor (CSF-1R) to target TAMs in a mouse proneural GBM model, which significantly increased survival and regressed established tumors.  CSF-1R blockade addnl. slowed intracranial growth of patient-derived glioma xenografts.  Surprisingly, TAMs were not depleted in treated mice.  Instead, glioma-secreted factors, including granulocyte-macrophage CSF (GM-CSF) and interferon-γ (IFN-γ), facilitated TAM survival in the context of CSF-1R inhibition.  Expression of alternatively activated M2 markers decreased in surviving TAMs, which is consistent with impaired tumor-promoting functions.  These gene signatures were assocd. with enhanced survival in patients with proneural GBM.  Our results identify TAMs as a promising therapeutic target for proneural gliomas and establish the translational potential of CSF-1R inhibition for GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrirwpRVIWUELVg90H21EOLACvtfcHk0lgBWdi_rfZmJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2jsr3N&md5=9b908e86c4a7da35a009bf322d492214</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnm.3337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3337%26sid%3Dliteratum%253Aachs%26aulast%3DPyonteck%26aufirst%3DS.%2BM.%26aulast%3DAkkari%26aufirst%3DL.%26aulast%3DSchuhmacher%26aufirst%3DA.%2BJ.%26aulast%3DBowman%26aufirst%3DR.%2BL.%26aulast%3DSevenich%26aufirst%3DL.%26aulast%3DQuail%26aufirst%3DD.%2BF.%26aulast%3DOlson%26aufirst%3DO.%2BC.%26aulast%3DQuick%26aufirst%3DM.%2BL.%26aulast%3DHuse%26aufirst%3DJ.%2BT.%26aulast%3DTeijeiro%26aufirst%3DV.%26aulast%3DSetty%26aufirst%3DM.%26aulast%3DLeslie%26aufirst%3DC.%2BS.%26aulast%3DOei%26aufirst%3DY.%26aulast%3DPedraza%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DC.%2BW.%26aulast%3DSutton%26aufirst%3DJ.%2BC.%26aulast%3DHolland%26aufirst%3DE.%2BC.%26aulast%3DDaniel%26aufirst%3DD.%26aulast%3DJoyce%26aufirst%3DJ.%2BA.%26atitle%3DCSF-1R%2520inhibition%2520alters%2520macrophage%2520polarization%2520and%2520blocks%2520glioma%2520progression%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1264%26epage%3D1272%26doi%3D10.1038%2Fnm.3337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belkowski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurmond, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthey, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenspan, A.</span></span> <span> </span><span class="NLM_article-title">Results from a phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1752</span>– <span class="NLM_lpage">1760</span>, <span class="refDoi"> DOI: 10.3899/jrheum.141580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.3899%2Fjrheum.141580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=26233509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVyqsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2015&pages=1752-1760&author=M.+C.+Genoveseauthor=E.+Hsiaauthor=S.+M.+Belkowskiauthor=C.+Chienauthor=T.+Mastersonauthor=R.+L.+Thurmondauthor=C.+L.+Mantheyauthor=X.+D.+Yanauthor=T.+Geauthor=C.+Franksauthor=A.+Greenspan&title=Results+from+a+phase+IIA+parallel+group+study+of+JNJ-40346527%2C+an+oral+CSF-1R+inhibitor%2C+in+patients+with+active+rheumatoid+arthritis+despite+disease-modifying+antirheumatic+drug+therapy&doi=10.3899%2Fjrheum.141580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Results from a phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy</span></div><div class="casAuthors">Genovese, Mark C.; Hsia, Elizabeth; Belkowski, Stanley M.; Chien, Caly; Masterson, Tara; Thurmond, Robin L.; Manthey, Carl L.; Yan, Xiaoyu; Ge, Tingting; Franks, Carol; Greenspan, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1752-1760</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">1499-2752</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective.  To assess the efficacy and safety of JNJ-40346527, a selective inhibitor of colony-stimulating factor-1 (CSF-1) receptor kinase that acts to inhibit macrophage survival, proliferation, and differentiation in patients with active rheumatoid arthritis (RA) despite disease-modifying antirheumatic drug (DMARD) therapy.  In this randomized, double-blind, placebo-controlled, parallel group study, adults were randomized (2:1) to receive oral JNJ-40346527 100 mg or placebo twice daily through Week 12.  Patients with RA had disease activity [≥ 6 swollen/≥ 6 tender joints, C-reactive protein (CRP) ≥ 0.8 mg/dL] despite DMARD therapy for ≥ 6 mo.  The primary endpoint was change from baseline at Week 12 in the 28-joint Disease Activity Score with CRP (DAS28-CRP).  Pharmacokinetic/pharmacodynamic analyses were also performed, and safety was assessed through Week 16.  Ninety-five patients were treated (63 JNJ-40346527, 32 placebo); 8 patients discontinued treatment (6 JNJ-40346527, 2 placebo) through Week 12.  Mean improvements in DAS28-CRP from baseline to Week 12 were 1.15 for the JNJ-40346527 group and 1.42 for the placebo group (p = 0.30); thus, a statistically significant difference was not obsd. for the primary endpoint.  Pharmacokinetic exposure to JNJ-40346527 and its active metabolites was above the projected concn. needed for pharmacol. activity, and effective target engagement and proof of activity were demonstrated by increased levels of CSF-1 and decreased CD16+ monocytes in JNJ-40346527-treated, but not placebo-treated, patients.  Thirty-seven (58.7%) JNJ-40346527-treated and 16 (50.0%) placebo-treated patients reported ≥ 1 adverse event (AE); 1 (1.6%) JNJ-40346527-treated and 3 (9.4%) placebo-treated patients reported ≥ 1 serious AE.  Conclusion.  Although adequate exposure and effective peripheral target engagement were evident, JNJ-40346527 efficacy was not obsd. in patients with DMARD-refractory active RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYP703ihQxAbVg90H21EOLACvtfcHk0ljDPjgjRv4l_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVyqsL7I&md5=691acfc23f3fdcb46c59da16c2d01455</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.141580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.141580%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DHsia%26aufirst%3DE.%26aulast%3DBelkowski%26aufirst%3DS.%2BM.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DMasterson%26aufirst%3DT.%26aulast%3DThurmond%26aufirst%3DR.%2BL.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DYan%26aufirst%3DX.%2BD.%26aulast%3DGe%26aufirst%3DT.%26aulast%3DFranks%26aufirst%3DC.%26aulast%3DGreenspan%26aufirst%3DA.%26atitle%3DResults%2520from%2520a%2520phase%2520IIA%2520parallel%2520group%2520study%2520of%2520JNJ-40346527%252C%2520an%2520oral%2520CSF-1R%2520inhibitor%252C%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520despite%2520disease-modifying%2520antirheumatic%2520drug%2520therapy%26jtitle%3DJ.%2520Rheumatol.%26date%3D2015%26volume%3D42%26spage%3D1752%26epage%3D1760%26doi%3D10.3899%2Fjrheum.141580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohzeki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murooka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serizawa, I.</span></span> <span> </span><span class="NLM_article-title">The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis</span>. <i>J. Neuroimmunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.jneuroim.2008.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.jneuroim.2008.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=18378004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVOrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2008&pages=73-80&author=Y.+Uemuraauthor=H.+Ohnoauthor=Y.+Ohzekiauthor=H.+Takanashiauthor=H.+Murookaauthor=K.+Kuboauthor=I.+Serizawa&title=The+selective+M-CSF+receptor+tyrosine+kinase+inhibitor+Ki20227+suppresses+experimental+autoimmune+encephalomyelitis&doi=10.1016%2Fj.jneuroim.2008.01.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis</span></div><div class="casAuthors">Uemura, Yasunori; Ohno, Hiroaki; Ohzeki, Yumiko; Takanashi, Hiromi; Murooka, Hideko; Kubo, Kazuo; Serizawa, Isao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroimmunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">73-80</span>CODEN:
                <span class="NLM_cas:coden">JNRIDW</span>;
        ISSN:<span class="NLM_cas:issn">0165-5728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Exptl. autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), can be induced by the immunization of mice with myelin antigens in the form of myelin oligodendrocyte glycoprotein (MOG).  Macrophage colony-stimulating factor (M-CSF) is required for the development of individual mononuclear phagocyte populations and is involved in the immune response.  We previously reported that Ki20227 (N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N'-[1-(1,3-thiazole-2-yl)ethyl]urea) is a highly selective M-CSF receptor (c-fms) tyrosine kinase inhibitor.  In our current study, we investigated whether Ki20227 has suppressive effects upon EAE and indeed found that this drug significantly reduced the severity of this disease both preventively and therapeutically.  Notably also, Ki20227 treatments inhibited the turn-over/expansion of myeloid cells provoked by the immunization and subsequent MOG-specific T cell responses in our EAE animal model.  These findings suggest that M-CSF plays a pivotal role in the development of EAE and that Ki20227 and its derivs. may be candidate drugs for the treatment of human MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobS3ECXzImwbVg90H21EOLACvtfcHk0ljDPjgjRv4l_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVOrsbc%253D&md5=92b102002c788d12d3ad7d7194b9607f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jneuroim.2008.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jneuroim.2008.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DUemura%26aufirst%3DY.%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DOhzeki%26aufirst%3DY.%26aulast%3DTakanashi%26aufirst%3DH.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DSerizawa%26aufirst%3DI.%26atitle%3DThe%2520selective%2520M-CSF%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520Ki20227%2520suppresses%2520experimental%2520autoimmune%2520encephalomyelitis%26jtitle%3DJ.%2520Neuroimmunol.%26date%3D2008%26volume%3D195%26spage%3D73%26epage%3D80%26doi%3D10.1016%2Fj.jneuroim.2008.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murooka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishitoba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoneda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isoe, T.</span></span> <span> </span><span class="NLM_article-title">A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2634</span>– <span class="NLM_lpage">2643</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-05-0313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F1535-7163.MCT-05-0313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=17121910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1els7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=2634-2643&author=H.+Ohnoauthor=K.+Kuboauthor=H.+Murookaauthor=Y.+Kobayashiauthor=T.+Nishitobaauthor=M.+Shibuyaauthor=T.+Yonedaauthor=T.+Isoe&title=A+c-fms+tyrosine+kinase+inhibitor%2C+Ki20227%2C+suppresses+osteoclast+differentiation+and+osteolytic+bone+destruction+in+a+bone+metastasis+model&doi=10.1158%2F1535-7163.MCT-05-0313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model</span></div><div class="casAuthors">Ohno, Hiroaki; Kubo, Kazuo; Murooka, Hideko; Kobayashi, Yoshiko; Nishitoba, Tsuyoshi; Shibuya, Masabumi; Yoneda, Toshiyuki; Isoe, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2634-2643</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In bone metastatic lesions, osteoclasts play a key role in the development of osteolysis.  Previous studies have shown that macrophage colony-stimulating factor (M-CSF) is important for the differentiation of osteoclasts.  In this study, we investigated whether an inhibitor of M-CSF receptor (c-Fms) suppresses osteoclast-dependent osteolysis in bone metastatic lesions.  We developed small mol. inhibitors against ligand-dependent phosphorylation of c-Fms and examd. the effects of these compds. on osteolytic bone destruction in a bone metastasis model.  We discovered a novel quinoline-urea deriv., Ki20227 (N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N'-[1-(1,3-thiazole-2-yl)ethyl]urea), which is a c-Fms tyrosine kinase inhibitor.  The IC50s of Ki20227 to inhibit c-Fms, vascular endothelial growth factor receptor-2 (KDR), stem cell factor receptor (c-Kit), and platelet-derived growth factor receptor {szligbeta} were found to be 2, 12, 451, and 217 nmol/L, resp.  Ki20227 did not inhibit other kinases tested, such as fms-like tyrosine kinase-3, epidermal growth factor receptor, or c-Src (c-src proto-oncogene product).  Ki20227 was also found to inhibit the M-CSF-dependent growth of M-NFS-60 cells but not the M-CSF-independent growth of A375 human melanoma cells in vitro.  Furthermore, in an osteoclast-like cell formation assay using mouse bone marrow cells, Ki20227 inhibited the development of tartrate-resistant acid phosphatase-pos. osteoclast-like cells in a dose-dependent manner.  In in vivo studies, oral administration of Ki20227 suppressed osteoclast-like cell accumulation and bone resorption induced by metastatic tumor cells in nude rats following intracardiac injection of A375 cells.  Moreover, Ki20227 decreased the no. of tartrate-resistant acid phosphatase-pos. osteoclast-like cells on bone surfaces in ovariectomized (ovx) rats.  These findings suggest that Ki20227 inhibits osteolytic bone destruction through the suppression of M-CSF-induced osteoclast accumulation in vivo.  Therefore, Ki20227 may be a useful therapeutic agent for osteolytic disease assocd. with bone metastasis and other bone diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpseoHCyJngCrVg90H21EOLACvtfcHk0ljDPjgjRv4l_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1els7jF&md5=1f7746c1735cdc91c3aa9789e030a1a5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0313%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DNishitoba%26aufirst%3DT.%26aulast%3DShibuya%26aufirst%3DM.%26aulast%3DYoneda%26aufirst%3DT.%26aulast%3DIsoe%26aufirst%3DT.%26atitle%3DA%2520c-fms%2520tyrosine%2520kinase%2520inhibitor%252C%2520Ki20227%252C%2520suppresses%2520osteoclast%2520differentiation%2520and%2520osteolytic%2520bone%2520destruction%2520in%2520a%2520bone%2520metastasis%2520model%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D2634%26epage%3D2643%26doi%3D10.1158%2F1535-7163.MCT-05-0313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cannarile, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jegg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruttinger, D.</span></span> <span> </span><span class="NLM_article-title">Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy</span>. <i>J. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1186/s40425-017-0257-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1186%2Fs40425-017-0257-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A280%3ADC%252BC1cjosVSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=53-66&author=M.+A.+Cannarileauthor=M.+Weisserauthor=W.+Jacobauthor=A.+M.+Jeggauthor=C.+H.+Riesauthor=D.+Ruttinger&title=Colony-stimulating+factor+1+receptor+%28CSF1R%29+inhibitors+in+cancer+therapy&doi=10.1186%2Fs40425-017-0257-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy</span></div><div class="casAuthors">Cannarile Michael A; Weisser Martin; Jacob Wolfgang; Jegg Anna-Maria; Ries Carola H; Ruttinger Dominik</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells.  In this context, the colony-stimulating factor 1 (CSF1)/colony-stimulating factor 1 receptor (CSF1R) axis has gained the most attention, and various approaches targeting either the ligands or the receptor are currently in clinical development.  Emerging data on the tolerability of CSF1/CSF1R-targeting agents suggest a favorable safety profile, making them attractive combination partners for both standard treatment modalities and immunotherapeutic agents.  The specificity of these agents and their potent blocking activity has been substantiated by impressive response rates in diffuse-type tenosynovial giant cell tumors, a benign connective tissue disorder driven by CSF1 in an autocrine fashion.  In the malignant disease setting, data on the clinical activity of immunotherapy combinations with CSF1/CSF1R-targeting agents are pending.  As our knowledge of macrophage biology expands, it becomes apparent that the complex phenotypic and functional properties of macrophages are heavily influenced by a continuum of survival, differentiation, recruitment, and polarization signals within their specific tissue environment.  Thus, the role of macrophages in regulating tumorigenesis and the impact of depleting and/or reprogramming TAM as therapeutic approaches for cancer patients may vary greatly depending on organ-specific characteristics of these cells.  We review the currently available clinical safety and efficacy data with CSF1/CSF1R-targeting agents and provide a comprehensive overview of ongoing clinical studies.  Furthermore, we discuss the local tissue macrophage and tumor-type specificities and their potential impact on CSF1/CSF1R-targeting treatment strategies for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQzjcxKO1-OQqdek-gHSrIfW6udTcc2eYJ7QzIMSmNXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjosVSnsg%253D%253D&md5=09fab249b606af3e00f545dc7e7121b4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1186%2Fs40425-017-0257-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-017-0257-y%26sid%3Dliteratum%253Aachs%26aulast%3DCannarile%26aufirst%3DM.%2BA.%26aulast%3DWeisser%26aufirst%3DM.%26aulast%3DJacob%26aufirst%3DW.%26aulast%3DJegg%26aufirst%3DA.%2BM.%26aulast%3DRies%26aufirst%3DC.%2BH.%26aulast%3DRuttinger%26aufirst%3DD.%26atitle%3DColony-stimulating%2520factor%25201%2520receptor%2520%2528CSF1R%2529%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DJ.%2520Immunother.%26date%3D2017%26volume%3D5%26spage%3D53%26epage%3D66%26doi%3D10.1186%2Fs40425-017-0257-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staddon, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterfy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, Z. A.</span></span> <span> </span><span class="NLM_article-title">A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">10503</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=10503&author=W.+D.+Tapauthor=S.+P.+Anthonyauthor=B.+Chmielowskiauthor=A.+P.+Staddonauthor=A.+L.+Cohnauthor=G.+Shapiroauthor=I.+Puzanovauthor=E.+L.+Kwakauthor=A.+J.+Wagnerauthor=C.+Peterfyauthor=H.+H.+Hsuauthor=C.+Geeauthor=P.+S.+Linauthor=S.+Tongauthor=Z.+A.+Wainberg&title=A+pilot+study+of+PLX3397%2C+a+selective+colony-stimulating+factor+1+receptor+%28CSF1R%29+kinase+inhibitor%2C+in+pigmented+villonodular+synovitis+%28PVNS%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DStaddon%26aufirst%3DA.%2BP.%26aulast%3DCohn%26aufirst%3DA.%2BL.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DPeterfy%26aufirst%3DC.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DGee%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DTong%26aufirst%3DS.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26atitle%3DA%2520pilot%2520study%2520of%2520PLX3397%252C%2520a%2520selective%2520colony-stimulating%2520factor%25201%2520receptor%2520%2528CSF1R%2529%2520kinase%2520inhibitor%252C%2520in%2520pigmented%2520villonodular%2520synovitis%2520%2528PVNS%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D10503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span> <span> </span><span class="NLM_article-title">Abstract PR01: blocking colony stimulating factor 1 receptor (CSF-1R) and tropomyosin receptor kinase (Trk) improves antitumor efficacy of immunotherapy</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">PR01</span>, <span class="refDoi"> DOI: 10.1158/2326-6074.TUMIMM16-PR01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F2326-6074.TUMIMM16-PR01" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=PR01&author=S.+Mokauthor=C.+Duffyauthor=R.+Duauthor=J.+P.+Allison&title=Abstract+PR01%3A+blocking+colony+stimulating+factor+1+receptor+%28CSF-1R%29+and+tropomyosin+receptor+kinase+%28Trk%29+improves+antitumor+efficacy+of+immunotherapy&doi=10.1158%2F2326-6074.TUMIMM16-PR01"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2326-6074.TUMIMM16-PR01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6074.TUMIMM16-PR01%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DS.%26aulast%3DDuffy%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DR.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26atitle%3DAbstract%2520PR01%253A%2520blocking%2520colony%2520stimulating%2520factor%25201%2520receptor%2520%2528CSF-1R%2529%2520and%2520tropomyosin%2520receptor%2520kinase%2520%2528Trk%2529%2520improves%2520antitumor%2520efficacy%2520of%2520immunotherapy%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2017%26volume%3D5%26spage%3DPR01%26doi%3D10.1158%2F2326-6074.TUMIMM16-PR01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrus, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cable, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span> <span> </span><span class="NLM_article-title">Abstract A252: a phase 1 study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF1R), in patients with advanced or metastatic cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">A252</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.TARG-13-A252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F1535-7163.TARG-13-A252" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=A252&author=J.+C.+Bendellauthor=A.+W.+Tolcherauthor=S.+F.+Jonesauthor=M.+Beeramauthor=J.+R.+Infanteauthor=P.+Larsenauthor=K.+Rasorauthor=J.+E.+Garrusauthor=J.+Liauthor=P.+L.+Cableauthor=C.+Eberhardtauthor=J.+Schreiberauthor=S.+Rushauthor=K.+W.+Woodauthor=E.+Barrettauthor=A.+Patnaik&title=Abstract+A252%3A+a+phase+1+study+of+ARRY-382%2C+an+oral+inhibitor+of+colony-stimulating+factor-1+receptor+%28CSF1R%29%2C+in+patients+with+advanced+or+metastatic+cancers&doi=10.1158%2F1535-7163.TARG-13-A252"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-13-A252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-13-A252%26sid%3Dliteratum%253Aachs%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DJones%26aufirst%3DS.%2BF.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DLarsen%26aufirst%3DP.%26aulast%3DRasor%26aufirst%3DK.%26aulast%3DGarrus%26aufirst%3DJ.%2BE.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCable%26aufirst%3DP.%2BL.%26aulast%3DEberhardt%26aufirst%3DC.%26aulast%3DSchreiber%26aufirst%3DJ.%26aulast%3DRush%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DK.%2BW.%26aulast%3DBarrett%26aufirst%3DE.%26aulast%3DPatnaik%26aufirst%3DA.%26atitle%3DAbstract%2520A252%253A%2520a%2520phase%25201%2520study%2520of%2520ARRY-382%252C%2520an%2520oral%2520inhibitor%2520of%2520colony-stimulating%2520factor-1%2520receptor%2520%2528CSF1R%2529%252C%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3DA252%26doi%3D10.1158%2F1535-7163.TARG-13-A252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Von
Tresckow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribrag, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topp, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seetharam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquino, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotoulek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engert, A.</span></span> <span> </span><span class="NLM_article-title">An open-label, multicenter, phase I/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory hodgkin lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1843</span>– <span class="NLM_lpage">1850</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F1078-0432.CCR-14-1845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=25628399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsl2gt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1843-1850&author=B.+Von%0ATresckowauthor=F.+Morschhauserauthor=V.+Ribragauthor=M.+S.+Toppauthor=C.+Chienauthor=S.+Seetharamauthor=R.+Aquinoauthor=S.+Kotoulekauthor=C.+J.+de+Boerauthor=A.+Engert&title=An+open-label%2C+multicenter%2C+phase+I%2FII+study+of+JNJ-40346527%2C+a+CSF-1R+inhibitor%2C+in+patients+with+relapsed+or+refractory+hodgkin+lymphoma&doi=10.1158%2F1078-0432.CCR-14-1845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma</span></div><div class="casAuthors">von Tresckow, Bastian; Morschhauser, Franck; Ribrag, Vincent; Topp, Max S.; Chien, Caly; Seetharam, Shobha; Aquino, Regina; Kotoulek, Sonja; de Boer, Carla J.; Engert, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1843-1850</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This phase I/II study investigated JNJ-40346527, a selective inhibitor of the colony-stimulating factor-1 receptor (CSF-1R) tyrosine kinase as treatment for relapsed or refractory classical Hodgkin lymphoma (cHL).  Patients ≥18 years with histopathol. confirmed initial diagnosis of cHL that had relapsed or was refractory after ≥1 appropriate therapies were assigned to sequential cohorts of oral daily doses of JNJ-40346527 (150, 300, 450, 600 mg every day, and 150 mg twice a day).  For the dose-escalation phase, the primary endpoint was to establish the recommended phase II dose.  Secondary endpoints included safety, pharmacokinetics, and pharmacodynamics.  Twenty-one patients [(150 mg: 3; 300 mg: 5; 450 mg: 3, 600 mg: 3) every day, and 150 mg twice a day: 7] were enrolled, 10 men, median age 40 (range, 19-75) years, median no. of prior systemic therapies 6 (range, 3-14).  No dose-limiting toxicities were obsd.; max.-tolerated dose was not established.  Best overall response was complete remission in 1 patient (duration, +352 days) and stable disease in 11 patients: (duration, 1.5-8 mo).  Median no. of cycles: 4 (range, 1-16).  Most common (≥20% patients) possibly drug-related adverse events (per investigator assessment) were nausea (n = 6), headache, and pyrexia (n = 5 each).  JNJ-40346527 exposure increased in near dose-proportional manner over a dose range of 150 to 450 mg every day, but plateaued at 600 mg every day.  Target engagement was confirmed (>80% inhibition of CSF-1R phosphorylation, 4 h after dosing).  JNJ-40346527, a selective inhibitor of CSF-1R was well tolerated, and preliminary antitumor results suggested limited activity in monotherapy for the treatment of cHL.  Clin Cancer Res; 21(8); 1843-50. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwZuUy9-7MhLVg90H21EOLACvtfcHk0lhLo7MF8FSGoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsl2gt7g%253D&md5=e3d4f2b2937078f85ef0ead51e093f82</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1845%26sid%3Dliteratum%253Aachs%26aulast%3DVon%2BTresckow%26aufirst%3DB.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DRibrag%26aufirst%3DV.%26aulast%3DTopp%26aufirst%3DM.%2BS.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DSeetharam%26aufirst%3DS.%26aulast%3DAquino%26aufirst%3DR.%26aulast%3DKotoulek%26aufirst%3DS.%26aulast%3Dde%2BBoer%26aufirst%3DC.%2BJ.%26aulast%3DEngert%26aufirst%3DA.%26atitle%3DAn%2520open-label%252C%2520multicenter%252C%2520phase%2520I%252FII%2520study%2520of%2520JNJ-40346527%252C%2520a%2520CSF-1R%2520inhibitor%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520hodgkin%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1843%26epage%3D1850%26doi%3D10.1158%2F1078-0432.CCR-14-1845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8803</span>– <span class="NLM_lpage">8813</span>, <span class="refDoi"> DOI: 10.1021/jm4012388</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4012388" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8803-8813&author=S.+Xuauthor=T.+Xuauthor=L.+Zhangauthor=Z.+Zhangauthor=J.+Luoauthor=Y.+Liuauthor=X.+Luauthor=Z.+Tuauthor=X.+Renauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+2-oxo-3%2C4-dihydropyrimido%5B4%2C5-d%5Dpyrimidinyl+derivatives+as+new+irreversible+epidermal+growth+factor+receptor+inhibitors+with+improved+pharmacokinetic+properties&doi=10.1021%2Fjm4012388"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm4012388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4012388%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25202-oxo-3%252C4-dihydropyrimido%255B4%252C5-d%255Dpyrimidinyl%2520derivatives%2520as%2520new%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520with%2520improved%2520pharmacokinetic%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8803%26epage%3D8813%26doi%3D10.1021%2Fjm4012388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790 → methionine790 mutant</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2711</span>– <span class="NLM_lpage">2723</span>, <span class="refDoi"> DOI: 10.1021/jm201591k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%E2%86%92+methionine790+mutant&doi=10.1021%2Fjm201591k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520%25E2%2586%2592%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723%26doi%3D10.1021%2Fjm201591k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Pyrimido[4,5-<i>d</i>]pyrimidin- 4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">8387</span>– <span class="NLM_lpage">8390</span>, <span class="refDoi"> DOI: 10.1002/anie.201302313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1002%2Fanie.201302313" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=8387-8390&author=T.+Xuauthor=L.+Zhangauthor=S.+Xuauthor=C.-Y.+Yangauthor=J.+Luoauthor=F.+Dingauthor=X.+Luauthor=Y.+Liuauthor=Z.+Tuauthor=S.+Liauthor=D.+Peiauthor=Q.+Caiauthor=H.+Liauthor=X.+Renauthor=S.+Wangauthor=K.+Ding&title=Pyrimido%5B4%2C5-d%5Dpyrimidin-+4%281H%29-one+derivatives+as+selective+inhibitors+of+EGFR+threonine790+to+methionine790+%28T790M%29+mutants&doi=10.1002%2Fanie.201302313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302313%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DPyrimido%255B4%252C5-d%255Dpyrimidin-%25204%25281H%2529-one%2520derivatives%2520as%2520selective%2520inhibitors%2520of%2520EGFR%2520threonine790%2520to%2520methionine790%2520%2528T790M%2529%2520mutants%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D8387%26epage%3D8390%26doi%3D10.1002%2Fanie.201302313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartual, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of tetrahydroisoquinoline-7-carboxamides as selective discoidin domain receptor 1 (DDR1) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5911</span>– <span class="NLM_lpage">5916</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00140</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00140" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5911-5916&author=Z.+Wangauthor=H.+Bianauthor=S.+G.+Bartualauthor=W.+Duauthor=J.+Luoauthor=H.+Zhaoauthor=S.+Zhangauthor=C.+Moauthor=Y.+Zhouauthor=Y.+Xuauthor=Z.+Tuauthor=X.+Renauthor=X.+Luauthor=R.+A.+Brekkenauthor=L.+Yaoauthor=A.+N.+Bullockauthor=J.+Suauthor=K.+Ding&title=Structure-based+design+of+tetrahydroisoquinoline-7-carboxamides+as+selective+discoidin+domain+receptor+1+%28DDR1%29+inhibitors&doi=10.1021%2Facs.jmedchem.6b00140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors</span></div><div class="casAuthors">Wang, Zhen; Bian, Huan; Bartual, Sergio G.; Du, Wenting; Luo, Jinfeng; Zhao, Hu; Zhang, Shasha; Mo, Cheng; Zhou, Yang; Xu, Yong; Tu, Zhengchao; Ren, Xiaomei; Lu, Xiaoyun; Brekken, Rolf A.; Yao, Libo; Bullock, Alex N.; Su, Jin; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5911-5916</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The structure-based design of 1, 2, 3, 4-tetrahydroisoquinoline derivs. as selective DDR1 inhibitors is reported.  One of the representative compds., 6j, binds to DDR1 with a Kd value of 4.7 nM and suppresses its kinase activity with an IC50 value of 9.4 nM, but it is significantly less potent for a panel of 400 nonmutated kinases. 6j also demonstrated reasonable pharmacokinetic properties and a promising oral therapeutic effect in a bleomycin-induced mouse pulmonary fibrosis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonNN4RHw3FiLVg90H21EOLACvtfcHk0lh3M8yZi80IBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSmsbc%253D&md5=9501db1f3b0dbc338749eccbd63bace8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00140%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DBartual%26aufirst%3DS.%2BG.%26aulast%3DDu%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DMo%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DBrekken%26aufirst%3DR.%2BA.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DStructure-based%2520design%2520of%2520tetrahydroisoquinoline-7-carboxamides%2520as%2520selective%2520discoidin%2520domain%2520receptor%25201%2520%2528DDR1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5911%26epage%3D5916%26doi%3D10.1021%2Facs.jmedchem.6b00140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartual, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Tetrahydroisoquinoline-7-carboxamide derivatives as new selective discoidin domain receptor 1 (DDR1) inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00497</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00497" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVSrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=327-332&author=Z.+Wangauthor=Y.+Zhangauthor=S.+G.+Bartualauthor=J.+Luoauthor=T.+Xuauthor=W.+Duauthor=Q.+Xunauthor=Z.+Tuauthor=R.+A.+Brekkenauthor=X.+Renauthor=A.+N.+Bullockauthor=G.+Liangauthor=X.+Luauthor=K.+Ding&title=Tetrahydroisoquinoline-7-carboxamide+derivatives+as+new+selective+discoidin+domain+receptor+1+%28DDR1%29+inhibitors&doi=10.1021%2Facsmedchemlett.6b00497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors</span></div><div class="casAuthors">Wang, Zhen; Zhang, Yali; Bartual, Sergio G.; Luo, Jinfeng; Xu, Tingting; Du, Wenting; Xun, Qiuju; Tu, Zhengchao; Brekken, Rolf A.; Ren, Xiaomei; Bullock, Alex N.; Liang, Guang; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-332</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acute lung injury (ALI) is a deadly symptom for serious lung inflammation.  Discoidin Domain Receptor 1 (DDR1) is a new potential target for anti-inflammatory drug discovery.  A new selective tetrahydroisoquinoline-7-carboxamide based DDR1 inhibitor (R)-4-methyl-N-(3-((4-methyl-1,4-diazepan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1, 2, 3, 4-tetrahydroisoquinoline-7-carboxamide (7ae) was discovered to tightly bind the DDR1 protein and potently inhibit its kinase function with a Kd value of 2.2 nM and an IC50 value of 6.6 nM, resp.  The compd. dose-dependently inhibited lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) release in mouse primary peritoneal macrophages (MPMs).  In addn., (7ae) also exhibited promising in vivo anti-inflammatory effects in a LPS-induced mouse ALI model.  To the best of the authors' knowledge, this is the first "proof of concept" investigation on the potential application of a small mol. DDR1 inhibitor to treat ALI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyzN2DN8OhvrVg90H21EOLACvtfcHk0lh3M8yZi80IBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVSrt78%253D&md5=2c1a3a6827e854718025672d24dacf4a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00497%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartual%26aufirst%3DS.%2BG.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DDu%26aufirst%3DW.%26aulast%3DXun%26aufirst%3DQ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DBrekken%26aufirst%3DR.%2BA.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DTetrahydroisoquinoline-7-carboxamide%2520derivatives%2520as%2520new%2520selective%2520discoidin%2520domain%2520receptor%25201%2520%2528DDR1%2529%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D327%26epage%3D332%26doi%3D10.1021%2Facsmedchemlett.6b00497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">4-Oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new Axl kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6807</span>– <span class="NLM_lpage">6825</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFersrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6807-6825&author=L.+Tanauthor=Z.+Zhangauthor=D.+Gaoauthor=J.+Luoauthor=Z.+Tuauthor=Z.+Liauthor=L.+Pengauthor=X.+Renauthor=K.+Ding&title=4-Oxo-1%2C4-dihydroquinoline-3-carboxamide+derivatives+as+new+Axl+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.6b00608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">4-Oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new Axl kinase inhibitors</span></div><div class="casAuthors">Tan, Li; Zhang, Zhang; Gao, Donglin; Luo, Jinfeng; Tu, Zheng-Chao; Li, Zhengqiu; Peng, Lijie; Ren, Xiaomei; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6807-6825</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Axl is a new potential target for anticancer drug discovery.  A series of 4-oxo-1,4-dihydroquinoline-3-carboxamides I (9a-u, 9ha-9hh, 9ia-9ic; R1 = H, Cl, F, Br, CF3, Me, Et, cyclopropyl, iPr, isopropenyl, OMe, CO2Me; R2, R3 = H, Me, Et, n-Pr, Bu, Ph; R4 = F, H, Me) and II [9id-9im; Z = CH, N; X = H, Cl; Y = H, NH2; X-Y = CPh:CHO, CPh:CHNH, CH:C(OMe)C(OMe):CH] were designed and synthesized as highly potent Axl kinase inhibitors.  One of the most promising compds., 9im [shown as II, X-Y = CH:C(OMe)C(OMe):CH], tightly bound with Axl protein and potently inhibited its kinase function with a Kd value of 2.7 nM and an IC50 value of 4.0 nM, resp., while was obviously less potent against most of the 403 wild-type kinases evaluated at a relatively high concn.  The compd. dose-dependently inhibited the TGF-β1-induced epithelial-mesenchymal transition (EMT) and suppressed the migration and invasion of MDA-MB-231 breast cancer cells.  In addn., 9im also demonstrated reasonable pharmacokinetics properties in rats and exhibited in vivo therapeutic effect on hepatic metastasis in a xenograft model of highly metastatic 4T1 murine breast cancer cells.  Compd. 9im may serve as a lead compd. for new anticancer drug discovery and a valuable research probe for further biol. investigation on Axl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtSA_rcxZaeLVg90H21EOLACvtfcHk0lh3M8yZi80IBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFersrnO&md5=2b737ed5ab9349788d82c0d1ec81b914</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00608%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3D4-Oxo-1%252C4-dihydroquinoline-3-carboxamide%2520derivatives%2520as%2520new%2520Axl%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6807%26epage%3D6825%26doi%3D10.1021%2Facs.jmedchem.6b00608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibu, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Structure based design of N-(3-((1<i>H</i>-Pyrazolo[3,4-<i>b</i>]pyridin-5-yl)ethynyl)benzenesulfonamides as selective leucine-zipper and sterile-α motif kinase (ZAK) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5927</span>– <span class="NLM_lpage">5932</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Kntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5927-5932&author=Y.+Changauthor=X.+Luauthor=M.+A.+Shibuauthor=Y.+Daiauthor=J.+Luoauthor=Y.+Zhangauthor=Y.+Liauthor=P.+Zhaoauthor=Z.+Zhangauthor=Y.+Xuauthor=Z.+Tuauthor=Q.+Zhangauthor=C.+Yunauthor=C.+Huangauthor=K.+Ding&title=Structure+based+design+of+N-%283-%28%281H-Pyrazolo%5B3%2C4-b%5Dpyridin-5-yl%29ethynyl%29benzenesulfonamides+as+selective+leucine-zipper+and+sterile-%CE%B1+motif+kinase+%28ZAK%29+inhibitors&doi=10.1021%2Facs.jmedchem.7b00572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Design of N-(3-(1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides as Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors</span></div><div class="casAuthors">Chang, Yu; Lu, Xiaoyun; Shibu, Marthandam Asokan; Dai, Yi-Bo; Luo, Jinfeng; Zhang, Yan; Li, Yingjun; Zhao, Peng; Zhang, Zhang; Xu, Yong; Tu, Zheng-Chao; Zhang, Qing-Wen; Yun, Cai-Hong; Huang, Chih-Yang; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5927-5932</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-(3-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides were designed as the first class of highly selective ZAK inhibitors.  The representative compd. I strongly inhibits the kinase activity of ZAK with an IC50 of 3.3 nM and dose-dependently suppresses the activation of ZAK downstream signals in vitro and in vivo, while it is significantly less potent for the majority of 403 nonmutated kinases evaluated.  Compd. I also exhibits orally therapeutic effects on cardiac hypertrophy in a spontaneous hypertensive rat model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotz-RCM9CJUbVg90H21EOLACvtfcHk0ljuwTNPWH3tiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Kntb4%253D&md5=897a22435eaf2f7721813f23eb40a62a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00572%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DShibu%26aufirst%3DM.%2BA.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DYun%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DStructure%2520based%2520design%2520of%2520N-%25283-%2528%25281H-Pyrazolo%255B3%252C4-b%255Dpyridin-5-yl%2529ethynyl%2529benzenesulfonamides%2520as%2520selective%2520leucine-zipper%2520and%2520sterile-%25CE%25B1%2520motif%2520kinase%2520%2528ZAK%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5927%26epage%3D5932%26doi%3D10.1021%2Facs.jmedchem.7b00572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guise, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">2-Aminopyrimidine derivatives as new selective fibroblast growth factor receptor 4 (FGFR4) inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00091</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=543-548&author=C.+Moauthor=Z.+Zhangauthor=C.+P.+Guiseauthor=X.+Liauthor=J.+Luoauthor=Z.+Tuauthor=Y.+Xuauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=X.+Renauthor=X.+Luauthor=K.+Ding&title=2-Aminopyrimidine+derivatives+as+new+selective+fibroblast+growth+factor+receptor+4+%28FGFR4%29+inhibitors&doi=10.1021%2Facsmedchemlett.7b00091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors</span></div><div class="casAuthors">Mo, Cheng; Zhang, Zhang; Guise, Christopher P.; Li, Xueqiang; Luo, Jinfeng; Tu, Zhengchao; Xu, Yong; Patterson, Adam V.; Smaill, Jeff B.; Ren, Xiaomei; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-548</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 2-aminopyrimidine derivs. were designed and synthesized as highly selective FGFR4 inhibitors.  One of the most promising compds. I tightly bound FGFR4 with a Kd value of 3.3 nM and potently inhibited its enzymic activity with an IC50 value of 2.6 nM, but completely spared FGFR1/2/3.  The compd. selectively suppressed proliferation of breast cancer cells harboring dysregulated FGFR4 signaling with an IC50 value of 0.38 μM.  Furthermore, I exhibited extraordinary target specificity in a Kinome-wide screen against 468 kinases, with S(35) and S(10) selectivity scores of 0.01 and 0.007 at 1.0 μM, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqZiLAE7lPj7Vg90H21EOLACvtfcHk0ljuwTNPWH3tiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7s%253D&md5=63aec200353c08090a50a9c5988442bd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00091%26sid%3Dliteratum%253Aachs%26aulast%3DMo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGuise%26aufirst%3DC.%2BP.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3D2-Aminopyrimidine%2520derivatives%2520as%2520new%2520selective%2520fibroblast%2520growth%2520factor%2520receptor%25204%2520%2528FGFR4%2529%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D543%26epage%3D548%26doi%3D10.1021%2Facsmedchemlett.7b00091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodems, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makings, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stack, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollok, B. A.</span></span> <span> </span><span class="NLM_article-title">A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1089/154065802761001266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1089%2F154065802761001266" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=9-19&author=S.+M.+Rodemsauthor=B.+D.+Hammanauthor=C.+Linauthor=J.+Zhaoauthor=S.+Shahauthor=D.+Heidaryauthor=L.+Makingsauthor=J.+H.+Stackauthor=B.+A.+Pollok&title=A+FRET-based+assay+platform+for+ultra-high+density+drug+screening+of+protein+kinases+and+phosphatases&doi=10.1089%2F154065802761001266"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1089%2F154065802761001266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F154065802761001266%26sid%3Dliteratum%253Aachs%26aulast%3DRodems%26aufirst%3DS.%2BM.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DHeidary%26aufirst%3DD.%26aulast%3DMakings%26aufirst%3DL.%26aulast%3DStack%26aufirst%3DJ.%2BH.%26aulast%3DPollok%26aufirst%3DB.%2BA.%26atitle%3DA%2520FRET-based%2520assay%2520platform%2520for%2520ultra-high%2520density%2520drug%2520screening%2520of%2520protein%2520kinases%2520and%2520phosphatases%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2002%26volume%3D1%26spage%3D9%26epage%3D19%26doi%3D10.1089%2F154065802761001266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruciani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carosati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Boeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vianello, R.</span></span> <span> </span><span class="NLM_article-title">MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6970</span>– <span class="NLM_lpage">6979</span>, <span class="refDoi"> DOI: 10.1021/jm050529c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050529c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGis73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6970-6979&author=G.+Crucianiauthor=E.+Carosatiauthor=B.+De+Boeckauthor=K.+Ethirajuluauthor=C.+Mackieauthor=T.+Howeauthor=R.+Vianello&title=MetaSite%3A+understanding+metabolism+in+human+cytochromes+from+the+perspective+of+the+chemist&doi=10.1021%2Fjm050529c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">MetaSite: Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist</span></div><div class="casAuthors">Cruciani, Gabriele; Carosati, Emanuele; De Boeck, Benoit; Ethirajulu, Kantharaj; Mackie, Claire; Howe, Trevor; Vianello, Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6970-6979</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification of metabolic biotransformations can significantly affect the drug discovery process.  Since bioavailability, activity, toxicity, distribution, and final elimination all depend on metabolic biotransformations, it would be extremely advantageous if this information could be produced early in the discovery phase.  Once obtained, this information can help chemists to judge whether a potential candidate should be eliminated from the pipeline or modified to improve chem. stability or safety of new compds.  The use of in silico methods to predict the site of metab. in phase I cytochrome-mediated reactions is a starting point in any metabolic pathway prediction.  This paper presents a new method, specifically designed for chemists, that provides the cytochrome involved and the site of metab. for any human cytochrome P 450 (CYP) mediated reaction acting on new substrates.  The methodol. can be applied automatically to all the cytochromes for which 3D structure is known and can be used by chemists to detect positions that should be protected in order to avoid metabolic degrdn. or to check the suitability of a new scaffold or prodrug.  The fully automated procedure is also a valuable new tool in early ADME-Tox assays (absorption, distribution, metab., and excretion toxicity assays), where drug safety and metabolic profile patterns must be evaluated as soon, and as early, as possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzNL56jqRMpbVg90H21EOLACvtfcHk0lgWWRsttp6dqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGis73F&md5=0a4576ffbea74e677832b7dbe8e036f0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm050529c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050529c%26sid%3Dliteratum%253Aachs%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DCarosati%26aufirst%3DE.%26aulast%3DDe%2BBoeck%26aufirst%3DB.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DHowe%26aufirst%3DT.%26aulast%3DVianello%26aufirst%3DR.%26atitle%3DMetaSite%253A%2520understanding%2520metabolism%2520in%2520human%2520cytochromes%2520from%2520the%2520perspective%2520of%2520the%2520chemist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6970%26epage%3D6979%26doi%3D10.1021%2Fjm050529c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors&doi=10.1016%2Fj.chembiol.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0lgWWRsttp6dqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.chembiol.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">4869</span>– <span class="NLM_lpage">4877</span>, <span class="refDoi"> DOI: 10.1073/pnas.1403438111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1073%2Fpnas.1403438111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=4869-4877&author=L.+Tanauthor=J.+Wangauthor=J.+Tanizakiauthor=Z.+Huangauthor=A.+R.+Arefauthor=M.+Rusanauthor=S.+J.+Zhuauthor=Y.+Zhangauthor=D.+Ercanauthor=R.+G.+Liaoauthor=M.+Capellettiauthor=W.+Zhouauthor=W.+Hurauthor=N.+Kimauthor=T.+Simauthor=S.+Gaudetauthor=D.+A.+Barbieauthor=J.+R.+Yehauthor=C.+H.+Yunauthor=P.+S.+Hammermanauthor=M.+Mohammadiauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Development+of+covalent+inhibitors+that+can+overcome+resistance+to+first-generation+FGFR+kinase+inhibitors&doi=10.1073%2Fpnas.1403438111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1403438111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1403438111%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DRusan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DR.%2BG.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGaudet%26aufirst%3DS.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DYeh%26aufirst%3DJ.%2BR.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520covalent%2520inhibitors%2520that%2520can%2520overcome%2520resistance%2520to%2520first-generation%2520FGFR%2520kinase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D4869%26epage%3D4877%26doi%3D10.1073%2Fpnas.1403438111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guise, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taghipouran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yosaatmadja, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashoorzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squire, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">2-Oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.ejmech.2017.04.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2017&pages=531-543&author=X.+Liauthor=C.+P.+Guiseauthor=R.+Taghipouranauthor=Y.+Yosaatmadjaauthor=A.+Ashoorzadehauthor=W.-K.+Paikauthor=C.+J.+Squireauthor=S.+Jiangauthor=J.+Luoauthor=Y.+Xuauthor=Z.-C.+Tuauthor=X.+Luauthor=X.+Renauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=K.+Ding&title=2-Oxo-3%2C4-dihydropyrimido%5B4%2C5-d%5Dpyrimidinyl+derivatives+as+new+irreversible+pan+fibroblast+growth+factor+receptor+%28FGFR%29+inhibitors&doi=10.1016%2Fj.ejmech.2017.04.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGuise%26aufirst%3DC.%2BP.%26aulast%3DTaghipouran%26aufirst%3DR.%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DAshoorzadeh%26aufirst%3DA.%26aulast%3DPaik%26aufirst%3DW.-K.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.-C.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDing%26aufirst%3DK.%26atitle%3D2-Oxo-3%252C4-dihydropyrimido%255B4%252C5-d%255Dpyrimidinyl%2520derivatives%2520as%2520new%2520irreversible%2520pan%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D135%26spage%3D531%26epage%3D543%26doi%3D10.1016%2Fj.ejmech.2017.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szklarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Azeez, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajczyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepetov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Haj Zen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourches, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tropsha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span> <span> </span><span class="NLM_article-title">Comprehensive characterization of the published kinase inhibitor set</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1038/nbt.3374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1038%2Fnbt.3374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=26501955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslantL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=95-103&author=J.+M.+Elkinsauthor=V.+Fedeleauthor=M.+Szklarzauthor=K.+R.+Abdul+Azeezauthor=E.+Salahauthor=J.+Mikolajczykauthor=S.+Romanovauthor=N.+Sepetovauthor=X.+P.+Huangauthor=B.+L.+Rothauthor=A.+Al+Haj+Zenauthor=D.+Fourchesauthor=E.+Muratovauthor=A.+Tropshaauthor=J.+Morrisauthor=B.+A.+Teicherauthor=M.+Kunkelauthor=E.+Polleyauthor=K.+E.+Lackeyauthor=F.+L.+Atkinsonauthor=J.+P.+Overingtonauthor=P.+Bamboroughauthor=S.+Mullerauthor=D.+J.+Priceauthor=T.+M.+Willsonauthor=D.+H.+Drewryauthor=S.+Knappauthor=W.+J.+Zuercher&title=Comprehensive+characterization+of+the+published+kinase+inhibitor+set&doi=10.1038%2Fnbt.3374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive characterization of the Published Kinase Inhibitor Set</span></div><div class="casAuthors">Elkins, Jonathan M.; Fedele, Vita; Szklarz, Marta; Abdul Azeez, Kamal R.; Salah, Eidarus; Mikolajczyk, Jowita; Romanov, Sergei; Sepetov, Nikolai; Huang, Xi-Ping; Roth, Bryan L.; Al Haj Zen, Ayman; Fourches, Denis; Muratov, Eugene; Tropsha, Alex; Morris, Joel; Teicher, Beverly A.; Kunkel, Mark; Polley, Eric; Lackey, Karen E.; Atkinson, Francis L.; Overington, John P.; Bamborough, Paul; Muller, Susanne; Price, Daniel J.; Willson, Timothy M.; Drewry, David H.; Knapp, Stefan; Zuercher, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-103</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite the success of protein kinase inhibitors as approved therapeutics, drug discovery has focused on a small subset of kinase targets.  Here we provide a thorough characterization of the Published Kinase Inhibitor Set (PKIS), a set of 367 small-mol. ATP-competitive kinase inhibitors that was recently made freely available with the aim of expanding research in this field and as an expt. in open-source target validation.  We screen the set in activity assays with 224 recombinant kinases and 24 G protein-coupled receptors and in cellular assays of cancer cell proliferation and angiogenesis.  We identify chem. starting points for designing new chem. probes of orphan kinases and illustrate the utility of these leads by developing a selective inhibitor for the previously untargeted kinases LOK and SLK.  Our cellular screens reveal compds. that modulate cancer cell growth and angiogenesis in vitro.  These reagents and assocd. data illustrate an efficient way forward to increasing understanding of the historically untargeted kinome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4P1WN3gdiXbVg90H21EOLACvtfcHk0lhcXuSN-K_I0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslantL%252FM&md5=3f15096e79632dbaaadf4460a6848e60</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnbt.3374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.3374%26sid%3Dliteratum%253Aachs%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFedele%26aufirst%3DV.%26aulast%3DSzklarz%26aufirst%3DM.%26aulast%3DAbdul%2BAzeez%26aufirst%3DK.%2BR.%26aulast%3DSalah%26aufirst%3DE.%26aulast%3DMikolajczyk%26aufirst%3DJ.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DSepetov%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DAl%2BHaj%2BZen%26aufirst%3DA.%26aulast%3DFourches%26aufirst%3DD.%26aulast%3DMuratov%26aufirst%3DE.%26aulast%3DTropsha%26aufirst%3DA.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DKunkel%26aufirst%3DM.%26aulast%3DPolley%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26aulast%3DAtkinson%26aufirst%3DF.%2BL.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DD.%2BJ.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26atitle%3DComprehensive%2520characterization%2520of%2520the%2520published%2520kinase%2520inhibitor%2520set%26jtitle%3DNat.%2520Biotechnol.%26date%3D2016%26volume%3D34%26spage%3D95%26epage%3D103%26doi%3D10.1038%2Fnbt.3374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dienstmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Garcia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuciforo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span> <span> </span><span class="NLM_article-title">Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdt419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1093%2Fannonc%2Fmdt419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=24265351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A280%3ADC%252BC2c7ptFWmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=552-563&author=R.+Dienstmannauthor=J.+Rodonauthor=A.+Pratauthor=J.+Perez-Garciaauthor=B.+Adamoauthor=E.+Felipauthor=J.+Cortesauthor=A.+J.+Iafrateauthor=P.+Nuciforoauthor=J.+Tabernero&title=Genomic+aberrations+in+the+FGFR+pathway%3A+opportunities+for+targeted+therapies+in+solid+tumors&doi=10.1093%2Fannonc%2Fmdt419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors</span></div><div class="casAuthors">Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate A J; Nuciforo P; Tabernero J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">552-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The fibroblast growth factor receptor (FGFR) cascade plays crucial roles in tumor cell proliferation, angiogenesis, migration and survival.  Accumulating evidence suggests that in some tumor types, FGFRs are bona fide oncogenes to which cancer cells are addicted.  Because FGFR inhibition can reduce proliferation and induce cell death in a variety of in vitro and in vivo tumor models harboring FGFR aberrations, a growing number of research groups have selected FGFRs as targets for anticancer drug development.  Multikinase FGFR/vascular endothelial growth factor receptor (VEGFR) inhibitors have shown promising activity in breast cancer patients with FGFR1 and/or FGF3 amplification.  Early clinical trials with selective FGFR inhibitors, which may overcome the toxicity constraints raised by multitarget kinase inhibition, are recruiting patients with known FGFR(1-4) status based on genomic screens.  Preliminary signs of antitumor activity have been demonstrated in some tumor types, including squamous cell lung carcinomas.  Rational combination of targeted therapies is expected to further increase the efficacy of selective FGFR inhibitors.  Herein, we discuss unsolved questions in the clinical development of these agents and suggest guidelines for management of hyperphosphatemia, a class-specific mechanism-based toxicity.  In addition, we propose standardized definitions for FGFR1 and FGFR2 gene amplification based on in situ hybridization methods.  Extended access to next-generation sequencing platforms will facilitate the identification of diseases in which somatic FGFR(1-4) mutations, amplifications and fusions are potentially driving cancer cell viability, further strengthening the role of FGFR signaling in cancer biology and providing more possibilities for the therapeutic application of FGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqiWGpXuCcvmx8TEN9K18QfW6udTcc2eaV8oatMEFbaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7ptFWmsA%253D%253D&md5=633eb08ba5e38f239a73dfbfff04064c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdt419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdt419%26sid%3Dliteratum%253Aachs%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DPerez-Garcia%26aufirst%3DJ.%26aulast%3DAdamo%26aufirst%3DB.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DNuciforo%26aufirst%3DP.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DGenomic%2520aberrations%2520in%2520the%2520FGFR%2520pathway%253A%2520opportunities%2520for%2520targeted%2520therapies%2520in%2520solid%2520tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D552%26epage%3D563%26doi%3D10.1093%2Fannonc%2Fmdt419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greuber, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith-Pearson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendergast, A. M.</span></span> <span> </span><span class="NLM_article-title">Role of ABL family kinases in cancer: from leukemia to solid tumors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">571</span>, <span class="refDoi"> DOI: 10.1038/nrc3563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1038%2Fnrc3563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=23842646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVykurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=559-571&author=E.+K.+Greuberauthor=P.+Smith-Pearsonauthor=J.+Wangauthor=A.+M.+Pendergast&title=Role+of+ABL+family+kinases+in+cancer%3A+from+leukemia+to+solid+tumors&doi=10.1038%2Fnrc3563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ABL family kinases in cancer: from leukaemia to solid tumours</span></div><div class="casAuthors">Greuber, Emileigh K.; Smith-Pearson, Pameeka; Wang, Jun; Pendergast, Ann Marie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-571</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Abelson (ABL) family of nonreceptor tyrosine kinases, ABL1 and ABL2, transduces diverse extracellular signals to protein networks that control proliferation, survival, migration and invasion.  ABL1 was first identified as an oncogene required for the development of leukemias initiated by retroviruses or chromosome translocations.  The demonstration that small-mol. ABL kinase inhibitors could effectively treat chronic myeloid leukemia opened the door to the era of targeted cancer therapies.  Recent reports have uncovered roles for ABL kinases in solid tumors.  Enhanced ABL expression and activation in some solid tumors, together with altered cell polarity, invasion or growth induced by activated ABL kinases, suggest that drugs targeting these kinases may be useful for treating selected solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr_ZQCA7IT4rVg90H21EOLACvtfcHk0lhHnCG_7IZOuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVykurnM&md5=78bcffba5a172619e55aaf54233e2b46</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrc3563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3563%26sid%3Dliteratum%253Aachs%26aulast%3DGreuber%26aufirst%3DE.%2BK.%26aulast%3DSmith-Pearson%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPendergast%26aufirst%3DA.%2BM.%26atitle%3DRole%2520of%2520ABL%2520family%2520kinases%2520in%2520cancer%253A%2520from%2520leukemia%2520to%2520solid%2520tumors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D559%26epage%3D571%26doi%3D10.1038%2Fnrc3563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Brucine suppresses colon cancer cells growth via mediating KDR signalling pathway</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1316</span>– <span class="NLM_lpage">1324</span>, <span class="refDoi"> DOI: 10.1111/jcmm.12108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1111%2Fjcmm.12108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=23905676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGrs7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=1316-1324&author=W.+Luoauthor=X.+Wangauthor=L.+Zhengauthor=Y.+Zhanauthor=D.+Zhangauthor=J.+Zhangauthor=Y.+Zhang&title=Brucine+suppresses+colon+cancer+cells+growth+via+mediating+KDR+signalling+pathway&doi=10.1111%2Fjcmm.12108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Brucine suppresses colon cancer cells growth via mediating KDR signalling pathway</span></div><div class="casAuthors">Luo, Wenjuan; Wang, Xiaoli; Zheng, Lei; Zhan, Yingzhuan; Zhang, Dongdong; Zhang, Jie; Zhang, Yanmin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1316-1324</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Angiogenesis plays an important role in colon cancer development.  This study aimed to demonstrate the effect of brucine on tumor angiogenesis and its mechanism of action.  The anti-angiogenic effect was evaluated on the chicken chorioallantoic membrane (CAM) model and tube formation.  The mechanism was demonstrated through detecting mRNA and protein expressions of VEGFR2 (KDR), PKCα, PLCγ and Raf1 by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot (WB), as well as expressions of VEGF and PKCβ and mTOR by ELISA and WB.  The results showed that brucine significantly reduced angiogenesis of CAM and tube formation, inhibited the VEGF secretion and mTOR expression in LoVo cell and down-regulated the mRNA and phosphorylation protein expressions of KDR,PKCα, PLCγ and Raf1.  In addn., the effects of brucine on KDR kinase activity, viability of LoVo cell and gene knockdown cell were detected with the Lance® assay, WST-1 assay and instantaneous siRNA.  Compared to that of normal LoVo cells, the inhibition on proliferation of knockdown cells by brucine decreased significantly.  These results suggest that brucine could inhibit angiogenesis and be a useful therapeutic candidate for colon cancer intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7t-a6zQzeHLVg90H21EOLACvtfcHk0lhHnCG_7IZOuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGrs7bL&md5=d8920252e1495fcc13ae205d520fef83</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12108%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DBrucine%2520suppresses%2520colon%2520cancer%2520cells%2520growth%2520via%2520mediating%2520KDR%2520signalling%2520pathway%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2013%26volume%3D17%26spage%3D1316%26epage%3D1324%26doi%3D10.1111%2Fjcmm.12108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, J.</span></span> <span> </span><span class="NLM_article-title">Transwell invasion assays</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>769</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1007/978-1-61779-207-6_8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1007%2F978-1-61779-207-6_8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=21748672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvValtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=769&publication_year=2011&pages=97-110&author=J.+Marshall&title=Transwell+invasion+assays&doi=10.1007%2F978-1-61779-207-6_8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Transwell invasion assays</span></div><div class="casAuthors">Marshall, John</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">769</span>
        (<span class="NLM_cas:issue">Cell Migration</span>),
    <span class="NLM_cas:pages">97-110</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The need to identify inhibitors of cancer invasion has driven the development of quant. in vitro invasion assays.  The most common assays used are based on the original Boyden assay system.  Today com. available plastic inserts for multi-well plates, which possess a cell-permeable membrane, as typified by Transwell Permeable Supports, permit accurate repeatable invasion assays.  When placed in the well of a multi-well tissue culture plate these inserts create a two-chamber system sepd. by the cell-permeable membrane.  To create an invasion assay the pores in the membrane are blocked with a gel composed of extracellular matrix that is meant to mimic the typical matrixes that tumor cells encounter during the invasion process in vivo.  By placing the cells on one side of the gel and a chemoattractant on the other side of the gel, invasion is detd. by counting those cells that have traversed the cell-permeable membrane having invaded towards the higher concn. of chemoattractant.  In this chapter, in addn. to protocols for performing Transwell invasion assays, there is consideration of the limitations of current assay designs with regard to available matrixes and the absence of tumor microenvironment cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7zbRBB-kc5LVg90H21EOLACvtfcHk0lhHnCG_7IZOuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvValtL3F&md5=0e1a7a2315e8891770ad14540bd8e9b5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-207-6_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-207-6_8%26sid%3Dliteratum%253Aachs%26aulast%3DMarshall%26aufirst%3DJ.%26atitle%3DTranswell%2520invasion%2520assays%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D769%26spage%3D97%26epage%3D110%26doi%3D10.1007%2F978-1-61779-207-6_8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 11 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Er-Jun Hao, Gong-Xin Li, Yu-Ru Liang, Ming-Sheng Xie, Dong-Chao Wang, Xiao-Han Jiang, Jia-Yi Cheng, Zhi-Xian Shi, Yang Wang, <span class="NLM_string-name hlFld-ContribAuthor">Hai-Ming Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Activity Evaluation of Novel Acyclic Nucleosides as Potential Anticancer Agents In Vitro and In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (4)
                                     , 2077-2109. <a href="https://doi.org/10.1021/acs.jmedchem.0c01717" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01717%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BActivity%252BEvaluation%252Bof%252BNovel%252BAcyclic%252BNucleosides%252Bas%252BPotential%252BAnticancer%252BAgents%252BIn%252BVitro%252Band%252BIn%252BVivo%26aulast%3DHao%26aufirst%3DEr-Jun%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D30092020%26date%3D04022021%26volume%3D64%26issue%3D4%26spage%3D2077%26epage%3D2109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Matthew D. Lloyd</span>. </span><span class="cited-content_cbyCitation_article-title">High-Throughput Screening for the Discovery of Enzyme Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10742-10772. <a href="https://doi.org/10.1021/acs.jmedchem.0c00523" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00523%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHigh-Throughput%252BScreening%252Bfor%252Bthe%252BDiscovery%252Bof%252BEnzyme%252BInhibitors%26aulast%3DLloyd%26aufirst%3DMatthew%2BD.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30032020%26date%3D10062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10742%26epage%3D10772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Tao Zhang, Su-Jie Zhu, Qiuju Xun, Lingjiang Tong, Xianglong Hu, Yan Li, Shingpan Chan, Yi Su, Yiming Sun, Yi Chen, Jian Ding, Cai-Hong Yun, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (11)
                                     , 1123-1127. <a href="https://doi.org/10.1021/acsmedchemlett.8b00373" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BJND3229%252Bas%252Ba%252BNew%252BEGFRC797S%252BMutant%252BInhibitor%252Bwith%252BIn%252BVivo%252BMonodrug%252BEfficacy%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15082018%26date%3D08102018%26date%3D10102018%26date%3D08102018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William A.  Denny</span>, <span class="hlFld-ContribAuthor ">Jack U.  Flanagan</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule CSF1R kinase inhibitors; review of patents 2015-present. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (2)
                                     , 107-117. <a href="https://doi.org/10.1080/13543776.2021.1839414" title="DOI URL">https://doi.org/10.1080/13543776.2021.1839414</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1839414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1839414%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall-molecule%252BCSF1R%252Bkinase%252Binhibitors%25253B%252Breview%252Bof%252Bpatents%252B2015-present%26aulast%3DDenny%26aufirst%3DWilliam%2BA.%26date%3D2021%26date%3D2020%26volume%3D31%26issue%3D2%26spage%3D107%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minhao  Huang</span>, <span class="hlFld-ContribAuthor ">Yongjun  Huang</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Yu  Chang</span>, <span class="hlFld-ContribAuthor ">Xiaolu  Wang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yanhui  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113023. <a href="https://doi.org/10.1016/j.ejmech.2020.113023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrido%25255B2%25252C%252B3-d%25255Dpyrimidin-7%2525288H%252529-ones%252Bas%252Bnew%252Bselective%252Borally%252Bbioavailable%252BThreonine%252BTyrosine%252BKinase%252B%252528TTK%252529%252Binhibitors%26aulast%3DHuang%26aufirst%3DMinhao%26date%3D2021%26volume%3D211%26spage%3D113023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin  Sun</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>210 </em>, 112995. <a href="https://doi.org/10.1016/j.ejmech.2020.112995" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112995%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bnew%252Bopportunities%252Bin%252Bmedicinal%252Bchemistry%252Bof%252Bfourth-generation%252BEGFR%252Binhibitors%252Bto%252Bovercome%252BC797S%252Bmutation%26aulast%3DHe%26aufirst%3DJie%26date%3D2021%26volume%3D210%26spage%3D112995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Han  Chu</span>, <span class="hlFld-ContribAuthor ">Qing-xiu  He</span>, <span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Yong  Hu</span>, <span class="hlFld-ContribAuthor ">Yuan-qiang  Wang</span>, <span class="hlFld-ContribAuthor ">Zhi-hua  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">In silico design novel dihydropyrimio[4, 5-d]pyrimidine derivatives as inhibitors for colony-stimulating factor-1 receptor based on 3D-QSAR, molecular docking and molecular dynamics simulation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2020,</strong> <em>1220 </em>, 128617. <a href="https://doi.org/10.1016/j.molstruc.2020.128617" title="DOI URL">https://doi.org/10.1016/j.molstruc.2020.128617</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2020.128617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2020.128617%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DIn%252Bsilico%252Bdesign%252Bnovel%252Bdihydropyrimio%25255B4%25252C%252B5-d%25255Dpyrimidine%252Bderivatives%252Bas%252Binhibitors%252Bfor%252Bcolony-stimulating%252Bfactor-1%252Breceptor%252Bbased%252Bon%252B3D-QSAR%25252C%252Bmolecular%252Bdocking%252Band%252Bmolecular%252Bdynamics%252Bsimulation%26aulast%3DChu%26aufirst%3DHan%26date%3D2020%26volume%3D1220%26spage%3D128617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiuju  Xun</span>, <span class="hlFld-ContribAuthor ">Zhen  Wang</span>, <span class="hlFld-ContribAuthor ">Xianglong  Hu</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule CSF1R Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (23)
                                     , 3944-3966. <a href="https://doi.org/10.2174/1573394715666190618121649" title="DOI URL">https://doi.org/10.2174/1573394715666190618121649</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573394715666190618121649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573394715666190618121649%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BCSF1R%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DXun%26aufirst%3DQiuju%26date%3D2020%26volume%3D27%26issue%3D23%26spage%3D3944%26epage%3D3966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Honggang  Xiang</span>, <span class="hlFld-ContribAuthor ">Yanmei  Chen</span>, <span class="hlFld-ContribAuthor ">Jifa  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Zhang</span>, <span class="hlFld-ContribAuthor ">Dabo  Pan</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a novel sodium taurocholate cotransporting polypeptide (NTCP) inhibitor: Design, synthesis, and anti-proliferative activities. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2020,</strong> <em>31 </em>
                                    (6)
                                     , 1422-1426. <a href="https://doi.org/10.1016/j.cclet.2020.03.017" title="DOI URL">https://doi.org/10.1016/j.cclet.2020.03.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2020.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2020.03.017%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252Bnovel%252Bsodium%252Btaurocholate%252Bcotransporting%252Bpolypeptide%252B%252528NTCP%252529%252Binhibitor%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Band%252Banti-proliferative%252Bactivities%26aulast%3DXiang%26aufirst%3DHonggang%26date%3D2020%26volume%3D31%26issue%3D6%26spage%3D1422%26epage%3D1426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ya-ting  Deng</span>, <span class="hlFld-ContribAuthor ">Jun-wei  Wang</span>, <span class="hlFld-ContribAuthor ">Han  Chu</span>, <span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Yong  Hu</span>, <span class="hlFld-ContribAuthor ">Yong  lin</span>, <span class="hlFld-ContribAuthor ">Mao  Shu</span>, <span class="hlFld-ContribAuthor ">Zhi-hua  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">3D-QSAR and Docking Studies on Pyrimidine Derivatives as CSF-1R Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Letters in Drug Design & Discovery</span><span> <strong>2020,</strong> <em>17 </em>
                                    (3)
                                     , 341-355. <a href="https://doi.org/10.2174/1570180816666190329224946" title="DOI URL">https://doi.org/10.2174/1570180816666190329224946</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570180816666190329224946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570180816666190329224946%26sid%3Dliteratum%253Aachs%26jtitle%3DLetters%2520in%2520Drug%2520Design%2520%2526%2520Discovery%26atitle%3D3D-QSAR%252Band%252BDocking%252BStudies%252Bon%252BPyrimidine%252BDerivatives%252Bas%252BCSF-1R%252BInhibitors%26aulast%3DDeng%26aufirst%3DYa-ting%26date%3D2020%26volume%3D17%26issue%3D3%26spage%3D341%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pascale  Moreau</span>, <span class="hlFld-ContribAuthor ">Fabrice  Anizon</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 6-6 Systems: Other Four Heteroatoms 2/2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.14956-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14956-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14956-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14956-X%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B6-6%252BSystems%25253A%252BOther%252BFour%252BHeteroatoms%252B2%25252F2%26aulast%3DMoreau%26aufirst%3DPascale%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3Dvol.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Design of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidines as CSF1R inhibitors by structural modification of an irreversible EGFR inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>3</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub> (2.0 equiv), <i>N</i>,<i>N</i>-dimethylformamide (DMF), 60 °C, 80–95%; (b) lithium aluminum hydride (LiAlH<sub>4</sub>) (2.0 equiv), tetrahydrofuran (THF), −40 to 0 °C, 45–58%; (c) MnO<sub>2</sub> (5.0 equiv), dichloromethane (DCM), room temperature (rt), 80–95%; (d) R<sub>1</sub>NH<sub>2</sub> (2.0 equiv), AcOH (1.0 equiv), NaBH<sub>4</sub> (2.0 equiv), PhMe, 0 °C to rt, 60–80%; (e) triphosgene (0.34 equiv), triethylamine (Et<sub>3</sub>N) (3.0 equiv), DCM, 0 °C to rt, 80–95%; (f) 3-chloroperbenzoic acid (m-CPBA) (3.0 equiv), DCM, rt, 80–92%; (g) RNH<sub>2</sub> (1.2 equiv), trifluoroacetic acid (F<sub>3</sub>CCOOH) (1.2 equiv), 2-butanol (2-BuOH), 110 °C; (h) F<sub>3</sub>CCOOH (10 equiv), DCM, rt, 45–60% (for two steps); (i) RCOOH (1.2 equiv), 2-(7-aza-1<i>H</i>-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (1.2 equiv), ethyl diisopropylamine (DIPEA) (2.0 equiv), DCM, rt, 75–90%; (j) 1-iodopropane (1.5 equiv), DIPEA (1.5 equiv), DCM, 0 °C, 56%.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding mode analysis of compound <b>2</b> to EGFR kinase and CSF1R kinase. (A) Molecular docking of compound <b>2</b> (yellow) into EGFR kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VJO">3VJO</a>, orange). Hydrogen bonds and cation−π interaction are indicated by red and green dashed lines, respectively. (B) Molecular docking of compound <b>2</b> (yellow) docked into CSF1R kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK">3DPK</a>, blue). Hydrogen bonds and cation−π interaction are indicated by red and green dashed lines, respectively. (C) Superposition of EGFR (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VJO">3VJO</a>, orange) and CSF1R kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK">3DPK</a>, blue). All the procedures were performed in Maestro (version 9.9, Schrödinger, LLC, New York, NY; 2014) implemented in the Schrödinger program.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representation of the predicted binding mode of compound <b>3aq</b> in the active site of CSF1R (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK">3DPK</a>). Blue lines represent important amino acid residues of CSF1R. The ligand is shown in a yellow stick representation. Interactions of <b>3aq</b> with D796 and the backbone of C666 are illustrated with red dash lines. Interaction of <b>3aq</b> with K616 is illustrated with green dash lines. The docking model is visualized using PyMOL Molecular Graphics System, version 1.3 (Schrödinger, LLC).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>3bw</b> dose dependently inhibited phosphorylation of CSF1R and its downstream signaling pathway in RAW264.7 cells. (A) Compound <b>3bw</b> inhibited phosphorylation of CSF1R and its downstream signaling pathway in RAW264.7 cells as determined by Western blot analysis. (B) Immunoblot quantification of p-CSF1R and p-AKT. All bands were quantified and normalized by GAPDH. The data are expressed as the mean ± SEM from at least three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibitory effect of compound <b>3bw</b> on LNCaP-MDV-CM-mediated macrophage migration. (A) Illustration of the in vitro macrophages migration model. (B) Compound <b>3bw</b> suppressed macrophage migration induced by the PCa cells CM. (C) Quantified results of B. The data are expressed as the mean ± SD (<i>n</i> = 3) and are representative of the results obtained from three independent experiments. Statistical significance relative to untreated is indicated: (∗) <i>p</i> < 0.05, (∗∗) <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>3bw</b> reduced mRNA levels of ARG1, IL10, MMP9, and VEGFA in a dose-dependent manner in RAW264.7 cells. Each bar represents the mean ± SE of 3–5 independent experiments. Statistical significance relative to untreated is indicated: (∗) <i>p</i> < 0.05, (∗∗) <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/medium/jm-2017-01612s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Antiproliferation effects of <b>3bw</b> in LNCaP cells. (A) <b>3bw</b> inhibited the proliferation of LNCaP cells induced by RAW264.7. (B) Quantified results of (A). The data are expressed as the mean ± SD (<i>n</i> = 3) and are representative of the results obtained from three independent experiments. Statistical significance relative to untreated is indicated: (∗) <i>p</i> < 0.05, (∗∗) <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01612/20180315/images/large/jm-2017-01612s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01612&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71862" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71862" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 47 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherr, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettenmier, C. W.</span></span> <span> </span><span class="NLM_article-title">Colony-stimulating factor-1 receptor (c-fms)</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1002/jcb.240380305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1002%2Fjcb.240380305" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1988&pages=179-187&author=C.+J.+Sherrauthor=M.+F.+Rousselauthor=C.+W.+Rettenmier&title=Colony-stimulating+factor-1+receptor+%28c-fms%29&doi=10.1002%2Fjcb.240380305"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fjcb.240380305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.240380305%26sid%3Dliteratum%253Aachs%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26aulast%3DRoussel%26aufirst%3DM.%2BF.%26aulast%3DRettenmier%26aufirst%3DC.%2BW.%26atitle%3DColony-stimulating%2520factor-1%2520receptor%2520%2528c-fms%2529%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D1988%26volume%3D38%26spage%3D179%26epage%3D187%26doi%3D10.1002%2Fjcb.240380305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Till, J. H.</span></span> <span> </span><span class="NLM_article-title">Protein tyrosine kinase structure and function</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.69.1.373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1146%2Fannurev.biochem.69.1.373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10966463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1ajtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2000&pages=373-398&author=S.+R.+Hubbardauthor=J.+H.+Till&title=Protein+tyrosine+kinase+structure+and+function&doi=10.1146%2Fannurev.biochem.69.1.373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Protein tyrosine kinase structure and function</span></div><div class="casAuthors">Hubbard, Stevan R.; Till, Jeffrey H.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">373-398</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 116 refs.  Tyr-phosphorylation is one of the key covalent modifications that occurs in multicellular organisms as a result of intercellular communication during embryogenesis and maintenance of adult tissues.  The enzymes that carry out this modification are the protein tyrosine kinases (PTKs), which catalyze the transfer of the γ-phosphate of ATP to Tyr residues on protein substrates.  Phosphorylation of Tyr residues modulates enzymic activity and creates binding sites for the recruitment of downstream signaling proteins.  Two classes of PTKs are present in cells: the transmembrane receptor PTKs and the nonreceptor PTKs.  Because PTKs are crit. components of cellular signaling pathways, their catalytic activity is strictly regulated.  Over the past several years, high-resoln. structural studies of PTKs have provided a mol. basis for understanding the mechanisms by which receptor and nonreceptor PTKs are regulated.  This review highlights the important results that have emerged from these structural studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogx8K1IKwbKLVg90H21EOLACvtfcHk0li5Jfz2sszCWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1ajtb0%253D&md5=2aae3e0c121c9e6652be99030af36af1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.69.1.373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.69.1.373%26sid%3Dliteratum%253Aachs%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DTill%26aufirst%3DJ.%2BH.%26atitle%3DProtein%2520tyrosine%2520kinase%2520structure%2520and%2520function%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2000%26volume%3D69%26spage%3D373%26epage%3D398%26doi%3D10.1146%2Fannurev.biochem.69.1.373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothwell, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrschneider, L.</span></span> <span> </span><span class="NLM_article-title">Characterization of the human c-fms gene product and its expression in cells of the monocyte-macrophage lineage</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3458</span>– <span class="NLM_lpage">3466</span>, <span class="refDoi"> DOI: 10.1128/MCB.5.12.3458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1128%2FMCB.5.12.3458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=3018521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADyaL28XivFOhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1985&pages=3458-3466&author=J.+Woolfordauthor=V.+Rothwellauthor=L.+Rohrschneider&title=Characterization+of+the+human+c-fms+gene+product+and+its+expression+in+cells+of+the+monocyte-macrophage+lineage&doi=10.1128%2FMCB.5.12.3458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the human c-fms gene product and its expression in cells of the monocyte-macrophage lineage</span></div><div class="casAuthors">Woolford, Joseph; Rothwell, Victoria; Rohrschneider, Larry</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3458-66</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The McDonough strain of feline sarcoma virus contains an oncogene called v-fms whose ultimate protein product (gp140v-fms) resembles a cell surface growth factor receptor.  To identify and characterize the protein product of the proto-oncogene c-fms, antisera were prepd. to the viral fms sequences and used to detect specific cross-reacting sequences in human choriocarcinoma cells (BeWo) known to express c-fms mRNA.  Both tumor-bearing rat sera and a rabbit antiserum prepd. to a segment of v-fms expressed in Escherichia coli detected a 140-kilodalton (kDa) glycoprotein in the BeWo cells.  Tryptic fingerprint anal. of [35S]methionine-labeled proteins indicated that the viral fms proteins and the 140-kDa BeWo cell protein were highly related.  This 140-kDa glycoprotein contained an assocd. tyrosine kinase activity in vitro and was labeled principally on serine after 32Pi metabolic labeling.  Thus, the 140-kDa protein in BeWo cells is the protein product of the human c-fms proto-oncogene.  This conclusion is supported by the finding that a similar protein is detectable only in other human cells that express c-fms mRNA.  These other human cells include adherent monocytes and the cell line ML-1, which can be induced to differentiate along the monocyte-macrophage pathway.  This is in agreement with current thought that the c-fms proto-oncogene product functions as the colony-stimulating factor-1 receptor specific to this pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyQC6ZdFdrfrVg90H21EOLACvtfcHk0li5Jfz2sszCWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XivFOhsQ%253D%253D&md5=183f3753f96a5a6165607014a93065d6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1128%2FMCB.5.12.3458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.5.12.3458%26sid%3Dliteratum%253Aachs%26aulast%3DWoolford%26aufirst%3DJ.%26aulast%3DRothwell%26aufirst%3DV.%26aulast%3DRohrschneider%26aufirst%3DL.%26atitle%3DCharacterization%2520of%2520the%2520human%2520c-fms%2520gene%2520product%2520and%2520its%2520expression%2520in%2520cells%2520of%2520the%2520monocyte-macrophage%2520lineage%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1985%26volume%3D5%26spage%3D3458%26epage%3D3466%26doi%3D10.1128%2FMCB.5.12.3458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pixley, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, E. R.</span></span> <span> </span><span class="NLM_article-title">Macrophage proliferation is regulated through CSF-1 receptor tyrosines 544, 559, and 807</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">13694</span>– <span class="NLM_lpage">13704</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.355610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1074%2Fjbc.M112.355610" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=13694-13704&author=W.+Yuauthor=J.+Chenauthor=Y.+Xiongauthor=F.+J.+Pixleyauthor=Y.+G.+Yeungauthor=E.+R.+Stanley&title=Macrophage+proliferation+is+regulated+through+CSF-1+receptor+tyrosines+544%2C+559%2C+and+807&doi=10.1074%2Fjbc.M112.355610"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.355610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.355610%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DPixley%26aufirst%3DF.%2BJ.%26aulast%3DYeung%26aufirst%3DY.%2BG.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DMacrophage%2520proliferation%2520is%2520regulated%2520through%2520CSF-1%2520receptor%2520tyrosines%2520544%252C%2520559%252C%2520and%2520807%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D13694%26epage%3D13704%26doi%3D10.1074%2Fjbc.M112.355610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hume, D. A.</span></span> <span> </span><span class="NLM_article-title">CSF-1 as a regulator of macrophage activation and immune responses</span>. <i>Arch. Immunol. Ther. Exp.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=12894871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvFOrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2003&pages=169-177&author=M.+J.+Sweetauthor=D.+A.+Hume&title=CSF-1+as+a+regulator+of+macrophage+activation+and+immune+responses"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CSF-1 as a regulator of macrophage activation and immune responses</span></div><div class="casAuthors">Sweet, Matthew J.; Hume, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Archivum Immunologiae et Therapiae Experimentalis</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-177</span>CODEN:
                <span class="NLM_cas:coden">AITEAT</span>;
        ISSN:<span class="NLM_cas:issn">0004-069X</span>.
    
            (<span class="NLM_cas:orgname">Ossolineum Publishing House</span>)
        </div><div class="casAbstract">A review.  Macrophage activation is a key determinant of susceptibility and pathol. in a variety of inflammatory diseases.  The extent of macrophage activation is tightly regulated by a no. of pro-inflammatory cytokines (e.g. IFN-γ, IL-2, GM-CSF, IL-3) and anti-inflammatory cytokines (e.g. IL-4, IL-10, TGF-β).  Macrophage colony-stimulating factor (CSF-1/M-CSF) is a key differentiation, growth and survival factor for monocytes/macrophages and osteoclasts.  The role of this factor in regulating macrophage activation is often overlooked.  This review summarizes the current understanding of the effects of CSF-1 on the activation state of mature macrophages and its role in regulating immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUPBgBJCtxHrVg90H21EOLACvtfcHk0ljV-Wmz1NSmmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvFOrtLk%253D&md5=40807f0f5023ba8c6ac7cd53cbe813b3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSweet%26aufirst%3DM.%2BJ.%26aulast%3DHume%26aufirst%3DD.%2BA.%26atitle%3DCSF-1%2520as%2520a%2520regulator%2520of%2520macrophage%2520activation%2520and%2520immune%2520responses%26jtitle%3DArch.%2520Immunol.%2520Ther.%2520Exp.%26date%3D2003%26volume%3D51%26spage%3D169%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherr, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettenmier, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussel, M. F.</span></span> <span> </span><span class="NLM_article-title">Macrophage colony-stimulating factor, CSF-1, and its proto-oncogene-encoded receptor</span>. <i>Cold Spring Harbor Symp. Quant. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1101/SQB.1988.053.01.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1101%2FSQB.1988.053.01.060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=2855492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADyaK3cXls12rsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1988&pages=521-530&author=C.+J.+Sherrauthor=C.+W.+Rettenmierauthor=M.+F.+Roussel&title=Macrophage+colony-stimulating+factor%2C+CSF-1%2C+and+its+proto-oncogene-encoded+receptor&doi=10.1101%2FSQB.1988.053.01.060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage colony-stimulating factor, CSF-1, and its proto-oncogene-encoded receptor</span></div><div class="casAuthors">Sherr, C. J.; Rettenmier, C. W.; Roussel, M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Symposia on Quantitative Biology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">Mol. Biol. Signal Transduction, Pt. 1</span>),
    <span class="NLM_cas:pages">521-30</span>CODEN:
                <span class="NLM_cas:coden">CSHSAZ</span>;
        ISSN:<span class="NLM_cas:issn">0091-7451</span>.
    </div><div class="casAbstract">A review with ∼100 refs.  The CSF-1 receptor is the product of the c-fms proto-oncogene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNptdlBxxGtbVg90H21EOLACvtfcHk0ljV-Wmz1NSmmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXls12rsLs%253D&md5=3bb763b62cd24ff85ea8a88ad046ee95</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1101%2FSQB.1988.053.01.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252FSQB.1988.053.01.060%26sid%3Dliteratum%253Aachs%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26aulast%3DRettenmier%26aufirst%3DC.%2BW.%26aulast%3DRoussel%26aufirst%3DM.%2BF.%26atitle%3DMacrophage%2520colony-stimulating%2520factor%252C%2520CSF-1%252C%2520and%2520its%2520proto-oncogene-encoded%2520receptor%26jtitle%3DCold%2520Spring%2520Harbor%2520Symp.%2520Quant.%2520Biol.%26date%3D1988%26volume%3D53%26spage%3D521%26epage%3D530%26doi%3D10.1101%2FSQB.1988.053.01.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chitu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, E. R.</span></span> <span> </span><span class="NLM_article-title">Colony-stimulating factor-1 in immunity and inflammation</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.coi.2005.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.coi.2005.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=16337366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2006&pages=39-48&author=V.+Chituauthor=E.+R.+Stanley&title=Colony-stimulating+factor-1+in+immunity+and+inflammation&doi=10.1016%2Fj.coi.2005.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Colony-stimulating factor-1 in immunity and inflammation</span></div><div class="casAuthors">Chitu, Violeta; Stanley, E. Richard</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-48</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Colony-stimulating factor-1 (CSF-1, also known as macrophage-CSF) is the primary regulator of the survival, proliferation, differentiation and function of mononuclear phagocytes.  Studies that involve CSF-1-deficient mice demonstrate that there is a variable requirement for CSF-1 in the development of individual mononuclear phagocyte populations.  However, these cells uniformly express the CSF-1 receptor, and their morphol., phagocytosis and responsiveness to infectious and non-infectious stimuli is regulated by CSF-1.  CSF-1 plays important roles in innate immunity, cancer and inflammatory diseases, including systemic lupus erythematosus, arthritis, atherosclerosis and obesity.  In several conditions, activation of macrophages involves a CSF-1 autocrine loop.  In addn., secreted and cell-surface isoforms of CSF-1 can have differential effects in inflammation and immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDWBfpwAK0KbVg90H21EOLACvtfcHk0ljV-Wmz1NSmmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOgsg%253D%253D&md5=c1734f38620b1689c7560514a7760189</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2005.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2005.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DChitu%26aufirst%3DV.%26aulast%3DStanley%26aufirst%3DE.%2BR.%26atitle%3DColony-stimulating%2520factor-1%2520in%2520immunity%2520and%2520inflammation%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2006%26volume%3D18%26spage%3D39%26epage%3D48%26doi%3D10.1016%2Fj.coi.2005.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pixley, F. J.</span></span> <span> </span><span class="NLM_article-title">Macrophage migration and its regulation by CSF-1</span>. <i>Int. J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">501962</span>, <span class="refDoi"> DOI: 10.1155/2012/501962</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1155%2F2012%2F501962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=22505929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A280%3ADC%252BC38rltlWnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=501962&author=F.+J.+Pixley&title=Macrophage+migration+and+its+regulation+by+CSF-1&doi=10.1155%2F2012%2F501962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage Migration and Its Regulation by CSF-1</span></div><div class="casAuthors">Pixley Fiona J</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cell biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">501962</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Macrophages are terminally differentiated cells of the mononuclear phagocytic lineage and develop under the stimulus of their primary growth and differentiation factor, CSF-1.  Although they differentiate into heterogeneous populations, depending upon their tissue of residence, motility is an important aspect of their function.  To facilitate their migration through tissues, macrophages express a unique range of adhesion and cytoskeletal proteins.  Notably, macrophages do not form large, stable adhesions or actin stress fibers but rely on small, short lived point contacts, focal complexes and podosomes for traction.  Thus, macrophages are built to respond rapidly to migratory stimuli.  As well as triggering growth and differentiation, CSF-1 is also a chemokine that regulates macrophage migration via activation the CSF-1 receptor tyrosine kinase.  CSF-1R autophosphorylation of several intracellular tyrosine residues leads to association and activation of many downstream signaling molecules.  However, phosphorylation of just one residue, Y721, mediates association of PI3K with the receptor to activate the major motility signaling pathways in macrophages.  Dissection of these pathways will identify drug targets for the inhibition of diseases in which macrophages contribute to adverse outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS3GaptlusG3dy3lHz94U-GfW6udTcc2eY8J5dC0Dtk4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rltlWnsQ%253D%253D&md5=4d85c088f146e975e1ee547260f717fd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1155%2F2012%2F501962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F501962%26sid%3Dliteratum%253Aachs%26aulast%3DPixley%26aufirst%3DF.%2BJ.%26atitle%3DMacrophage%2520migration%2520and%2520its%2520regulation%2520by%2520CSF-1%26jtitle%3DInt.%2520J.%2520Cell%2520Biol.%26date%3D2012%26volume%3D2012%26spage%3D501962%26doi%3D10.1155%2F2012%2F501962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanley, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitu, V.</span></span> <span> </span><span class="NLM_article-title">CSF-1 receptor signaling in myeloid cells</span>. <i>Cold Spring Harbor Perspect. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">a021857</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a021857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1101%2Fcshperspect.a021857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=24890514" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=a021857&author=E.+R.+Stanleyauthor=V.+Chitu&title=CSF-1+receptor+signaling+in+myeloid+cells&doi=10.1101%2Fcshperspect.a021857"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a021857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a021857%26sid%3Dliteratum%253Aachs%26aulast%3DStanley%26aufirst%3DE.%2BR.%26aulast%3DChitu%26aufirst%3DV.%26atitle%3DCSF-1%2520receptor%2520signaling%2520in%2520myeloid%2520cells%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Biol.%26date%3D2014%26volume%3D6%26spage%3Da021857%26doi%3D10.1101%2Fcshperspect.a021857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. W.</span></span> <span> </span><span class="NLM_article-title">Tumor-associated macrophages: from mechanisms to therapy</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2014.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.immuni.2014.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=25035953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOrsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=49-61&author=R.+Noyauthor=J.+W.+Pollard&title=Tumor-associated+macrophages%3A+from+mechanisms+to+therapy&doi=10.1016%2Fj.immuni.2014.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-Associated Macrophages: From Mechanisms to Therapy</span></div><div class="casAuthors">Noy, Roy; Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-61</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The tumor microenvironment is a complex ecol. of cells that evolves with and provides support to tumor cells during the transition to malignancy.  Among the innate and adaptive immune cells recruited to the tumor site, macrophages are particularly abundant and are present at all stages of tumor progression.  Clin. studies and exptl. mouse models indicate that these macrophages generally play a protumoral role.  In the primary tumor, macrophages can stimulate angiogenesis and enhance tumor cell invasion, motility, and intravasation.  During metastasis, monocytes and/or macrophages prime the premetastatic site and promote tumor cell extravasation, survival, and persistent growth.  Macrophages are also immunosuppressive, preventing tumor cell attack by natural killer and T cells during tumor progression and after recovery from chemo- or immunotherapy.  Therapeutic success in targeting these protumoral roles in preclin. models and in early clin. trials suggests that macrophages are attractive targets as part of combination therapy in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbrnEPk0kD97Vg90H21EOLACvtfcHk0lhFbNsNFrVa8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOrsLvL&md5=23ffcaefccbfc01237956857607e4066</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2014.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2014.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DNoy%26aufirst%3DR.%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DTumor-associated%2520macrophages%253A%2520from%2520mechanisms%2520to%2520therapy%26jtitle%3DImmunity%26date%3D2014%26volume%3D41%26spage%3D49%26epage%3D61%26doi%3D10.1016%2Fj.immuni.2014.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostuni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochvill, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natoli, G.</span></span> <span> </span><span class="NLM_article-title">Macrophages and cancer: from mechanisms to therapeutic implications</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1016/j.it.2015.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.it.2015.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=25770924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjslCksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=229-239&author=R.+Ostuniauthor=F.+Kratochvillauthor=P.+J.+Murrayauthor=G.+Natoli&title=Macrophages+and+cancer%3A+from+mechanisms+to+therapeutic+implications&doi=10.1016%2Fj.it.2015.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophages and cancer: from mechanisms to therapeutic implications</span></div><div class="casAuthors">Ostuni, Renato; Kratochvill, Franz; Murray, Peter J.; Natoli, Gioacchino</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">229-239</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Infiltration by immune cells is a hallmark of most forms of malignancy.  In this context, tumor-assocd. macrophages (TAMs) represent key regulators of the complex interplay between the immune system and cancer.  We discuss evidence indicating that in many settings TAMs fuel, rather than limit, tumor progression, and neg. impact on responses to therapy.  We discuss how the unique functional properties of TAMs are shaped by tumor-derived signals, placing TAM development in the context of the broader understanding of the cellular and mol. mechanisms controlling macrophage origin, differentiation, and maintenance in tissues.  Finally, we provide examples of how a mol. understanding of the relationships between TAMs and the tumor microenvironment may lead to improved cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJFig-CHupnrVg90H21EOLACvtfcHk0lhFbNsNFrVa8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjslCksbk%253D&md5=2e9c1992f8b7564205b3820eb0fe1d78</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2015.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2015.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DOstuni%26aufirst%3DR.%26aulast%3DKratochvill%26aufirst%3DF.%26aulast%3DMurray%26aufirst%3DP.%2BJ.%26aulast%3DNatoli%26aufirst%3DG.%26atitle%3DMacrophages%2520and%2520cancer%253A%2520from%2520mechanisms%2520to%2520therapeutic%2520implications%26jtitle%3DTrends%2520Immunol.%26date%3D2015%26volume%3D36%26spage%3D229%26epage%3D239%26doi%3D10.1016%2Fj.it.2015.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linsley, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germain, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevach, E. M.</span></span> <span> </span><span class="NLM_article-title">IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">1224</span>– <span class="NLM_lpage">1234</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=1993&pages=1224-1234&author=L.+Dingauthor=P.+S.+Linsleyauthor=L.+Y.+Huangauthor=R.+N.+Germainauthor=E.+M.+Shevach&title=IL-10+inhibits+macrophage+costimulatory+activity+by+selectively+inhibiting+the+up-regulation+of+B7+expression"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DL.%26aulast%3DLinsley%26aufirst%3DP.%2BS.%26aulast%3DHuang%26aufirst%3DL.%2BY.%26aulast%3DGermain%26aufirst%3DR.%2BN.%26aulast%3DShevach%26aufirst%3DE.%2BM.%26atitle%3DIL-10%2520inhibits%2520macrophage%2520costimulatory%2520activity%2520by%2520selectively%2520inhibiting%2520the%2520up-regulation%2520of%2520B7%2520expression%26jtitle%3DJ.%2520Immunol.%26date%3D1993%26volume%3D151%26spage%3D1224%26epage%3D1234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M. O.</span></span> <span> </span><span class="NLM_article-title">TGF-β: guardian of T cell function</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">3973</span>– <span class="NLM_lpage">3979</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1301843</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.4049%2Fjimmunol.1301843" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=3973-3979&author=S.+A.+Ohauthor=M.+O.+Li&title=TGF-%CE%B2%3A+guardian+of+T+cell+function&doi=10.4049%2Fjimmunol.1301843"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301843%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DM.%2BO.%26atitle%3DTGF-%25CE%25B2%253A%2520guardian%2520of%2520T%2520cell%2520function%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D3973%26epage%3D3979%26doi%3D10.4049%2Fjimmunol.1301843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coukos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evdemon-Hogan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conejo-Garcia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryczek, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disis, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span> <span> </span><span class="NLM_article-title">Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">949</span>, <span class="refDoi"> DOI: 10.1038/nm1093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1038%2Fnm1093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=15322536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFSkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=942-949&author=T.+J.+Curielauthor=G.+Coukosauthor=L.+Zouauthor=X.+Alvarezauthor=P.+Chengauthor=P.+Mottramauthor=M.+Evdemon-Hoganauthor=J.+R.+Conejo-Garciaauthor=L.+Zhangauthor=M.+Burowauthor=Y.+Zhuauthor=S.+Weiauthor=I.+Kryczekauthor=B.+Danielauthor=A.+Gordonauthor=L.+Myersauthor=A.+Lacknerauthor=M.+L.+Disisauthor=K.+L.+Knutsonauthor=L.+Chenauthor=W.+Zou&title=Specific+recruitment+of+regulatory+T+cells+in+ovarian+carcinoma+fosters+immune+privilege+and+predicts+reduced+survival&doi=10.1038%2Fnm1093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival</span></div><div class="casAuthors">Curiel, Tyler J.; Coukos, George; Zou, Linhua; Alvarez, Xavier; Cheng, Pui; Mottram, Peter; Evdemon-Hogan, Melina; Conejo-Garcia, Jose R.; Zhang, Lin; Burow, Matthew; Zhu, Yun; Wei, Shuang; Kryczek, Ilona; Daniel, Ben; Gordon, Alan; Myers, Leann; Lackner, Andrew; Disis, Mary L.; Knutson, Keith L.; Chen, Lieping; Zou, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">942-949</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Regulatory T (Treg) cells mediate homeostatic peripheral tolerance by suppressing autoreactive T cells.  Failure of host antitumor immunity may be caused by exaggerated suppression of tumor-assocd. antigen-reactive lymphocytes mediated by Treg cells; however, definitive evidence that Treg cells have an immunopathol. role in human cancer is lacking.  Here the authors show, in detailed studies of CD4+CD25+FOXP3+ Treg cells in 104 individuals affected with ovarian carcinoma, that human tumor Treg cells suppress tumor-specific T cell immunity and contribute to growth of human tumors in vivo.  The authors also show that tumor Treg cells are assocd. with a high death hazard and reduced survival.  Human Treg cells preferentially move to and accumulate in tumors and ascites, but rarely enter draining lymph nodes in later cancer stages.  Tumor cells and microenvironmental macrophages produce the chemokine CCL22, which mediates trafficking of Treg cells to the tumor.  This specific recruitment of Treg cells represents a mechanism by which tumors may foster immune privilege.  Thus, blocking Treg cell migration or function may help to defeat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUuPjm7zZim7Vg90H21EOLACvtfcHk0lg2tMD-pSBcnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFSkt7g%253D&md5=eaf598e6096d6e92381c1b26f4b2fe91</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnm1093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1093%26sid%3Dliteratum%253Aachs%26aulast%3DCuriel%26aufirst%3DT.%2BJ.%26aulast%3DCoukos%26aufirst%3DG.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DAlvarez%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DP.%26aulast%3DMottram%26aufirst%3DP.%26aulast%3DEvdemon-Hogan%26aufirst%3DM.%26aulast%3DConejo-Garcia%26aufirst%3DJ.%2BR.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBurow%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DKryczek%26aufirst%3DI.%26aulast%3DDaniel%26aufirst%3DB.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DMyers%26aufirst%3DL.%26aulast%3DLackner%26aufirst%3DA.%26aulast%3DDisis%26aufirst%3DM.%2BL.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DW.%26atitle%3DSpecific%2520recruitment%2520of%2520regulatory%2520T%2520cells%2520in%2520ovarian%2520carcinoma%2520fosters%2520immune%2520privilege%2520and%2520predicts%2520reduced%2520survival%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D942%26epage%3D949%26doi%3D10.1038%2Fnm1093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phamduy, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span> <span> </span><span class="NLM_article-title">Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2007.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.immuni.2007.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=17629517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=111-122&author=M.+J.+Butteauthor=M.+E.+Keirauthor=T.+B.+Phamduyauthor=A.+H.+Sharpeauthor=G.+J.+Freeman&title=Programmed+death-1+ligand+1+interacts+specifically+with+the+B7-1+costimulatory+molecule+to+inhibit+T+cell+responses&doi=10.1016%2Fj.immuni.2007.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed Death-1 Ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</span></div><div class="casAuthors">Butte, Manish J.; Keir, Mary E.; Phamduy, Theresa B.; Sharpe, Arlene H.; Freeman, Gordon J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-122</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Pathways in the B7:CD28 family of costimulatory mols. regulate T cell activation and tolerance.  B7-dependent responses in Cd28-/- Ctla4-/- T cells together with reports of stimulatory and inhibitory functions for Programmed Death-1 Ligand 1 or 2 mols. (PD-L1 or PD-L2) have suggested addnl. receptors for these B7 family members.  The authors show that B7-1 and PD-L1 interacted with affinity intermediate to that of B7-1:CD28 and B7-1:CTLA-4.  The PD-L1:B7-1 interface overlapped with the B7-1:CTLA-4 and PD-L1:PD-1 (Programmed Death-1) interfaces.  T cell activation and cytokine prodn. were inhibited by the interaction of B7-1 with PD-L1.  The responses of PD-1-deficient vs. PD-1,B7-1 double-deficient T cells to PD-L1 and of CD28,CTLA-4 double-deficient vs. CD28,CTLA-4,PD-L1 triple-deficient T cells to B7-1 demonstrated that PD-L1 and B7-1 interact specifically to inhibit T cell activation.  The authors' findings point to a substantial bidirectional inhibitory interaction between B7-1 and PD-L1 and add an addnl. dimension to immunoregulatory functions of the B7:CD28 family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMR5dpv_Vr5LVg90H21EOLACvtfcHk0lg2tMD-pSBcnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFeqtrk%253D&md5=8fabef0e1244a1d356378867d92a248e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2007.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2007.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DButte%26aufirst%3DM.%2BJ.%26aulast%3DKeir%26aufirst%3DM.%2BE.%26aulast%3DPhamduy%26aufirst%3DT.%2BB.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26atitle%3DProgrammed%2520death-1%2520ligand%25201%2520interacts%2520specifically%2520with%2520the%2520B7-1%2520costimulatory%2520molecule%2520to%2520inhibit%2520T%2520cell%2520responses%26jtitle%3DImmunity%26date%3D2007%26volume%3D27%26spage%3D111%26epage%3D122%26doi%3D10.1016%2Fj.immuni.2007.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daurkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eruslanov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffs, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosser, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieweg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusmartsev, S.</span></span> <span> </span><span class="NLM_article-title">Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">6400</span>– <span class="NLM_lpage">6409</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F0008-5472.CAN-11-1261" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=6400-6409&author=I.+Daurkinauthor=E.+Eruslanovauthor=T.+Stoffsauthor=G.+Q.+Perrinauthor=C.+Algoodauthor=S.+M.+Gilbertauthor=C.+J.+Rosserauthor=L.-M.+Suauthor=J.+Viewegauthor=S.+Kusmartsev&title=Tumor-associated+macrophages+mediate+immunosuppression+in+the+renal+cancer+microenvironment+by+activating+the+15-lipoxygenase-2+pathway&doi=10.1158%2F0008-5472.CAN-11-1261"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1261%26sid%3Dliteratum%253Aachs%26aulast%3DDaurkin%26aufirst%3DI.%26aulast%3DEruslanov%26aufirst%3DE.%26aulast%3DStoffs%26aufirst%3DT.%26aulast%3DPerrin%26aufirst%3DG.%2BQ.%26aulast%3DAlgood%26aufirst%3DC.%26aulast%3DGilbert%26aufirst%3DS.%2BM.%26aulast%3DRosser%26aufirst%3DC.%2BJ.%26aulast%3DSu%26aufirst%3DL.-M.%26aulast%3DVieweg%26aufirst%3DJ.%26aulast%3DKusmartsev%26aufirst%3DS.%26atitle%3DTumor-associated%2520macrophages%2520mediate%2520immunosuppression%2520in%2520the%2520renal%2520cancer%2520microenvironment%2520by%2520activating%2520the%252015-lipoxygenase-2%2520pathway%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D6400%26epage%3D6409%26doi%3D10.1158%2F0008-5472.CAN-11-1261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latchman, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">Negative co-receptors on lymphocytes</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1016/S0952-7915(02)00341-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2FS0952-7915%2802%2900341-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=11973140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVeitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2002&pages=391-396&author=R.+J.+Greenwaldauthor=Y.+E.+Latchmanauthor=A.+H.+Sharpe&title=Negative+co-receptors+on+lymphocytes&doi=10.1016%2FS0952-7915%2802%2900341-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Negative co-receptors on lymphocytes</span></div><div class="casAuthors">Greenwald, Rebecca J.; Latchman, Yvette E.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">391-396</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The past year has seen significant advances in the authors' understanding of crit. roles of neg. immunoregulatory signals delivered through the B7-CD28 superfamily in regulating T cell activation and tolerance.  Structural data on CTLA-4 have provided novel insights into the inhibitory functions of CTLA-4.  Initial characterization of the PD-1-PD-1-ligand pathway has revealed that this pathway can down-regulate TCR- and CD28-mediated signals.  Recent studies indicate that ICOS exerts distinct effects at different phases of an immune response: ICOS can inhibit as well as stimulate T cell responses.  Recent studies show that signals through CTLA-4, ICOS and PD-1 provide crit. neg. signals for regulatory T cell activation and tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLLfsqd8NdiLVg90H21EOLACvtfcHk0lg2tMD-pSBcnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVeitLY%253D&md5=03f53ff49c0590c58800d68c9c054e73</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2802%2900341-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252802%252900341-2%26sid%3Dliteratum%253Aachs%26aulast%3DGreenwald%26aufirst%3DR.%2BJ.%26aulast%3DLatchman%26aufirst%3DY.%2BE.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DNegative%2520co-receptors%2520on%2520lymphocytes%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2002%26volume%3D14%26spage%3D391%26epage%3D396%26doi%3D10.1016%2FS0952-7915%2802%2900341-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y. Q.</span></span> <span> </span><span class="NLM_article-title">Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e50946</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0050946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1371%2Fjournal.pone.0050946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=23284651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e50946&author=Q.+W.+Zhangauthor=L.+Liuauthor=C.+Y.+Gongauthor=H.+S.+Shiauthor=Y.+H.+Zengauthor=X.+Z.+Wangauthor=Y.+W.+Zhaoauthor=Y.+Q.+Wei&title=Prognostic+significance+of+tumor-associated+macrophages+in+solid+tumor%3A+a+meta-analysis+of+the+literature&doi=10.1371%2Fjournal.pone.0050946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature</span></div><div class="casAuthors">Zhang, Qiong-Wen; Liu, Lei; Gong, Chang-Yang; Shi, Hua-Shan; Zeng, Yun-Hui; Wang, Xiao-Ze; Zhao, Yu-Wei; Wei, Yu-Quan</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e50946</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Purpose: Tumor assocd. macrophages (TAMs) are considered with the capacity to have both neg. and pos. effects on tumor growth.  The prognostic value of TAM for survival in patients with solid tumor remains controversial.  Exptl. Design: We conducted a meta-anal. of 55 studies (n = 8,692 patients) that evaluated the correlation between TAM (detected by immunohistochem.) and clin. staging, overall survival (OS) and disease free survival (DFS).  The impact of M1 and M2 type TAM (n = 5) on survival was also examd.  Results: High d. of TAM was significantly assocd. with late clin. staging in patients with breast cancer [risk ratio (RR) = 1.20 (95% confidence interval (CI), 1.14-1.28)] and bladder cancer [RR = 3.30 (95% CI, 1.56-6.96)] and with early clin. staging in patients with ovarian cancer [RR = 0.52 (95% CI, 0.35-0.77)].  Neg. effects of TAM on OS was shown in patients with gastric cancer [RR = 1.64 (95% CI, 1.24-2.16)], breast cancer [RR = 8.62 (95% CI, 3.10-23.95)], bladder cancer [RR = 5.00 (95% CI, 1.98-12.63)], ovarian cancer [RR = 2.55 (95% CI, 1.60-4.06)], oral cancer [RR = 2.03 (95% CI, 1.47-2.80)] and thyroid cancer [RR = 2.72 (95% CI, 1.26-5.86)] and pos. effects was displayed in patients with colorectal cancer [RR = 0.64 (95% CI, 0.43-0.96)].  No significant effect was shown between TAM and DFS.  There was also no significant effect of two phenotypes of TAM on survival.  Conclusions: Although some modest bias cannot be excluded, high d. of TAM seems to be assocd. with worse OS in patients with gastric cancer, urogenital cancer and head and neck cancer, with better OS in patients with colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_X3L2OOPlvLVg90H21EOLACvtfcHk0ljxQ-WNOyBEFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVygsg%253D%253D&md5=1052f33d7a701af2fda965a43c4b3221</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0050946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0050946%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%2BW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGong%26aufirst%3DC.%2BY.%26aulast%3DShi%26aufirst%3DH.%2BS.%26aulast%3DZeng%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DX.%2BZ.%26aulast%3DZhao%26aufirst%3DY.%2BW.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26atitle%3DPrognostic%2520significance%2520of%2520tumor-associated%2520macrophages%2520in%2520solid%2520tumor%253A%2520a%2520meta-analysis%2520of%2520the%2520literature%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De50946%26doi%3D10.1371%2Fjournal.pone.0050946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escamilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priceman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span> <span> </span><span class="NLM_article-title">CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2782</span>– <span class="NLM_lpage">2794</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-3981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F0008-5472.CAN-12-3981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=23418320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVShtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=2782-2794&author=J.+Xuauthor=J.+Escamillaauthor=S.+Mokauthor=J.+Davidauthor=S.+Pricemanauthor=B.+Westauthor=G.+Bollagauthor=W.+McBrideauthor=L.+Wu&title=CSF1R+signaling+blockade+stanches+tumor-infiltrating+myeloid+cells+and+improves+the+efficacy+of+radiotherapy+in+prostate+cancer&doi=10.1158%2F0008-5472.CAN-12-3981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer</span></div><div class="casAuthors">Xu, Jingying; Escamilla, Jemima; Mok, Stephen; David, John; Priceman, Saul; West, Brian; Bollag, Gideon; McBride, William; Wu, Lily</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2782-2794</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Radiotherapy is used to treat many types of cancer, but many treated patients relapse with local tumor recurrence.  Tumor-infiltrating myeloid cells (TIM), including CD11b+ (ITGAM)+F4/80 (EMR1)+ tumor-assocd. macrophages (TAM), and CD11b+Gr-1 (LY6G)+ myeloid-derived suppressor cells (MDSC), respond to cancer-related stresses and play crit. roles in promoting tumor angiogenesis, tissue remodeling, and immunosuppression.  In this report, we used a prostate cancer model to investigate the effects of irradn. on TAMs and MDSCs in tumor-bearing animals.  Unexpectedly, when primary tumor sites were irradiated, we obsd. a systemic increase of MDSCs in spleen, lung, lymph nodes, and peripheral blood.  Cytokine anal. showed that the macrophage colony-stimulating factor CSF1 increased by two-fold in irradiated tumors.  Enhanced macrophage migration induced by conditioned media from irradiated tumor cells was completely blocked by a selective inhibitor of CSF1R.  These findings were confirmed in patients with prostate cancer, where serum levels of CSF1 increased after radiotherapy.  Mechanistic investigations revealed the recruitment of the DNA damage-induced kinase ABL1 into cell nuclei where it bound the CSFl gene promoter and enhanced CSFl gene transcription.  When added to radiotherapy, a selective inhibitor of CSF1R suppressed tumor growth more effectively than irradn. alone.  Our results highlight the importance of CSF1/CSF1R signaling in the recruitment of TIMs that can limit the efficacy of radiotherapy.  Furthermore, they suggest that CSF1 inhibitors should be evaluated in clin. trials in combination with radiotherapy as a strategy to improve outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomWESrA4ObubVg90H21EOLACvtfcHk0lhOHKkDgJwonA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVShtb8%253D&md5=6a6ca9efb87ed1c1c8b73aa6f0f042cd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-3981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-3981%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DEscamilla%26aufirst%3DJ.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DDavid%26aufirst%3DJ.%26aulast%3DPriceman%26aufirst%3DS.%26aulast%3DWest%26aufirst%3DB.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DMcBride%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DL.%26atitle%3DCSF1R%2520signaling%2520blockade%2520stanches%2520tumor-infiltrating%2520myeloid%2520cells%2520and%2520improves%2520the%2520efficacy%2520of%2520radiotherapy%2520in%2520prostate%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D2782%26epage%3D2794%26doi%3D10.1158%2F0008-5472.CAN-12-3981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escamilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schokrpur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priceman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moughon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magyar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fradet, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span> <span> </span><span class="NLM_article-title">CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">950</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0992</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F0008-5472.CAN-14-0992" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=950-962&author=J.+Escamillaauthor=S.+Schokrpurauthor=C.+Liuauthor=S.+J.+Pricemanauthor=D.+Moughonauthor=Z.+Jiangauthor=F.+Pouliotauthor=C.+Magyarauthor=J.+L.+Sungauthor=J.+Xuauthor=G.+Dengauthor=B.+L.+Westauthor=G.+Bollagauthor=Y.+Fradetauthor=L.+Lacombeauthor=M.+E.+Jungauthor=J.+Huangauthor=L.+Wu&title=CSF1+receptor+targeting+in+prostate+cancer+reverses+macrophage-mediated+resistance+to+androgen+blockade+therapy&doi=10.1158%2F0008-5472.CAN-14-0992"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0992%26sid%3Dliteratum%253Aachs%26aulast%3DEscamilla%26aufirst%3DJ.%26aulast%3DSchokrpur%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DPriceman%26aufirst%3DS.%2BJ.%26aulast%3DMoughon%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DPouliot%26aufirst%3DF.%26aulast%3DMagyar%26aufirst%3DC.%26aulast%3DSung%26aufirst%3DJ.%2BL.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DFradet%26aufirst%3DY.%26aulast%3DLacombe%26aufirst%3DL.%26aulast%3DJung%26aufirst%3DM.%2BE.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%26atitle%3DCSF1%2520receptor%2520targeting%2520in%2520prostate%2520cancer%2520reverses%2520macrophage-mediated%2520resistance%2520to%2520androgen%2520blockade%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D950%26epage%3D962%26doi%3D10.1158%2F0008-5472.CAN-14-0992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pyonteck, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akkari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuhmacher, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevenich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quail, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quick, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huse, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teijeiro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedraza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, J. A.</span></span> <span> </span><span class="NLM_article-title">CSF-1R inhibition alters macrophage polarization and blocks glioma progression</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1264</span>– <span class="NLM_lpage">1272</span>, <span class="refDoi"> DOI: 10.1038/nm.3337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1038%2Fnm.3337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=24056773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2jsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1264-1272&author=S.+M.+Pyonteckauthor=L.+Akkariauthor=A.+J.+Schuhmacherauthor=R.+L.+Bowmanauthor=L.+Sevenichauthor=D.+F.+Quailauthor=O.+C.+Olsonauthor=M.+L.+Quickauthor=J.+T.+Huseauthor=V.+Teijeiroauthor=M.+Settyauthor=C.+S.+Leslieauthor=Y.+Oeiauthor=A.+Pedrazaauthor=J.+Zhangauthor=C.+W.+Brennanauthor=J.+C.+Suttonauthor=E.+C.+Hollandauthor=D.+Danielauthor=J.+A.+Joyce&title=CSF-1R+inhibition+alters+macrophage+polarization+and+blocks+glioma+progression&doi=10.1038%2Fnm.3337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">CSF-1R inhibition alters macrophage polarization and blocks glioma progression</span></div><div class="casAuthors">Pyonteck, Stephanie M.; Akkari, Leila; Schuhmacher, Alberto J.; Bowman, Robert L.; Sevenich, Lisa; Quail, Daniela F.; Olson, Oakley C.; Quick, Marsha L.; Huse, Jason T.; Teijeiro, Virginia; Setty, Manu; Leslie, Christina S.; Oei, Yoko; Pedraza, Alicia; Zhang, Jianan; Brennan, Cameron W.; Sutton, James C.; Holland, Eric C.; Daniel, Dylan; Joyce, Johanna A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1264-1272</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) comprises several mol. subtypes, including proneural GBM.  Most therapeutic approaches targeting glioma cells have failed.  An alternative strategy is to target cells in the glioma microenvironment, such as tumor-assocd. macrophages and microglia (TAMs).  Macrophages depend on colony stimulating factor-1 (CSF-1) for differentiation and survival.  We used an inhibitor of the CSF-1 receptor (CSF-1R) to target TAMs in a mouse proneural GBM model, which significantly increased survival and regressed established tumors.  CSF-1R blockade addnl. slowed intracranial growth of patient-derived glioma xenografts.  Surprisingly, TAMs were not depleted in treated mice.  Instead, glioma-secreted factors, including granulocyte-macrophage CSF (GM-CSF) and interferon-γ (IFN-γ), facilitated TAM survival in the context of CSF-1R inhibition.  Expression of alternatively activated M2 markers decreased in surviving TAMs, which is consistent with impaired tumor-promoting functions.  These gene signatures were assocd. with enhanced survival in patients with proneural GBM.  Our results identify TAMs as a promising therapeutic target for proneural gliomas and establish the translational potential of CSF-1R inhibition for GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrirwpRVIWUELVg90H21EOLACvtfcHk0lhOHKkDgJwonA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2jsr3N&md5=9b908e86c4a7da35a009bf322d492214</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnm.3337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3337%26sid%3Dliteratum%253Aachs%26aulast%3DPyonteck%26aufirst%3DS.%2BM.%26aulast%3DAkkari%26aufirst%3DL.%26aulast%3DSchuhmacher%26aufirst%3DA.%2BJ.%26aulast%3DBowman%26aufirst%3DR.%2BL.%26aulast%3DSevenich%26aufirst%3DL.%26aulast%3DQuail%26aufirst%3DD.%2BF.%26aulast%3DOlson%26aufirst%3DO.%2BC.%26aulast%3DQuick%26aufirst%3DM.%2BL.%26aulast%3DHuse%26aufirst%3DJ.%2BT.%26aulast%3DTeijeiro%26aufirst%3DV.%26aulast%3DSetty%26aufirst%3DM.%26aulast%3DLeslie%26aufirst%3DC.%2BS.%26aulast%3DOei%26aufirst%3DY.%26aulast%3DPedraza%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DC.%2BW.%26aulast%3DSutton%26aufirst%3DJ.%2BC.%26aulast%3DHolland%26aufirst%3DE.%2BC.%26aulast%3DDaniel%26aufirst%3DD.%26aulast%3DJoyce%26aufirst%3DJ.%2BA.%26atitle%3DCSF-1R%2520inhibition%2520alters%2520macrophage%2520polarization%2520and%2520blocks%2520glioma%2520progression%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1264%26epage%3D1272%26doi%3D10.1038%2Fnm.3337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belkowski, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurmond, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthey, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenspan, A.</span></span> <span> </span><span class="NLM_article-title">Results from a phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1752</span>– <span class="NLM_lpage">1760</span>, <span class="refDoi"> DOI: 10.3899/jrheum.141580</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.3899%2Fjrheum.141580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=26233509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVyqsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2015&pages=1752-1760&author=M.+C.+Genoveseauthor=E.+Hsiaauthor=S.+M.+Belkowskiauthor=C.+Chienauthor=T.+Mastersonauthor=R.+L.+Thurmondauthor=C.+L.+Mantheyauthor=X.+D.+Yanauthor=T.+Geauthor=C.+Franksauthor=A.+Greenspan&title=Results+from+a+phase+IIA+parallel+group+study+of+JNJ-40346527%2C+an+oral+CSF-1R+inhibitor%2C+in+patients+with+active+rheumatoid+arthritis+despite+disease-modifying+antirheumatic+drug+therapy&doi=10.3899%2Fjrheum.141580"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Results from a phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy</span></div><div class="casAuthors">Genovese, Mark C.; Hsia, Elizabeth; Belkowski, Stanley M.; Chien, Caly; Masterson, Tara; Thurmond, Robin L.; Manthey, Carl L.; Yan, Xiaoyu; Ge, Tingting; Franks, Carol; Greenspan, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1752-1760</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">1499-2752</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective.  To assess the efficacy and safety of JNJ-40346527, a selective inhibitor of colony-stimulating factor-1 (CSF-1) receptor kinase that acts to inhibit macrophage survival, proliferation, and differentiation in patients with active rheumatoid arthritis (RA) despite disease-modifying antirheumatic drug (DMARD) therapy.  In this randomized, double-blind, placebo-controlled, parallel group study, adults were randomized (2:1) to receive oral JNJ-40346527 100 mg or placebo twice daily through Week 12.  Patients with RA had disease activity [≥ 6 swollen/≥ 6 tender joints, C-reactive protein (CRP) ≥ 0.8 mg/dL] despite DMARD therapy for ≥ 6 mo.  The primary endpoint was change from baseline at Week 12 in the 28-joint Disease Activity Score with CRP (DAS28-CRP).  Pharmacokinetic/pharmacodynamic analyses were also performed, and safety was assessed through Week 16.  Ninety-five patients were treated (63 JNJ-40346527, 32 placebo); 8 patients discontinued treatment (6 JNJ-40346527, 2 placebo) through Week 12.  Mean improvements in DAS28-CRP from baseline to Week 12 were 1.15 for the JNJ-40346527 group and 1.42 for the placebo group (p = 0.30); thus, a statistically significant difference was not obsd. for the primary endpoint.  Pharmacokinetic exposure to JNJ-40346527 and its active metabolites was above the projected concn. needed for pharmacol. activity, and effective target engagement and proof of activity were demonstrated by increased levels of CSF-1 and decreased CD16+ monocytes in JNJ-40346527-treated, but not placebo-treated, patients.  Thirty-seven (58.7%) JNJ-40346527-treated and 16 (50.0%) placebo-treated patients reported ≥ 1 adverse event (AE); 1 (1.6%) JNJ-40346527-treated and 3 (9.4%) placebo-treated patients reported ≥ 1 serious AE.  Conclusion.  Although adequate exposure and effective peripheral target engagement were evident, JNJ-40346527 efficacy was not obsd. in patients with DMARD-refractory active RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYP703ihQxAbVg90H21EOLACvtfcHk0lj0bAsTaPK6oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVyqsL7I&md5=691acfc23f3fdcb46c59da16c2d01455</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.141580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.141580%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DHsia%26aufirst%3DE.%26aulast%3DBelkowski%26aufirst%3DS.%2BM.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DMasterson%26aufirst%3DT.%26aulast%3DThurmond%26aufirst%3DR.%2BL.%26aulast%3DManthey%26aufirst%3DC.%2BL.%26aulast%3DYan%26aufirst%3DX.%2BD.%26aulast%3DGe%26aufirst%3DT.%26aulast%3DFranks%26aufirst%3DC.%26aulast%3DGreenspan%26aufirst%3DA.%26atitle%3DResults%2520from%2520a%2520phase%2520IIA%2520parallel%2520group%2520study%2520of%2520JNJ-40346527%252C%2520an%2520oral%2520CSF-1R%2520inhibitor%252C%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520despite%2520disease-modifying%2520antirheumatic%2520drug%2520therapy%26jtitle%3DJ.%2520Rheumatol.%26date%3D2015%26volume%3D42%26spage%3D1752%26epage%3D1760%26doi%3D10.3899%2Fjrheum.141580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uemura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohzeki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murooka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serizawa, I.</span></span> <span> </span><span class="NLM_article-title">The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis</span>. <i>J. Neuroimmunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.jneuroim.2008.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.jneuroim.2008.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=18378004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVOrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2008&pages=73-80&author=Y.+Uemuraauthor=H.+Ohnoauthor=Y.+Ohzekiauthor=H.+Takanashiauthor=H.+Murookaauthor=K.+Kuboauthor=I.+Serizawa&title=The+selective+M-CSF+receptor+tyrosine+kinase+inhibitor+Ki20227+suppresses+experimental+autoimmune+encephalomyelitis&doi=10.1016%2Fj.jneuroim.2008.01.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The selective M-CSF receptor tyrosine kinase inhibitor Ki20227 suppresses experimental autoimmune encephalomyelitis</span></div><div class="casAuthors">Uemura, Yasunori; Ohno, Hiroaki; Ohzeki, Yumiko; Takanashi, Hiromi; Murooka, Hideko; Kubo, Kazuo; Serizawa, Isao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroimmunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">73-80</span>CODEN:
                <span class="NLM_cas:coden">JNRIDW</span>;
        ISSN:<span class="NLM_cas:issn">0165-5728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Exptl. autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), can be induced by the immunization of mice with myelin antigens in the form of myelin oligodendrocyte glycoprotein (MOG).  Macrophage colony-stimulating factor (M-CSF) is required for the development of individual mononuclear phagocyte populations and is involved in the immune response.  We previously reported that Ki20227 (N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N'-[1-(1,3-thiazole-2-yl)ethyl]urea) is a highly selective M-CSF receptor (c-fms) tyrosine kinase inhibitor.  In our current study, we investigated whether Ki20227 has suppressive effects upon EAE and indeed found that this drug significantly reduced the severity of this disease both preventively and therapeutically.  Notably also, Ki20227 treatments inhibited the turn-over/expansion of myeloid cells provoked by the immunization and subsequent MOG-specific T cell responses in our EAE animal model.  These findings suggest that M-CSF plays a pivotal role in the development of EAE and that Ki20227 and its derivs. may be candidate drugs for the treatment of human MS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobS3ECXzImwbVg90H21EOLACvtfcHk0lj0bAsTaPK6oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVOrsbc%253D&md5=92b102002c788d12d3ad7d7194b9607f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jneuroim.2008.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jneuroim.2008.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DUemura%26aufirst%3DY.%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DOhzeki%26aufirst%3DY.%26aulast%3DTakanashi%26aufirst%3DH.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DSerizawa%26aufirst%3DI.%26atitle%3DThe%2520selective%2520M-CSF%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520Ki20227%2520suppresses%2520experimental%2520autoimmune%2520encephalomyelitis%26jtitle%3DJ.%2520Neuroimmunol.%26date%3D2008%26volume%3D195%26spage%3D73%26epage%3D80%26doi%3D10.1016%2Fj.jneuroim.2008.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murooka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishitoba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoneda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isoe, T.</span></span> <span> </span><span class="NLM_article-title">A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2634</span>– <span class="NLM_lpage">2643</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-05-0313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F1535-7163.MCT-05-0313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=17121910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1els7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=2634-2643&author=H.+Ohnoauthor=K.+Kuboauthor=H.+Murookaauthor=Y.+Kobayashiauthor=T.+Nishitobaauthor=M.+Shibuyaauthor=T.+Yonedaauthor=T.+Isoe&title=A+c-fms+tyrosine+kinase+inhibitor%2C+Ki20227%2C+suppresses+osteoclast+differentiation+and+osteolytic+bone+destruction+in+a+bone+metastasis+model&doi=10.1158%2F1535-7163.MCT-05-0313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model</span></div><div class="casAuthors">Ohno, Hiroaki; Kubo, Kazuo; Murooka, Hideko; Kobayashi, Yoshiko; Nishitoba, Tsuyoshi; Shibuya, Masabumi; Yoneda, Toshiyuki; Isoe, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2634-2643</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In bone metastatic lesions, osteoclasts play a key role in the development of osteolysis.  Previous studies have shown that macrophage colony-stimulating factor (M-CSF) is important for the differentiation of osteoclasts.  In this study, we investigated whether an inhibitor of M-CSF receptor (c-Fms) suppresses osteoclast-dependent osteolysis in bone metastatic lesions.  We developed small mol. inhibitors against ligand-dependent phosphorylation of c-Fms and examd. the effects of these compds. on osteolytic bone destruction in a bone metastasis model.  We discovered a novel quinoline-urea deriv., Ki20227 (N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N'-[1-(1,3-thiazole-2-yl)ethyl]urea), which is a c-Fms tyrosine kinase inhibitor.  The IC50s of Ki20227 to inhibit c-Fms, vascular endothelial growth factor receptor-2 (KDR), stem cell factor receptor (c-Kit), and platelet-derived growth factor receptor {szligbeta} were found to be 2, 12, 451, and 217 nmol/L, resp.  Ki20227 did not inhibit other kinases tested, such as fms-like tyrosine kinase-3, epidermal growth factor receptor, or c-Src (c-src proto-oncogene product).  Ki20227 was also found to inhibit the M-CSF-dependent growth of M-NFS-60 cells but not the M-CSF-independent growth of A375 human melanoma cells in vitro.  Furthermore, in an osteoclast-like cell formation assay using mouse bone marrow cells, Ki20227 inhibited the development of tartrate-resistant acid phosphatase-pos. osteoclast-like cells in a dose-dependent manner.  In in vivo studies, oral administration of Ki20227 suppressed osteoclast-like cell accumulation and bone resorption induced by metastatic tumor cells in nude rats following intracardiac injection of A375 cells.  Moreover, Ki20227 decreased the no. of tartrate-resistant acid phosphatase-pos. osteoclast-like cells on bone surfaces in ovariectomized (ovx) rats.  These findings suggest that Ki20227 inhibits osteolytic bone destruction through the suppression of M-CSF-induced osteoclast accumulation in vivo.  Therefore, Ki20227 may be a useful therapeutic agent for osteolytic disease assocd. with bone metastasis and other bone diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpseoHCyJngCrVg90H21EOLACvtfcHk0lj0bAsTaPK6oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1els7jF&md5=1f7746c1735cdc91c3aa9789e030a1a5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0313%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DNishitoba%26aufirst%3DT.%26aulast%3DShibuya%26aufirst%3DM.%26aulast%3DYoneda%26aufirst%3DT.%26aulast%3DIsoe%26aufirst%3DT.%26atitle%3DA%2520c-fms%2520tyrosine%2520kinase%2520inhibitor%252C%2520Ki20227%252C%2520suppresses%2520osteoclast%2520differentiation%2520and%2520osteolytic%2520bone%2520destruction%2520in%2520a%2520bone%2520metastasis%2520model%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D2634%26epage%3D2643%26doi%3D10.1158%2F1535-7163.MCT-05-0313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cannarile, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jegg, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ries, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruttinger, D.</span></span> <span> </span><span class="NLM_article-title">Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy</span>. <i>J. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1186/s40425-017-0257-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1186%2Fs40425-017-0257-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A280%3ADC%252BC1cjosVSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=53-66&author=M.+A.+Cannarileauthor=M.+Weisserauthor=W.+Jacobauthor=A.+M.+Jeggauthor=C.+H.+Riesauthor=D.+Ruttinger&title=Colony-stimulating+factor+1+receptor+%28CSF1R%29+inhibitors+in+cancer+therapy&doi=10.1186%2Fs40425-017-0257-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy</span></div><div class="casAuthors">Cannarile Michael A; Weisser Martin; Jacob Wolfgang; Jegg Anna-Maria; Ries Carola H; Ruttinger Dominik</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells.  In this context, the colony-stimulating factor 1 (CSF1)/colony-stimulating factor 1 receptor (CSF1R) axis has gained the most attention, and various approaches targeting either the ligands or the receptor are currently in clinical development.  Emerging data on the tolerability of CSF1/CSF1R-targeting agents suggest a favorable safety profile, making them attractive combination partners for both standard treatment modalities and immunotherapeutic agents.  The specificity of these agents and their potent blocking activity has been substantiated by impressive response rates in diffuse-type tenosynovial giant cell tumors, a benign connective tissue disorder driven by CSF1 in an autocrine fashion.  In the malignant disease setting, data on the clinical activity of immunotherapy combinations with CSF1/CSF1R-targeting agents are pending.  As our knowledge of macrophage biology expands, it becomes apparent that the complex phenotypic and functional properties of macrophages are heavily influenced by a continuum of survival, differentiation, recruitment, and polarization signals within their specific tissue environment.  Thus, the role of macrophages in regulating tumorigenesis and the impact of depleting and/or reprogramming TAM as therapeutic approaches for cancer patients may vary greatly depending on organ-specific characteristics of these cells.  We review the currently available clinical safety and efficacy data with CSF1/CSF1R-targeting agents and provide a comprehensive overview of ongoing clinical studies.  Furthermore, we discuss the local tissue macrophage and tumor-type specificities and their potential impact on CSF1/CSF1R-targeting treatment strategies for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQzjcxKO1-OQqdek-gHSrIfW6udTcc2eZ52AxDFdxttLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjosVSnsg%253D%253D&md5=09fab249b606af3e00f545dc7e7121b4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1186%2Fs40425-017-0257-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-017-0257-y%26sid%3Dliteratum%253Aachs%26aulast%3DCannarile%26aufirst%3DM.%2BA.%26aulast%3DWeisser%26aufirst%3DM.%26aulast%3DJacob%26aufirst%3DW.%26aulast%3DJegg%26aufirst%3DA.%2BM.%26aulast%3DRies%26aufirst%3DC.%2BH.%26aulast%3DRuttinger%26aufirst%3DD.%26atitle%3DColony-stimulating%2520factor%25201%2520receptor%2520%2528CSF1R%2529%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DJ.%2520Immunother.%26date%3D2017%26volume%3D5%26spage%3D53%26epage%3D66%26doi%3D10.1186%2Fs40425-017-0257-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staddon, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterfy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, Z. A.</span></span> <span> </span><span class="NLM_article-title">A pilot study of PLX3397, a selective colony-stimulating factor 1 receptor (CSF1R) kinase inhibitor, in pigmented villonodular synovitis (PVNS)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">10503</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=10503&author=W.+D.+Tapauthor=S.+P.+Anthonyauthor=B.+Chmielowskiauthor=A.+P.+Staddonauthor=A.+L.+Cohnauthor=G.+Shapiroauthor=I.+Puzanovauthor=E.+L.+Kwakauthor=A.+J.+Wagnerauthor=C.+Peterfyauthor=H.+H.+Hsuauthor=C.+Geeauthor=P.+S.+Linauthor=S.+Tongauthor=Z.+A.+Wainberg&title=A+pilot+study+of+PLX3397%2C+a+selective+colony-stimulating+factor+1+receptor+%28CSF1R%29+kinase+inhibitor%2C+in+pigmented+villonodular+synovitis+%28PVNS%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DStaddon%26aufirst%3DA.%2BP.%26aulast%3DCohn%26aufirst%3DA.%2BL.%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DPeterfy%26aufirst%3DC.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DGee%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DTong%26aufirst%3DS.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26atitle%3DA%2520pilot%2520study%2520of%2520PLX3397%252C%2520a%2520selective%2520colony-stimulating%2520factor%25201%2520receptor%2520%2528CSF1R%2529%2520kinase%2520inhibitor%252C%2520in%2520pigmented%2520villonodular%2520synovitis%2520%2528PVNS%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D10503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span> <span> </span><span class="NLM_article-title">Abstract PR01: blocking colony stimulating factor 1 receptor (CSF-1R) and tropomyosin receptor kinase (Trk) improves antitumor efficacy of immunotherapy</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">PR01</span>, <span class="refDoi"> DOI: 10.1158/2326-6074.TUMIMM16-PR01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F2326-6074.TUMIMM16-PR01" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=PR01&author=S.+Mokauthor=C.+Duffyauthor=R.+Duauthor=J.+P.+Allison&title=Abstract+PR01%3A+blocking+colony+stimulating+factor+1+receptor+%28CSF-1R%29+and+tropomyosin+receptor+kinase+%28Trk%29+improves+antitumor+efficacy+of+immunotherapy&doi=10.1158%2F2326-6074.TUMIMM16-PR01"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F2326-6074.TUMIMM16-PR01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6074.TUMIMM16-PR01%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DS.%26aulast%3DDuffy%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DR.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26atitle%3DAbstract%2520PR01%253A%2520blocking%2520colony%2520stimulating%2520factor%25201%2520receptor%2520%2528CSF-1R%2529%2520and%2520tropomyosin%2520receptor%2520kinase%2520%2528Trk%2529%2520improves%2520antitumor%2520efficacy%2520of%2520immunotherapy%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2017%26volume%3D5%26spage%3DPR01%26doi%3D10.1158%2F2326-6074.TUMIMM16-PR01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrus, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cable, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span> <span> </span><span class="NLM_article-title">Abstract A252: a phase 1 study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF1R), in patients with advanced or metastatic cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">A252</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.TARG-13-A252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F1535-7163.TARG-13-A252" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=A252&author=J.+C.+Bendellauthor=A.+W.+Tolcherauthor=S.+F.+Jonesauthor=M.+Beeramauthor=J.+R.+Infanteauthor=P.+Larsenauthor=K.+Rasorauthor=J.+E.+Garrusauthor=J.+Liauthor=P.+L.+Cableauthor=C.+Eberhardtauthor=J.+Schreiberauthor=S.+Rushauthor=K.+W.+Woodauthor=E.+Barrettauthor=A.+Patnaik&title=Abstract+A252%3A+a+phase+1+study+of+ARRY-382%2C+an+oral+inhibitor+of+colony-stimulating+factor-1+receptor+%28CSF1R%29%2C+in+patients+with+advanced+or+metastatic+cancers&doi=10.1158%2F1535-7163.TARG-13-A252"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-13-A252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-13-A252%26sid%3Dliteratum%253Aachs%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DJones%26aufirst%3DS.%2BF.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DLarsen%26aufirst%3DP.%26aulast%3DRasor%26aufirst%3DK.%26aulast%3DGarrus%26aufirst%3DJ.%2BE.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCable%26aufirst%3DP.%2BL.%26aulast%3DEberhardt%26aufirst%3DC.%26aulast%3DSchreiber%26aufirst%3DJ.%26aulast%3DRush%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DK.%2BW.%26aulast%3DBarrett%26aufirst%3DE.%26aulast%3DPatnaik%26aufirst%3DA.%26atitle%3DAbstract%2520A252%253A%2520a%2520phase%25201%2520study%2520of%2520ARRY-382%252C%2520an%2520oral%2520inhibitor%2520of%2520colony-stimulating%2520factor-1%2520receptor%2520%2528CSF1R%2529%252C%2520in%2520patients%2520with%2520advanced%2520or%2520metastatic%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3DA252%26doi%3D10.1158%2F1535-7163.TARG-13-A252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Von
Tresckow, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribrag, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topp, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seetharam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquino, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotoulek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engert, A.</span></span> <span> </span><span class="NLM_article-title">An open-label, multicenter, phase I/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory hodgkin lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1843</span>– <span class="NLM_lpage">1850</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1158%2F1078-0432.CCR-14-1845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=25628399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsl2gt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1843-1850&author=B.+Von%0ATresckowauthor=F.+Morschhauserauthor=V.+Ribragauthor=M.+S.+Toppauthor=C.+Chienauthor=S.+Seetharamauthor=R.+Aquinoauthor=S.+Kotoulekauthor=C.+J.+de+Boerauthor=A.+Engert&title=An+open-label%2C+multicenter%2C+phase+I%2FII+study+of+JNJ-40346527%2C+a+CSF-1R+inhibitor%2C+in+patients+with+relapsed+or+refractory+hodgkin+lymphoma&doi=10.1158%2F1078-0432.CCR-14-1845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma</span></div><div class="casAuthors">von Tresckow, Bastian; Morschhauser, Franck; Ribrag, Vincent; Topp, Max S.; Chien, Caly; Seetharam, Shobha; Aquino, Regina; Kotoulek, Sonja; de Boer, Carla J.; Engert, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1843-1850</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This phase I/II study investigated JNJ-40346527, a selective inhibitor of the colony-stimulating factor-1 receptor (CSF-1R) tyrosine kinase as treatment for relapsed or refractory classical Hodgkin lymphoma (cHL).  Patients ≥18 years with histopathol. confirmed initial diagnosis of cHL that had relapsed or was refractory after ≥1 appropriate therapies were assigned to sequential cohorts of oral daily doses of JNJ-40346527 (150, 300, 450, 600 mg every day, and 150 mg twice a day).  For the dose-escalation phase, the primary endpoint was to establish the recommended phase II dose.  Secondary endpoints included safety, pharmacokinetics, and pharmacodynamics.  Twenty-one patients [(150 mg: 3; 300 mg: 5; 450 mg: 3, 600 mg: 3) every day, and 150 mg twice a day: 7] were enrolled, 10 men, median age 40 (range, 19-75) years, median no. of prior systemic therapies 6 (range, 3-14).  No dose-limiting toxicities were obsd.; max.-tolerated dose was not established.  Best overall response was complete remission in 1 patient (duration, +352 days) and stable disease in 11 patients: (duration, 1.5-8 mo).  Median no. of cycles: 4 (range, 1-16).  Most common (≥20% patients) possibly drug-related adverse events (per investigator assessment) were nausea (n = 6), headache, and pyrexia (n = 5 each).  JNJ-40346527 exposure increased in near dose-proportional manner over a dose range of 150 to 450 mg every day, but plateaued at 600 mg every day.  Target engagement was confirmed (>80% inhibition of CSF-1R phosphorylation, 4 h after dosing).  JNJ-40346527, a selective inhibitor of CSF-1R was well tolerated, and preliminary antitumor results suggested limited activity in monotherapy for the treatment of cHL.  Clin Cancer Res; 21(8); 1843-50. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwZuUy9-7MhLVg90H21EOLACvtfcHk0ljCf_ksi2GKHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsl2gt7g%253D&md5=e3d4f2b2937078f85ef0ead51e093f82</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1845%26sid%3Dliteratum%253Aachs%26aulast%3DVon%2BTresckow%26aufirst%3DB.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DRibrag%26aufirst%3DV.%26aulast%3DTopp%26aufirst%3DM.%2BS.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DSeetharam%26aufirst%3DS.%26aulast%3DAquino%26aufirst%3DR.%26aulast%3DKotoulek%26aufirst%3DS.%26aulast%3Dde%2BBoer%26aufirst%3DC.%2BJ.%26aulast%3DEngert%26aufirst%3DA.%26atitle%3DAn%2520open-label%252C%2520multicenter%252C%2520phase%2520I%252FII%2520study%2520of%2520JNJ-40346527%252C%2520a%2520CSF-1R%2520inhibitor%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520hodgkin%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1843%26epage%3D1850%26doi%3D10.1158%2F1078-0432.CCR-14-1845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8803</span>– <span class="NLM_lpage">8813</span>, <span class="refDoi"> DOI: 10.1021/jm4012388</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4012388" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8803-8813&author=S.+Xuauthor=T.+Xuauthor=L.+Zhangauthor=Z.+Zhangauthor=J.+Luoauthor=Y.+Liuauthor=X.+Luauthor=Z.+Tuauthor=X.+Renauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+2-oxo-3%2C4-dihydropyrimido%5B4%2C5-d%5Dpyrimidinyl+derivatives+as+new+irreversible+epidermal+growth+factor+receptor+inhibitors+with+improved+pharmacokinetic+properties&doi=10.1021%2Fjm4012388"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm4012388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4012388%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25202-oxo-3%252C4-dihydropyrimido%255B4%252C5-d%255Dpyrimidinyl%2520derivatives%2520as%2520new%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520with%2520improved%2520pharmacokinetic%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8803%26epage%3D8813%26doi%3D10.1021%2Fjm4012388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790 → methionine790 mutant</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2711</span>– <span class="NLM_lpage">2723</span>, <span class="refDoi"> DOI: 10.1021/jm201591k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%E2%86%92+methionine790+mutant&doi=10.1021%2Fjm201591k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520%25E2%2586%2592%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723%26doi%3D10.1021%2Fjm201591k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Pyrimido[4,5-<i>d</i>]pyrimidin- 4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">8387</span>– <span class="NLM_lpage">8390</span>, <span class="refDoi"> DOI: 10.1002/anie.201302313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1002%2Fanie.201302313" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=8387-8390&author=T.+Xuauthor=L.+Zhangauthor=S.+Xuauthor=C.-Y.+Yangauthor=J.+Luoauthor=F.+Dingauthor=X.+Luauthor=Y.+Liuauthor=Z.+Tuauthor=S.+Liauthor=D.+Peiauthor=Q.+Caiauthor=H.+Liauthor=X.+Renauthor=S.+Wangauthor=K.+Ding&title=Pyrimido%5B4%2C5-d%5Dpyrimidin-+4%281H%29-one+derivatives+as+selective+inhibitors+of+EGFR+threonine790+to+methionine790+%28T790M%29+mutants&doi=10.1002%2Fanie.201302313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302313%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DPyrimido%255B4%252C5-d%255Dpyrimidin-%25204%25281H%2529-one%2520derivatives%2520as%2520selective%2520inhibitors%2520of%2520EGFR%2520threonine790%2520to%2520methionine790%2520%2528T790M%2529%2520mutants%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D8387%26epage%3D8390%26doi%3D10.1002%2Fanie.201302313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartual, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of tetrahydroisoquinoline-7-carboxamides as selective discoidin domain receptor 1 (DDR1) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5911</span>– <span class="NLM_lpage">5916</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00140</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00140" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5911-5916&author=Z.+Wangauthor=H.+Bianauthor=S.+G.+Bartualauthor=W.+Duauthor=J.+Luoauthor=H.+Zhaoauthor=S.+Zhangauthor=C.+Moauthor=Y.+Zhouauthor=Y.+Xuauthor=Z.+Tuauthor=X.+Renauthor=X.+Luauthor=R.+A.+Brekkenauthor=L.+Yaoauthor=A.+N.+Bullockauthor=J.+Suauthor=K.+Ding&title=Structure-based+design+of+tetrahydroisoquinoline-7-carboxamides+as+selective+discoidin+domain+receptor+1+%28DDR1%29+inhibitors&doi=10.1021%2Facs.jmedchem.6b00140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors</span></div><div class="casAuthors">Wang, Zhen; Bian, Huan; Bartual, Sergio G.; Du, Wenting; Luo, Jinfeng; Zhao, Hu; Zhang, Shasha; Mo, Cheng; Zhou, Yang; Xu, Yong; Tu, Zhengchao; Ren, Xiaomei; Lu, Xiaoyun; Brekken, Rolf A.; Yao, Libo; Bullock, Alex N.; Su, Jin; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5911-5916</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The structure-based design of 1, 2, 3, 4-tetrahydroisoquinoline derivs. as selective DDR1 inhibitors is reported.  One of the representative compds., 6j, binds to DDR1 with a Kd value of 4.7 nM and suppresses its kinase activity with an IC50 value of 9.4 nM, but it is significantly less potent for a panel of 400 nonmutated kinases. 6j also demonstrated reasonable pharmacokinetic properties and a promising oral therapeutic effect in a bleomycin-induced mouse pulmonary fibrosis model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonNN4RHw3FiLVg90H21EOLACvtfcHk0lj_QgPqqs7nDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSmsbc%253D&md5=9501db1f3b0dbc338749eccbd63bace8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00140%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DBartual%26aufirst%3DS.%2BG.%26aulast%3DDu%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DMo%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DBrekken%26aufirst%3DR.%2BA.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DStructure-based%2520design%2520of%2520tetrahydroisoquinoline-7-carboxamides%2520as%2520selective%2520discoidin%2520domain%2520receptor%25201%2520%2528DDR1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5911%26epage%3D5916%26doi%3D10.1021%2Facs.jmedchem.6b00140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartual, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Tetrahydroisoquinoline-7-carboxamide derivatives as new selective discoidin domain receptor 1 (DDR1) inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00497</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00497" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisVSrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=327-332&author=Z.+Wangauthor=Y.+Zhangauthor=S.+G.+Bartualauthor=J.+Luoauthor=T.+Xuauthor=W.+Duauthor=Q.+Xunauthor=Z.+Tuauthor=R.+A.+Brekkenauthor=X.+Renauthor=A.+N.+Bullockauthor=G.+Liangauthor=X.+Luauthor=K.+Ding&title=Tetrahydroisoquinoline-7-carboxamide+derivatives+as+new+selective+discoidin+domain+receptor+1+%28DDR1%29+inhibitors&doi=10.1021%2Facsmedchemlett.6b00497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors</span></div><div class="casAuthors">Wang, Zhen; Zhang, Yali; Bartual, Sergio G.; Luo, Jinfeng; Xu, Tingting; Du, Wenting; Xun, Qiuju; Tu, Zhengchao; Brekken, Rolf A.; Ren, Xiaomei; Bullock, Alex N.; Liang, Guang; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-332</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acute lung injury (ALI) is a deadly symptom for serious lung inflammation.  Discoidin Domain Receptor 1 (DDR1) is a new potential target for anti-inflammatory drug discovery.  A new selective tetrahydroisoquinoline-7-carboxamide based DDR1 inhibitor (R)-4-methyl-N-(3-((4-methyl-1,4-diazepan-1-yl)methyl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1, 2, 3, 4-tetrahydroisoquinoline-7-carboxamide (7ae) was discovered to tightly bind the DDR1 protein and potently inhibit its kinase function with a Kd value of 2.2 nM and an IC50 value of 6.6 nM, resp.  The compd. dose-dependently inhibited lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) release in mouse primary peritoneal macrophages (MPMs).  In addn., (7ae) also exhibited promising in vivo anti-inflammatory effects in a LPS-induced mouse ALI model.  To the best of the authors' knowledge, this is the first "proof of concept" investigation on the potential application of a small mol. DDR1 inhibitor to treat ALI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyzN2DN8OhvrVg90H21EOLACvtfcHk0lgYh62PH2hioQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisVSrt78%253D&md5=2c1a3a6827e854718025672d24dacf4a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00497%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartual%26aufirst%3DS.%2BG.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DDu%26aufirst%3DW.%26aulast%3DXun%26aufirst%3DQ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DBrekken%26aufirst%3DR.%2BA.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DTetrahydroisoquinoline-7-carboxamide%2520derivatives%2520as%2520new%2520selective%2520discoidin%2520domain%2520receptor%25201%2520%2528DDR1%2529%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D327%26epage%3D332%26doi%3D10.1021%2Facsmedchemlett.6b00497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">4-Oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new Axl kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6807</span>– <span class="NLM_lpage">6825</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFersrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6807-6825&author=L.+Tanauthor=Z.+Zhangauthor=D.+Gaoauthor=J.+Luoauthor=Z.+Tuauthor=Z.+Liauthor=L.+Pengauthor=X.+Renauthor=K.+Ding&title=4-Oxo-1%2C4-dihydroquinoline-3-carboxamide+derivatives+as+new+Axl+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.6b00608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">4-Oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new Axl kinase inhibitors</span></div><div class="casAuthors">Tan, Li; Zhang, Zhang; Gao, Donglin; Luo, Jinfeng; Tu, Zheng-Chao; Li, Zhengqiu; Peng, Lijie; Ren, Xiaomei; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6807-6825</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Axl is a new potential target for anticancer drug discovery.  A series of 4-oxo-1,4-dihydroquinoline-3-carboxamides I (9a-u, 9ha-9hh, 9ia-9ic; R1 = H, Cl, F, Br, CF3, Me, Et, cyclopropyl, iPr, isopropenyl, OMe, CO2Me; R2, R3 = H, Me, Et, n-Pr, Bu, Ph; R4 = F, H, Me) and II [9id-9im; Z = CH, N; X = H, Cl; Y = H, NH2; X-Y = CPh:CHO, CPh:CHNH, CH:C(OMe)C(OMe):CH] were designed and synthesized as highly potent Axl kinase inhibitors.  One of the most promising compds., 9im [shown as II, X-Y = CH:C(OMe)C(OMe):CH], tightly bound with Axl protein and potently inhibited its kinase function with a Kd value of 2.7 nM and an IC50 value of 4.0 nM, resp., while was obviously less potent against most of the 403 wild-type kinases evaluated at a relatively high concn.  The compd. dose-dependently inhibited the TGF-β1-induced epithelial-mesenchymal transition (EMT) and suppressed the migration and invasion of MDA-MB-231 breast cancer cells.  In addn., 9im also demonstrated reasonable pharmacokinetics properties in rats and exhibited in vivo therapeutic effect on hepatic metastasis in a xenograft model of highly metastatic 4T1 murine breast cancer cells.  Compd. 9im may serve as a lead compd. for new anticancer drug discovery and a valuable research probe for further biol. investigation on Axl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtSA_rcxZaeLVg90H21EOLACvtfcHk0lgYh62PH2hioQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFersrnO&md5=2b737ed5ab9349788d82c0d1ec81b914</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00608%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3D4-Oxo-1%252C4-dihydroquinoline-3-carboxamide%2520derivatives%2520as%2520new%2520Axl%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6807%26epage%3D6825%26doi%3D10.1021%2Facs.jmedchem.6b00608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibu, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Structure based design of N-(3-((1<i>H</i>-Pyrazolo[3,4-<i>b</i>]pyridin-5-yl)ethynyl)benzenesulfonamides as selective leucine-zipper and sterile-α motif kinase (ZAK) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5927</span>– <span class="NLM_lpage">5932</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Kntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5927-5932&author=Y.+Changauthor=X.+Luauthor=M.+A.+Shibuauthor=Y.+Daiauthor=J.+Luoauthor=Y.+Zhangauthor=Y.+Liauthor=P.+Zhaoauthor=Z.+Zhangauthor=Y.+Xuauthor=Z.+Tuauthor=Q.+Zhangauthor=C.+Yunauthor=C.+Huangauthor=K.+Ding&title=Structure+based+design+of+N-%283-%28%281H-Pyrazolo%5B3%2C4-b%5Dpyridin-5-yl%29ethynyl%29benzenesulfonamides+as+selective+leucine-zipper+and+sterile-%CE%B1+motif+kinase+%28ZAK%29+inhibitors&doi=10.1021%2Facs.jmedchem.7b00572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Design of N-(3-(1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides as Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors</span></div><div class="casAuthors">Chang, Yu; Lu, Xiaoyun; Shibu, Marthandam Asokan; Dai, Yi-Bo; Luo, Jinfeng; Zhang, Yan; Li, Yingjun; Zhao, Peng; Zhang, Zhang; Xu, Yong; Tu, Zheng-Chao; Zhang, Qing-Wen; Yun, Cai-Hong; Huang, Chih-Yang; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5927-5932</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-(3-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides were designed as the first class of highly selective ZAK inhibitors.  The representative compd. I strongly inhibits the kinase activity of ZAK with an IC50 of 3.3 nM and dose-dependently suppresses the activation of ZAK downstream signals in vitro and in vivo, while it is significantly less potent for the majority of 403 nonmutated kinases evaluated.  Compd. I also exhibits orally therapeutic effects on cardiac hypertrophy in a spontaneous hypertensive rat model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotz-RCM9CJUbVg90H21EOLACvtfcHk0ljSjhN1Ij9Zig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Kntb4%253D&md5=897a22435eaf2f7721813f23eb40a62a</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00572%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DShibu%26aufirst%3DM.%2BA.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DYun%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DStructure%2520based%2520design%2520of%2520N-%25283-%2528%25281H-Pyrazolo%255B3%252C4-b%255Dpyridin-5-yl%2529ethynyl%2529benzenesulfonamides%2520as%2520selective%2520leucine-zipper%2520and%2520sterile-%25CE%25B1%2520motif%2520kinase%2520%2528ZAK%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5927%26epage%3D5932%26doi%3D10.1021%2Facs.jmedchem.7b00572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guise, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">2-Aminopyrimidine derivatives as new selective fibroblast growth factor receptor 4 (FGFR4) inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00091</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=543-548&author=C.+Moauthor=Z.+Zhangauthor=C.+P.+Guiseauthor=X.+Liauthor=J.+Luoauthor=Z.+Tuauthor=Y.+Xuauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=X.+Renauthor=X.+Luauthor=K.+Ding&title=2-Aminopyrimidine+derivatives+as+new+selective+fibroblast+growth+factor+receptor+4+%28FGFR4%29+inhibitors&doi=10.1021%2Facsmedchemlett.7b00091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors</span></div><div class="casAuthors">Mo, Cheng; Zhang, Zhang; Guise, Christopher P.; Li, Xueqiang; Luo, Jinfeng; Tu, Zhengchao; Xu, Yong; Patterson, Adam V.; Smaill, Jeff B.; Ren, Xiaomei; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-548</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 2-aminopyrimidine derivs. were designed and synthesized as highly selective FGFR4 inhibitors.  One of the most promising compds. I tightly bound FGFR4 with a Kd value of 3.3 nM and potently inhibited its enzymic activity with an IC50 value of 2.6 nM, but completely spared FGFR1/2/3.  The compd. selectively suppressed proliferation of breast cancer cells harboring dysregulated FGFR4 signaling with an IC50 value of 0.38 μM.  Furthermore, I exhibited extraordinary target specificity in a Kinome-wide screen against 468 kinases, with S(35) and S(10) selectivity scores of 0.01 and 0.007 at 1.0 μM, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqZiLAE7lPj7Vg90H21EOLACvtfcHk0ljSjhN1Ij9Zig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVWhu7s%253D&md5=63aec200353c08090a50a9c5988442bd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00091%26sid%3Dliteratum%253Aachs%26aulast%3DMo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGuise%26aufirst%3DC.%2BP.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3D2-Aminopyrimidine%2520derivatives%2520as%2520new%2520selective%2520fibroblast%2520growth%2520factor%2520receptor%25204%2520%2528FGFR4%2529%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D543%26epage%3D548%26doi%3D10.1021%2Facsmedchemlett.7b00091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodems, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makings, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stack, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollok, B. A.</span></span> <span> </span><span class="NLM_article-title">A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1089/154065802761001266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1089%2F154065802761001266" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=9-19&author=S.+M.+Rodemsauthor=B.+D.+Hammanauthor=C.+Linauthor=J.+Zhaoauthor=S.+Shahauthor=D.+Heidaryauthor=L.+Makingsauthor=J.+H.+Stackauthor=B.+A.+Pollok&title=A+FRET-based+assay+platform+for+ultra-high+density+drug+screening+of+protein+kinases+and+phosphatases&doi=10.1089%2F154065802761001266"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1089%2F154065802761001266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F154065802761001266%26sid%3Dliteratum%253Aachs%26aulast%3DRodems%26aufirst%3DS.%2BM.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DS.%26aulast%3DHeidary%26aufirst%3DD.%26aulast%3DMakings%26aufirst%3DL.%26aulast%3DStack%26aufirst%3DJ.%2BH.%26aulast%3DPollok%26aufirst%3DB.%2BA.%26atitle%3DA%2520FRET-based%2520assay%2520platform%2520for%2520ultra-high%2520density%2520drug%2520screening%2520of%2520protein%2520kinases%2520and%2520phosphatases%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2002%26volume%3D1%26spage%3D9%26epage%3D19%26doi%3D10.1089%2F154065802761001266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruciani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carosati, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Boeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vianello, R.</span></span> <span> </span><span class="NLM_article-title">MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6970</span>– <span class="NLM_lpage">6979</span>, <span class="refDoi"> DOI: 10.1021/jm050529c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050529c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGis73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6970-6979&author=G.+Crucianiauthor=E.+Carosatiauthor=B.+De+Boeckauthor=K.+Ethirajuluauthor=C.+Mackieauthor=T.+Howeauthor=R.+Vianello&title=MetaSite%3A+understanding+metabolism+in+human+cytochromes+from+the+perspective+of+the+chemist&doi=10.1021%2Fjm050529c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">MetaSite: Understanding Metabolism in Human Cytochromes from the Perspective of the Chemist</span></div><div class="casAuthors">Cruciani, Gabriele; Carosati, Emanuele; De Boeck, Benoit; Ethirajulu, Kantharaj; Mackie, Claire; Howe, Trevor; Vianello, Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6970-6979</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Identification of metabolic biotransformations can significantly affect the drug discovery process.  Since bioavailability, activity, toxicity, distribution, and final elimination all depend on metabolic biotransformations, it would be extremely advantageous if this information could be produced early in the discovery phase.  Once obtained, this information can help chemists to judge whether a potential candidate should be eliminated from the pipeline or modified to improve chem. stability or safety of new compds.  The use of in silico methods to predict the site of metab. in phase I cytochrome-mediated reactions is a starting point in any metabolic pathway prediction.  This paper presents a new method, specifically designed for chemists, that provides the cytochrome involved and the site of metab. for any human cytochrome P 450 (CYP) mediated reaction acting on new substrates.  The methodol. can be applied automatically to all the cytochromes for which 3D structure is known and can be used by chemists to detect positions that should be protected in order to avoid metabolic degrdn. or to check the suitability of a new scaffold or prodrug.  The fully automated procedure is also a valuable new tool in early ADME-Tox assays (absorption, distribution, metab., and excretion toxicity assays), where drug safety and metabolic profile patterns must be evaluated as soon, and as early, as possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzNL56jqRMpbVg90H21EOLACvtfcHk0lhp7QpDd5HRxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGis73F&md5=0a4576ffbea74e677832b7dbe8e036f0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm050529c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050529c%26sid%3Dliteratum%253Aachs%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DCarosati%26aufirst%3DE.%26aulast%3DDe%2BBoeck%26aufirst%3DB.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DHowe%26aufirst%3DT.%26aulast%3DVianello%26aufirst%3DR.%26atitle%3DMetaSite%253A%2520understanding%2520metabolism%2520in%2520human%2520cytochromes%2520from%2520the%2520perspective%2520of%2520the%2520chemist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6970%26epage%3D6979%26doi%3D10.1021%2Fjm050529c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors&doi=10.1016%2Fj.chembiol.2010.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0lhp7QpDd5HRxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D285%26epage%3D295%26doi%3D10.1016%2Fj.chembiol.2010.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">4869</span>– <span class="NLM_lpage">4877</span>, <span class="refDoi"> DOI: 10.1073/pnas.1403438111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1073%2Fpnas.1403438111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=4869-4877&author=L.+Tanauthor=J.+Wangauthor=J.+Tanizakiauthor=Z.+Huangauthor=A.+R.+Arefauthor=M.+Rusanauthor=S.+J.+Zhuauthor=Y.+Zhangauthor=D.+Ercanauthor=R.+G.+Liaoauthor=M.+Capellettiauthor=W.+Zhouauthor=W.+Hurauthor=N.+Kimauthor=T.+Simauthor=S.+Gaudetauthor=D.+A.+Barbieauthor=J.+R.+Yehauthor=C.+H.+Yunauthor=P.+S.+Hammermanauthor=M.+Mohammadiauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Development+of+covalent+inhibitors+that+can+overcome+resistance+to+first-generation+FGFR+kinase+inhibitors&doi=10.1073%2Fpnas.1403438111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1403438111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1403438111%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DRusan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DR.%2BG.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGaudet%26aufirst%3DS.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DYeh%26aufirst%3DJ.%2BR.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520covalent%2520inhibitors%2520that%2520can%2520overcome%2520resistance%2520to%2520first-generation%2520FGFR%2520kinase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D4869%26epage%3D4877%26doi%3D10.1073%2Fpnas.1403438111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guise, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taghipouran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yosaatmadja, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashoorzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squire, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">2-Oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1016%2Fj.ejmech.2017.04.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2017&pages=531-543&author=X.+Liauthor=C.+P.+Guiseauthor=R.+Taghipouranauthor=Y.+Yosaatmadjaauthor=A.+Ashoorzadehauthor=W.-K.+Paikauthor=C.+J.+Squireauthor=S.+Jiangauthor=J.+Luoauthor=Y.+Xuauthor=Z.-C.+Tuauthor=X.+Luauthor=X.+Renauthor=A.+V.+Pattersonauthor=J.+B.+Smaillauthor=K.+Ding&title=2-Oxo-3%2C4-dihydropyrimido%5B4%2C5-d%5Dpyrimidinyl+derivatives+as+new+irreversible+pan+fibroblast+growth+factor+receptor+%28FGFR%29+inhibitors&doi=10.1016%2Fj.ejmech.2017.04.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGuise%26aufirst%3DC.%2BP.%26aulast%3DTaghipouran%26aufirst%3DR.%26aulast%3DYosaatmadja%26aufirst%3DY.%26aulast%3DAshoorzadeh%26aufirst%3DA.%26aulast%3DPaik%26aufirst%3DW.-K.%26aulast%3DSquire%26aufirst%3DC.%2BJ.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.-C.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDing%26aufirst%3DK.%26atitle%3D2-Oxo-3%252C4-dihydropyrimido%255B4%252C5-d%255Dpyrimidinyl%2520derivatives%2520as%2520new%2520irreversible%2520pan%2520fibroblast%2520growth%2520factor%2520receptor%2520%2528FGFR%2529%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D135%26spage%3D531%26epage%3D543%26doi%3D10.1016%2Fj.ejmech.2017.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szklarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Azeez, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajczyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepetov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Haj Zen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourches, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tropsha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span> <span> </span><span class="NLM_article-title">Comprehensive characterization of the published kinase inhibitor set</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1038/nbt.3374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1038%2Fnbt.3374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=26501955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslantL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=95-103&author=J.+M.+Elkinsauthor=V.+Fedeleauthor=M.+Szklarzauthor=K.+R.+Abdul+Azeezauthor=E.+Salahauthor=J.+Mikolajczykauthor=S.+Romanovauthor=N.+Sepetovauthor=X.+P.+Huangauthor=B.+L.+Rothauthor=A.+Al+Haj+Zenauthor=D.+Fourchesauthor=E.+Muratovauthor=A.+Tropshaauthor=J.+Morrisauthor=B.+A.+Teicherauthor=M.+Kunkelauthor=E.+Polleyauthor=K.+E.+Lackeyauthor=F.+L.+Atkinsonauthor=J.+P.+Overingtonauthor=P.+Bamboroughauthor=S.+Mullerauthor=D.+J.+Priceauthor=T.+M.+Willsonauthor=D.+H.+Drewryauthor=S.+Knappauthor=W.+J.+Zuercher&title=Comprehensive+characterization+of+the+published+kinase+inhibitor+set&doi=10.1038%2Fnbt.3374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive characterization of the Published Kinase Inhibitor Set</span></div><div class="casAuthors">Elkins, Jonathan M.; Fedele, Vita; Szklarz, Marta; Abdul Azeez, Kamal R.; Salah, Eidarus; Mikolajczyk, Jowita; Romanov, Sergei; Sepetov, Nikolai; Huang, Xi-Ping; Roth, Bryan L.; Al Haj Zen, Ayman; Fourches, Denis; Muratov, Eugene; Tropsha, Alex; Morris, Joel; Teicher, Beverly A.; Kunkel, Mark; Polley, Eric; Lackey, Karen E.; Atkinson, Francis L.; Overington, John P.; Bamborough, Paul; Muller, Susanne; Price, Daniel J.; Willson, Timothy M.; Drewry, David H.; Knapp, Stefan; Zuercher, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-103</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite the success of protein kinase inhibitors as approved therapeutics, drug discovery has focused on a small subset of kinase targets.  Here we provide a thorough characterization of the Published Kinase Inhibitor Set (PKIS), a set of 367 small-mol. ATP-competitive kinase inhibitors that was recently made freely available with the aim of expanding research in this field and as an expt. in open-source target validation.  We screen the set in activity assays with 224 recombinant kinases and 24 G protein-coupled receptors and in cellular assays of cancer cell proliferation and angiogenesis.  We identify chem. starting points for designing new chem. probes of orphan kinases and illustrate the utility of these leads by developing a selective inhibitor for the previously untargeted kinases LOK and SLK.  Our cellular screens reveal compds. that modulate cancer cell growth and angiogenesis in vitro.  These reagents and assocd. data illustrate an efficient way forward to increasing understanding of the historically untargeted kinome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4P1WN3gdiXbVg90H21EOLACvtfcHk0ljV__9CnvtG6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslantL%252FM&md5=3f15096e79632dbaaadf4460a6848e60</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnbt.3374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.3374%26sid%3Dliteratum%253Aachs%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFedele%26aufirst%3DV.%26aulast%3DSzklarz%26aufirst%3DM.%26aulast%3DAbdul%2BAzeez%26aufirst%3DK.%2BR.%26aulast%3DSalah%26aufirst%3DE.%26aulast%3DMikolajczyk%26aufirst%3DJ.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DSepetov%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DAl%2BHaj%2BZen%26aufirst%3DA.%26aulast%3DFourches%26aufirst%3DD.%26aulast%3DMuratov%26aufirst%3DE.%26aulast%3DTropsha%26aufirst%3DA.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DKunkel%26aufirst%3DM.%26aulast%3DPolley%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26aulast%3DAtkinson%26aufirst%3DF.%2BL.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DD.%2BJ.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26atitle%3DComprehensive%2520characterization%2520of%2520the%2520published%2520kinase%2520inhibitor%2520set%26jtitle%3DNat.%2520Biotechnol.%26date%3D2016%26volume%3D34%26spage%3D95%26epage%3D103%26doi%3D10.1038%2Fnbt.3374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dienstmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Garcia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuciforo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span> <span> </span><span class="NLM_article-title">Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdt419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1093%2Fannonc%2Fmdt419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=24265351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A280%3ADC%252BC2c7ptFWmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=552-563&author=R.+Dienstmannauthor=J.+Rodonauthor=A.+Pratauthor=J.+Perez-Garciaauthor=B.+Adamoauthor=E.+Felipauthor=J.+Cortesauthor=A.+J.+Iafrateauthor=P.+Nuciforoauthor=J.+Tabernero&title=Genomic+aberrations+in+the+FGFR+pathway%3A+opportunities+for+targeted+therapies+in+solid+tumors&doi=10.1093%2Fannonc%2Fmdt419"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors</span></div><div class="casAuthors">Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate A J; Nuciforo P; Tabernero J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">552-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The fibroblast growth factor receptor (FGFR) cascade plays crucial roles in tumor cell proliferation, angiogenesis, migration and survival.  Accumulating evidence suggests that in some tumor types, FGFRs are bona fide oncogenes to which cancer cells are addicted.  Because FGFR inhibition can reduce proliferation and induce cell death in a variety of in vitro and in vivo tumor models harboring FGFR aberrations, a growing number of research groups have selected FGFRs as targets for anticancer drug development.  Multikinase FGFR/vascular endothelial growth factor receptor (VEGFR) inhibitors have shown promising activity in breast cancer patients with FGFR1 and/or FGF3 amplification.  Early clinical trials with selective FGFR inhibitors, which may overcome the toxicity constraints raised by multitarget kinase inhibition, are recruiting patients with known FGFR(1-4) status based on genomic screens.  Preliminary signs of antitumor activity have been demonstrated in some tumor types, including squamous cell lung carcinomas.  Rational combination of targeted therapies is expected to further increase the efficacy of selective FGFR inhibitors.  Herein, we discuss unsolved questions in the clinical development of these agents and suggest guidelines for management of hyperphosphatemia, a class-specific mechanism-based toxicity.  In addition, we propose standardized definitions for FGFR1 and FGFR2 gene amplification based on in situ hybridization methods.  Extended access to next-generation sequencing platforms will facilitate the identification of diseases in which somatic FGFR(1-4) mutations, amplifications and fusions are potentially driving cancer cell viability, further strengthening the role of FGFR signaling in cancer biology and providing more possibilities for the therapeutic application of FGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqiWGpXuCcvmx8TEN9K18QfW6udTcc2eZ3l8G1Fb8zfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7ptFWmsA%253D%253D&md5=633eb08ba5e38f239a73dfbfff04064c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdt419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdt419%26sid%3Dliteratum%253Aachs%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DPerez-Garcia%26aufirst%3DJ.%26aulast%3DAdamo%26aufirst%3DB.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DNuciforo%26aufirst%3DP.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DGenomic%2520aberrations%2520in%2520the%2520FGFR%2520pathway%253A%2520opportunities%2520for%2520targeted%2520therapies%2520in%2520solid%2520tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D552%26epage%3D563%26doi%3D10.1093%2Fannonc%2Fmdt419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greuber, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith-Pearson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendergast, A. M.</span></span> <span> </span><span class="NLM_article-title">Role of ABL family kinases in cancer: from leukemia to solid tumors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">571</span>, <span class="refDoi"> DOI: 10.1038/nrc3563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1038%2Fnrc3563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=23842646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVykurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=559-571&author=E.+K.+Greuberauthor=P.+Smith-Pearsonauthor=J.+Wangauthor=A.+M.+Pendergast&title=Role+of+ABL+family+kinases+in+cancer%3A+from+leukemia+to+solid+tumors&doi=10.1038%2Fnrc3563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ABL family kinases in cancer: from leukaemia to solid tumours</span></div><div class="casAuthors">Greuber, Emileigh K.; Smith-Pearson, Pameeka; Wang, Jun; Pendergast, Ann Marie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-571</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Abelson (ABL) family of nonreceptor tyrosine kinases, ABL1 and ABL2, transduces diverse extracellular signals to protein networks that control proliferation, survival, migration and invasion.  ABL1 was first identified as an oncogene required for the development of leukemias initiated by retroviruses or chromosome translocations.  The demonstration that small-mol. ABL kinase inhibitors could effectively treat chronic myeloid leukemia opened the door to the era of targeted cancer therapies.  Recent reports have uncovered roles for ABL kinases in solid tumors.  Enhanced ABL expression and activation in some solid tumors, together with altered cell polarity, invasion or growth induced by activated ABL kinases, suggest that drugs targeting these kinases may be useful for treating selected solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr_ZQCA7IT4rVg90H21EOLACvtfcHk0ljV__9CnvtG6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVykurnM&md5=78bcffba5a172619e55aaf54233e2b46</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrc3563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3563%26sid%3Dliteratum%253Aachs%26aulast%3DGreuber%26aufirst%3DE.%2BK.%26aulast%3DSmith-Pearson%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPendergast%26aufirst%3DA.%2BM.%26atitle%3DRole%2520of%2520ABL%2520family%2520kinases%2520in%2520cancer%253A%2520from%2520leukemia%2520to%2520solid%2520tumors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D559%26epage%3D571%26doi%3D10.1038%2Fnrc3563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Brucine suppresses colon cancer cells growth via mediating KDR signalling pathway</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1316</span>– <span class="NLM_lpage">1324</span>, <span class="refDoi"> DOI: 10.1111/jcmm.12108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1111%2Fjcmm.12108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=23905676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGrs7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=1316-1324&author=W.+Luoauthor=X.+Wangauthor=L.+Zhengauthor=Y.+Zhanauthor=D.+Zhangauthor=J.+Zhangauthor=Y.+Zhang&title=Brucine+suppresses+colon+cancer+cells+growth+via+mediating+KDR+signalling+pathway&doi=10.1111%2Fjcmm.12108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Brucine suppresses colon cancer cells growth via mediating KDR signalling pathway</span></div><div class="casAuthors">Luo, Wenjuan; Wang, Xiaoli; Zheng, Lei; Zhan, Yingzhuan; Zhang, Dongdong; Zhang, Jie; Zhang, Yanmin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1316-1324</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Angiogenesis plays an important role in colon cancer development.  This study aimed to demonstrate the effect of brucine on tumor angiogenesis and its mechanism of action.  The anti-angiogenic effect was evaluated on the chicken chorioallantoic membrane (CAM) model and tube formation.  The mechanism was demonstrated through detecting mRNA and protein expressions of VEGFR2 (KDR), PKCα, PLCγ and Raf1 by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot (WB), as well as expressions of VEGF and PKCβ and mTOR by ELISA and WB.  The results showed that brucine significantly reduced angiogenesis of CAM and tube formation, inhibited the VEGF secretion and mTOR expression in LoVo cell and down-regulated the mRNA and phosphorylation protein expressions of KDR,PKCα, PLCγ and Raf1.  In addn., the effects of brucine on KDR kinase activity, viability of LoVo cell and gene knockdown cell were detected with the Lance® assay, WST-1 assay and instantaneous siRNA.  Compared to that of normal LoVo cells, the inhibition on proliferation of knockdown cells by brucine decreased significantly.  These results suggest that brucine could inhibit angiogenesis and be a useful therapeutic candidate for colon cancer intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7t-a6zQzeHLVg90H21EOLACvtfcHk0lhnpleD_cB7xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGrs7bL&md5=d8920252e1495fcc13ae205d520fef83</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12108%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DBrucine%2520suppresses%2520colon%2520cancer%2520cells%2520growth%2520via%2520mediating%2520KDR%2520signalling%2520pathway%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2013%26volume%3D17%26spage%3D1316%26epage%3D1324%26doi%3D10.1111%2Fjcmm.12108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, J.</span></span> <span> </span><span class="NLM_article-title">Transwell invasion assays</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>769</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1007/978-1-61779-207-6_8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=10.1007%2F978-1-61779-207-6_8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=21748672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvValtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=769&publication_year=2011&pages=97-110&author=J.+Marshall&title=Transwell+invasion+assays&doi=10.1007%2F978-1-61779-207-6_8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Transwell invasion assays</span></div><div class="casAuthors">Marshall, John</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">769</span>
        (<span class="NLM_cas:issue">Cell Migration</span>),
    <span class="NLM_cas:pages">97-110</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The need to identify inhibitors of cancer invasion has driven the development of quant. in vitro invasion assays.  The most common assays used are based on the original Boyden assay system.  Today com. available plastic inserts for multi-well plates, which possess a cell-permeable membrane, as typified by Transwell Permeable Supports, permit accurate repeatable invasion assays.  When placed in the well of a multi-well tissue culture plate these inserts create a two-chamber system sepd. by the cell-permeable membrane.  To create an invasion assay the pores in the membrane are blocked with a gel composed of extracellular matrix that is meant to mimic the typical matrixes that tumor cells encounter during the invasion process in vivo.  By placing the cells on one side of the gel and a chemoattractant on the other side of the gel, invasion is detd. by counting those cells that have traversed the cell-permeable membrane having invaded towards the higher concn. of chemoattractant.  In this chapter, in addn. to protocols for performing Transwell invasion assays, there is consideration of the limitations of current assay designs with regard to available matrixes and the absence of tumor microenvironment cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7zbRBB-kc5LVg90H21EOLACvtfcHk0lhnpleD_cB7xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvValtL3F&md5=0e1a7a2315e8891770ad14540bd8e9b5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-207-6_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-207-6_8%26sid%3Dliteratum%253Aachs%26aulast%3DMarshall%26aufirst%3DJ.%26atitle%3DTranswell%2520invasion%2520assays%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D769%26spage%3D97%26epage%3D110%26doi%3D10.1007%2F978-1-61779-207-6_8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VJO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VJO','PDB','3VJO'); return false;">PDB: 3VJO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3DPK','PDB','3DPK'); return false;">PDB: 3DPK</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i82"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01612">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_18152"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01612">10.1021/acs.jmedchem.7b01612</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H NMR and <sup>13</sup>C NMR for final compounds, biological data, and assay details (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Compound characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_002.xls">XLS</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_001.pdf">jm7b01612_si_001.pdf (9.56 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_002.xls">jm7b01612_si_002.xls (102.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01612/suppl_file/jm7b01612_si_003.csv">jm7b01612_si_003.csv (5.48 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01612&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-6%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01612%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01612" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a6e0e6e493ce8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
